FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Sabino, TE
   Avelino-Silva, VI
   Cavalcantte, C
   Goulart, SP
   Luiz, OC
   Fonseca, LAM
   Casseb, JS
AF Sabino, Thiago E.
   Avelino-Silva, Vivian, I
   Cavalcantte, Clara
   Goulart, Silvia P.
   Luiz, Olinda C.
   Fonseca, Luiz A. M.
   Casseb, Jorge S.
TI Adherence to antiretroviral treatment and quality of life among
   transgender women living with HIV/AIDS in Sao Paulo, Brazil
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article; Early Access
DE Transgender women; HIV; AIDS; adherence; quality of life
ID HUMAN-IMMUNODEFICIENCY-VIRUS; THERAPY ADHERENCE; HIV PREVENTION; CARE;
   PEOPLE; TRANSMISSION; HEALTH; RESISTANCE; SERVICES; AIDS
AB This study focused on factors associated with antiretroviral therapy (ART) adherence and quality of life among transgenderwomen in Sao Paulo, Brazil, using univariable and adjusted analysis. Adherence was evaluated with a self-report tool and with HIV viral load (VL) measurement. PROQOL-HIV was used to assess quality of life. 106 TGW with median 41 years old were included; most were white (56%) and had >10 years of education (57%). Median time since HIV/AIDS diagnosis was 10 years. Overall, participants had high T CD4+ counts (median 659 cells/mm(3)) and most (75%) had undetectable HIV VL. 85% were considered adherent using self-report (95%CI 77-91), whereas 72% (95%CI 62-80) were considered adherent when self-report and undetectable HIV VL were analyzed jointly. Older age was associated with higher ART adherence; each year increase in age was associated with 5% higher odds of adherence (p = 0.021). Quality of life ranged from good-excellent in 5 of 8 domains. Younger age, lower education, higher time since HIV diagnosis, comorbidities, illicit drugs use and depression were associated with lower PROQOL scores in specific domains in univariable analysis, while depression was also associated with lower total PROQOL score even after adjustment for age, comorbidities and time since HIV diagnosis (p = 0.048).
C1 [Sabino, Thiago E.; Fonseca, Luiz A. M.; Casseb, Jorge S.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian, I] Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Cavalcantte, Clara] Univ Sao Paulo, Fac Saude PUbl, Sch Publ Hlth, Sao Paulo, Brazil.
   [Goulart, Silvia P.] Ctr Referencia & Tratamento DST Aids, HIV AIDS Reference & Treatment Ctr Sao Paulo, Sao Paulo, Brazil.
   [Luiz, Olinda C.] Univ Sao Paulo, Fac Med, Dept Prevent Med, Sao Paulo, Brazil.
RP Sabino, TE (corresponding author), Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
EM thiagosabino@usp.br
RI Avelino-Silva, Vivian I/L-2640-2013; Luiz, Olinda/C-6075-2012
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Luiz,
   Olinda/0000-0002-2596-3626
CR Arnsten JH, 2001, CLIN INFECT DIS, V33, P1417, DOI 10.1086/323201
   Asia Pacific Coalition on Male Sexual Health (APOCOM), 2008, MAPP TRANSG GROUPS O
   Baguso GN, 2016, AIDS CARE, V28, P976, DOI 10.1080/09540121.2016.1146401
   Baral SD, 2013, LANCET INFECT DIS, V13, P214, DOI 10.1016/S1473-3099(12)70315-8
   Beith A., 2006, INTERVENTIONS UNPUB
   Caraciolo M. M. J., 2007, ADESAO DA TEORIA PRA
   Casseb J., 2017, AIDS RES HUM RETROV, V34, P1
   Cohen MS, 2016, NEW ENGL J MED, V375, P830, DOI 10.1056/NEJMoa1600693
   Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243
   da Silva J, 2013, AIDS CARE, V25, P71, DOI 10.1080/09540121.2012.686594
   Duracinsky M, 2012, JAIDS-J ACQ IMM DEF, V59, P498, DOI 10.1097/QAI.0b013e318245cafe
   Jalil EM, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21873
   Kellogg TA, 2001, J ACQ IMMUN DEF SYND, V28, P380, DOI 10.1097/00126334-200112010-00012
   Kozal MJ, 2004, AIDS, V18, P2185, DOI 10.1097/00002030-200411050-00011
   Lifson AR, 2015, HIV MED, V16, P88, DOI 10.1111/hiv.12237
   Lucas Gregory M, 2004, Curr HIV/AIDS Rep, V1, P172, DOI 10.1007/s11904-004-0027-6
   Mannheimer S, 2002, CLIN INFECT DIS, V34, P1115, DOI 10.1086/339074
   Mannheimer SB, 2005, AIDS CARE, V17, P10, DOI 10.1080/09540120412331305098
   Mayer KH, 2016, JAIDS-J ACQ IMM DEF, V72, pS207, DOI 10.1097/QAI.0000000000001086
   Meyer IH, 2003, PSYCHOL BULL, V129, P674, DOI 10.1037/0033-2909.129.5.674
   Ministerio da Saude (MS), 2013, POL NAC INT LESB GAY
   Ministerio da Saude (MS), 2008, MAN AD AO TRAT PASS
   Mizuno Y, 2017, LGBT HEALTH, V4, P181, DOI 10.1089/lgbt.2017.0003
   Murad MH, 2010, CLIN ENDOCRINOL, V72, P214, DOI 10.1111/j.1365-2265.2009.03625.x
   Nemes MIB, 2004, AIDS, V18, pS15, DOI 10.1097/00002030-200406003-00004
   Nobre N, 2017, AIDS CARE, V29, P1074, DOI 10.1080/09540121.2017.1281879
   Oguntibeju OO, 2012, HIV AIDS-RES PALLIAT, V4, P117, DOI 10.2147/HIV.S32321
   Valencia CP, 2010, COLOMB MEDICA, V41, P206
   Poteat T, 2014, CURR OPIN HIV AIDS, V9, P168, DOI 10.1097/COH.0000000000000030
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Rocha M. B. A., 2017, 10 C BRAS EP
   Santos MA, 2018, MEDICINE, V97, pS38, DOI [10.1097/MD.0000000000009015, 10.1097/md.0000000000009015]
   Sevelius JM, 2014, ANN BEHAV MED, V47, P5, DOI 10.1007/s12160-013-9565-8
   Sevelius JM, 2010, J ASSOC NURSE AIDS C, V21, P256, DOI 10.1016/j.jana.2010.01.005
   Simon PA, 2000, AIDS, V14, P2953, DOI 10.1097/00002030-200012220-00024
   Simoni Jane M, 2008, Curr Infect Dis Rep, V10, P515, DOI 10.1007/s11908-008-0083-y
   Soeters HM, 2013, AIDS, V27, P2873, DOI 10.1097/01.aids.0000433240.78739.30
   Thompson HM, 2015, INT J TRANSGENDERISM, V16, P36, DOI 10.1080/15532739.2015.1039176
   Turan JM, 2019, BMC MED, V17, DOI 10.1186/s12916-018-1246-9
   UNAIDS, 2015, UNAIDS TERM GUID
   UNAIDS, 2014, GAP REP
   UNAIDS Report on the Global AIDS Epidemic, 2012, UNAIDS REP GLOB AIDS
   United Nations Programme on HIV/Aids (UNAIDS), 2009, ACT FRAM UN ACC MEM
   WHO, 2012, STRAT US ANT HELP EN
   Wilson EC, 2013, INT J TRANSGENDERISM, V14, P182, DOI 10.1080/15532739.2014.890090
   World Health Organization, 2003, ADHERENCE LONG TERM
   Yang XS, 2016, J SEX MED, V13, P977, DOI 10.1016/j.jsxm.2016.03.369
   Zimpel RR, 2007, AIDS CARE, V19, P923, DOI 10.1080/09540120701213765
NR 48
TC 0
Z9 0
U1 1
U2 1
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0954-0121
EI 1360-0451
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
DI 10.1080/09540121.2019.1710449
EA JAN 2020
PG 8
WC Health Policy & Services; Public, Environmental & Occupational Health;
   Psychology, Multidisciplinary; Respiratory System; Social Sciences,
   Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Psychology; Respiratory System; Biomedical Social Sciences
GA KA6GT
UT WOS:000505896000001
PM 31906696
DA 2020-12-01
ER

PT J
AU Picone, CM
   Freitas, AC
   Gutierrez, EB
   Avelino-Silva, VI
AF Picone, Camila Melo
   Freitas, Angela Carvalho
   Gutierrez, Eliana B.
   Avelino-Silva, Vivian Iida
TI Access and adherence to isoniazid preventive therapy and occurrence of
   active TB in a cohort of people living with HIV: a retrospective cohort
   study in Sao Paulo, Brazil
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE Active tuberculosis; Adherence; HIV; Isoniazid preventive therapy;
   Prophylactic therapy; Tuberculin skin test; Tuberculin test;
   Tuberculosis
ID LATENT TUBERCULOSIS INFECTION; RIO-DE-JANEIRO; CLINICS; IMPLEMENTATION;
   COMPLETION; PREDICTORS; ADULTS; TB/HIV; TRIAL; CARE
AB Tuberculosis (TB) is still a leading cause of morbidity and mortality among people living with HIV (PLHIV). The diagnosis of latent TB is required for the implementation of prophylactic therapy with isoniazid (PTI). However, low access to diagnosis of latent TB and non-adherence to PTI may hinder potential benefits of this essential intervention. In this study, we addressed the access and adherence to PTI in a cohort of PLHIV with positive tuberculin skin test (TST) in a reference HIV clinic in Sao Paulo, Brazil. We have also analyzed the occurrence of active TB over a median of 131 months after a positive TST among study participants. Our findings revealed that 88.3% of the 238 TST-positive patients had access to PTI, and 196 (93.3%) of those with access adhered to PTI. Active tuberculosis was diagnosed in three of the 196 TST-positive patients who adhered to PTI (1.5%; 95% confidence interval [CI] 0.3-4.4%). whereas seven cases were detected among 42 patients without access or who did not adhere to PTI (16.6%; 95% CI 7.0-31.3%). The apparent beneficial effect of PIT in our cohort is consistent with previous studies including PLHIV, and highlights the importance of reliably delivering each of the steps between screening for latent TB and provision of PTI.
C1 [Picone, Camila Melo; Freitas, Angela Carvalho; Gutierrez, Eliana B.; Avelino-Silva, Vivian Iida] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
EM viviansilva87@gmail.com
RI Avelino-Silva, Vivian I/L-2640-2013
OI Avelino-Silva, Vivian I/0000-0002-6660-3088
CR Akolo Christopher, 2015, World J Virol, V4, P105, DOI 10.5501/wjv.v4.i2.105
   Alsdurf H, 2016, LANCET INFECT DIS, V16, P1269, DOI 10.1016/S1473-3099(16)30216-X
   [Anonymous], 2019, MMWR-MORBID MORTAL W, V68, P552, DOI 10.15585/mmwr.mm6824a4
   Ayele HT, 2016, INT J TUBERC LUNG D, V20, P1342, DOI 10.5588/ijtld.15.0805
   Ayele HT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142290
   Kussen GMB, 2016, BRAZ J INFECT DIS, V20, P69, DOI 10.1016/j.bjid.2015.10.007
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia das Doencas Transmissiveis, 2014, SECR VIG SAUD
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia das Doencas Transmissiveis, 2019, MANUAL RECOMENDACOES
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia Epidemiologica, 2011, TRAT DIR OBS TDO TUB
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia Prevencao e Controle das Infeccoes Sexualmente Transmissiveis do HIV/AIDS e das Hepatites Virais, 2018, PREV CONTR INF SEX T
   Briggs MA, 2015, JAIDS-J ACQ IMM DEF, V68, pS297, DOI 10.1097/QAI.0000000000000497
   Bruins WSC, 2017, INFECT DIS-NOR, V49, P161, DOI 10.1080/23744235.2016.1262059
   Carneiro AJ, 1986, J PNEUMOL, V12, P21
   Conde MB, 2009, J BRAS PNEUMOL, V35, P1018, DOI 10.1590/S1806-37132009001000011
   Daher A, 2015, MEM I OSWALDO CRUZ, V110, P543, DOI 10.1590/0074-02760140458
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Durovni B, 2013, LANCET INFECT DIS, V13, P852, DOI 10.1016/S1473-3099(13)70187-7
   Durovni B, 2010, AIDS, V24, pS49, DOI 10.1097/01.aids.0000391022.95412.a6
   Eldred LJ, 2010, AIDS, V24, pS1, DOI 10.1097/01.aids.0000391009.95149.ec
   Golub JE, 2015, CLIN INFECT DIS, V60, P639, DOI 10.1093/cid/ciu849
   Gutierrez EB, 2009, HIV MED, V10, P564, DOI 10.1111/j.1468-1293.2009.00730.x
   Lester R, 2010, AIDS, V24, pS45, DOI 10.1097/01.aids.0000391021.18284.12
   Little KM, 2018, INT J TUBERC LUNG D, V22, P371, DOI 10.5588/ijtld.16.0836
   Machado A, 2009, INT J TUBERC LUNG D, V13, P719
   MAGNUSSON M, 1958, Bull World Health Organ, V19, P829
   Nsengiyumva NP, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01363-2018
   Santos DT, 2017, CAD SAUDE PUBLICA, V33
   Sao Paulo. Secretaria de Estado da Saude. Coordenadoria de Controle de Doencas. Centro de Vigilancia Epidemiologica Prof. Alexandre Vranjac. Programa de Controle da Tuberculose do Estado de Sao Paulo, PROGRAMA CONTROLE TU
   Saraceni V, 2011, BRAZ J INFECT DIS, V15, P249, DOI [10.1590/S1413-86702011000300012, 10.1016/S1413-8670(11)70184-2]
   Secretaria de Vigilancia em Saude Ministerio da Saude, 2019, B EPIDEMIOL, V50, P1
   Siqueira KZ, 2012, EPIDEMIOL SERV SAUDE, V21, P635, DOI 10.5123/S1679-49742012000400013
   Sociedade Brasileira de MedicinaTropical, BRAS EST HA MAIS AN
   Tebruegge M, 2014, LANCET, V384, P2026, DOI 10.1016/S0140-6736(14)62335-7
   Thindwa D, 2018, INT J TUBERC LUNG D, V22, P273, DOI 10.5588/ijtld.17.0370
   Trajman A, 2010, INT J TUBERC LUNG D, V14, P551
   Vidal JS, 2015, REV SOC BRAS MED TRO, V48, P507, DOI 10.1590/0037-8682-0156-2014
   World Health Organization, 2019, GLOB TUB REP 2019
   World Health Organization (WHO), 2018, LAT TUB INF UPD CONS
   Zenner D, 2017, ANN INTERN MED, V167, P248, DOI 10.7326/M17-0609
NR 39
TC 0
Z9 0
U1 1
U2 1
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PY 2020
VL 62
AR e8
DI 10.1590/S1678-9946202062008
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA KM5AJ
UT WOS:000514146500005
PM 32049259
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Mayaud, P
   Tami, A
   Miranda, MC
   Rosenberger, KD
   Alexander, N
   Nacul, L
   Segurado, A
   Pohl, M
   Bethencourt, S
   Villar, LA
   Viana, IFT
   Rabello, R
   Soria, C
   Salgado, SP
   Gotuzzo, E
   Guzman, MG
   Martinez, PA
   Lopez-Gatell, H
   Hegewisch-Taylor, J
   Borja-Aburto, VH
   Gonzalez, C
   Netto, EM
   Villarroel, PMS
   Hoen, B
   Brasil, P
   Marques, ETA
   Rockx, B
   Koopmans, M
   de Lamballerie, X
   Jaenisch, T
   Jaenisch, T
   Rosenberger, KD
   Morales, I
   Tobian, F
   Uhlmann, L
   Pohl, M
   Schretzmann, J
   Leege, A
   Marques, ETA
   Marques, ETA
   Viana, IFT
   Lins, RD
   de Filippis, AMB
   Duarte, ACM
   Espindola, OD
   Bonaldo, M
   Rabello, R
   Damasceno, L
   Mendes-Correa, MC
   Mayaud, P
   Nacul, L
   Alexander, N
   Netto, EM
   Tami, A
   Bethencourt, S
   Tinedo, MJ
   La Rosa, Y
   Murillo, M
   Villar, LA
   Miranda, MC
   Lozano, A
   Herrera, VM
   Gomez, A
   Gelvez, RM
   Ortiz, R
   Herrera, VM
   Soria, C
   Dimitrakis, L
   Salgado, SP
   Arrata, MR
   Gotuzzo, E
   Allison, HG
   Talledo, M
   Villarroel, PMS
   Torres, EM
   Guzman, MG
   Rodriguez, PAM
   Vera, MA
   Santana, BG
   Reyes, A
   Alvarez, SS
   Dorticos, DF
   Hegewisch-Taylor, J
   Alpuche-Aranda, C
   Lopez-Gatell, H
   Gonzalez-Diaz, E
   Pavia-Ruz, N
   Borja-Aburto, VH
   Gonzalez, C
   Grajales, C
   Rojas, T
   Arriaga, L
   Vallejos, A
   Tynevez, D
   Thirion, L
   Drexler, JF
   Rockx, B
   van Gorp, E
   Koopmans, M
AF Avelino-Silva, Vivian I.
   Mayaud, Philippe
   Tami, Adriana
   Miranda, Maria C.
   Rosenberger, Kerstin D.
   Alexander, Neal
   Nacul, Luis
   Segurado, Aluisio
   Pohl, Moritz
   Bethencourt, Sarah
   Villar, Luis A.
   Viana, Isabelle F. T.
   Rabello, Renata
   Soria, Carmen
   Salgado, Silvia P.
   Gotuzzo, Eduardo
   Guzman, Maria G.
   Martinez, Pedro A.
   Lopez-Gatell, Hugo
   Hegewisch-Taylor, Jennifer
   Borja-Aburto, Victor H.
   Gonzalez, Cesar
   Netto, Eduardo M.
   Villarroel, Paola M. Saba
   Hoen, Bruno
   Brasil, Patricia
   Marques, Ernesto T. A.
   Rockx, Barry
   Koopmans, Marion
   de Lamballerie, Xavier
   Jaenisch, Thomas
   Jaenisch, Thomas
   Rosenberger, Kerstin Daniela
   Morales, Ivonne
   Tobian, Frank
   Uhlmann, Lorenz
   Pohl, Moritz
   Schretzmann, Julius
   Leege, Annika
   Marques, Ernesto T. A.
   Marques, Ernesto T. A.
   Viana, Isabelle F. T.
   Lins, Roberto D.
   Bispo de Filippis, Ana Maria
   Machado Duarte, Ana Claudia
   Espindola, Otavio de Melo
   Bonaldo, Myrna
   Rabello, Renata
   Damasceno, Luana
   Mendes-Correa, Maria Cassia
   Mayaud, Philippe
   Nacul, Luis
   Alexander, Neal
   Netto, Eduardo Martins
   Tami, Adriana
   Bethencourt, Sarah
   Tinedo, Maria Jose
   La Rosa, Yenifer
   Murillo, Marianela
   Angel Villar, Luis
   Consuelo Miranda, Maria
   Lozano, Anyela
   Mauricio Herrera, Victor
   Gomez, Adriana
   Margarita Gelvez, Rosa
   Ortiz, Ricardo
   Mauricio Herrera, Victor
   Soria, Carmen
   Dimitrakis, Lady
   Paola Salgado, Silvia
   Regato Arrata, Mary
   Gotuzzo, Eduardo
   Guerra Allison, Humberto
   Talledo, Michael
   Saba Villarroel, Paola Mariela
   Torres, Eric Martinez
   Guzman, Maria G.
   Martinez Rodriguez, Pedro A.
   Alvarez Vera, Mayling
   Galindo Santana, Belkis
   Reyes, Alicia
   Serrano Alvarez, Silvia
   Ferriol Dorticos, Diana
   Hegewisch-Taylor, Jennifer
   Alpuche-Aranda, Celia
   Lopez-Gatell, Hugo
   Gonzalez-Diaz, Esteban
   Pavia-Ruz, Norma
   Hugo Borja-Aburto, Victor
   Gonzalez, Cesar
   Grajales, Concepcion
   Rojas, Teresita
   Arriaga, Lumumba
   Vallejos, Alfonso
   Tynevez, Dominique
   Thirion, Laurence
   Drexler, Jan Felix
   Rockx, Barry
   van Gorp, Eric
   Koopmans, Marion
CA ZIKAlliance Clinical Study Grp
TI Study protocol for the multicentre cohorts of Zika virus infection in
   pregnant women, infants, and acute clinical cases in Latin America and
   the Caribbean: the ZIKAlliance consortium
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Zika; Pregnant women; Children; Cohort; Latin America; Caribbean; Risk;
   Congenital abnormalities; Natural history; Arboviruses; Mosquito-borne
   viruses; Vector-borne viruses
ID EXTERNAL QUALITY ASSESSMENT; GUILLAIN-BARRE-SYNDROME; BIRTH-DEFECTS;
   SEXUAL TRANSMISSION; MOLECULAR-DETECTION; BRAZIL; EPIDEMIC;
   LABORATORIES; TERRITORIES; OUTCOMES
AB Background: The European Commission (EC) Horizon 2020 (H2020)-funded ZIKAlliance Consortium designed a multicentre study including pregnant women (PW), children (CH) and natural history (NH) cohorts. Clinical sites were selected over a wide geographic range within Latin America and the Caribbean, taking into account the dynamic course of the ZIKV epidemic.
   Methods: Recruitment to the PW cohort will take place in antenatal care clinics. PW will be enrolled regardless of symptoms and followed over the course of pregnancy, approximately every 4 weeks. PW will be revisited at delivery (or after miscarriage/abortion) to assess birth outcomes, including microcephaly and other congenital abnormalities according to the evolving definition of congenital Zika syndrome (CZS). After birth, children will be followed for 2 years in the CH cohort. Follow-up visits are scheduled at ages 1-3, 4-6, 12, and 24 months to assess neurocognitive and developmental milestones. In addition, a NH cohort for the characterization of symptomatic rash/fever illness was designed, including follow-up to capture persisting health problems.
   Blood, urine, and other biological materials will be collected, and tested for ZIKV and other relevant arboviral diseases (dengue, chikungunya, yellow fever) using RT-PCR or serological methods. A virtual, decentralized biobank will be created. Reciprocal clinical monitoring has been established between partner sites. Substudies of ZIKV seroprevalence, transmission clustering, disabilities and health economics, viral kinetics, the potential role of antibody enhancement, and co-infections will be linked to the cohort studies.
   Discussion: Results of these large cohort studies will provide better risk estimates for birth defects and other developmental abnormalities associated with ZIKV infection including possible co-factors for the variability of risk estimates between other countries and regions. Additional outcomes include incidence and transmission estimates of ZIKV during and after pregnancy, characterization of short and long-term clinical course following infection and viral kinetics of ZIKV.
C1 [Jaenisch, Thomas; Rosenberger, Kerstin Daniela; Morales, Ivonne; Tobian, Frank; Uhlmann, Lorenz; Pohl, Moritz; Schretzmann, Julius; Leege, Annika] Univ Heidelberg Hosp, Heidelberg, Germany.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Viana, Isabelle F. T.; Lins, Roberto D.; Bispo de Filippis, Ana Maria; Machado Duarte, Ana Claudia; Espindola, Otavio de Melo; Bonaldo, Myrna; Rabello, Renata; Damasceno, Luana] Aggeu Magalhaes Inst, Oswaldo Cruz Fdn, Recife, PE, Brazil.
   [Avelino-Silva, Vivian I.; Segurado, Aluisio; Angel Villar, Luis; Consuelo Miranda, Maria] Univ Sao Paulo, Sao Paulo, Brazil.
   [Mayaud, Philippe; Alexander, Neal; Angel Villar, Luis] LSHTM, London, England.
   [Gotuzzo, Eduardo] Fed Univ Bahia UFB, Salvador, BA, Brazil.
   [Tami, Adriana] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol, Groningen, Netherlands.
   [Marques, Ernesto T. A.] Univ Carabobo, Fac Ciencias Salud, Valencia, Venezuela.
   [Tami, Adriana] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol, Groningen, Netherlands.
   [Tami, Adriana] Univ Carabobo, Fac Ciencias Salud, Valencia, Venezuela.
   [Consuelo Miranda, Maria; Lozano, Anyela] Ciudad Hosp Enrique Tejera, Valencia, Spain.
   [La Rosa, Yenifer] Ctr Policlin Valencia Vina, Lab Clin Vina, Valencia, Venezuela.
   [Murillo, Marianela] Inst Especialidades Quirurg Ios Mangos, Valencia, Venezuela.
   [Angel Villar, Luis; Consuelo Miranda, Maria; Lozano, Anyela; Mauricio Herrera, Victor; Gomez, Adriana; Margarita Gelvez, Rosa] Univ Ind Santander, Bucaramanga, Colombia.
   [Ortiz, Ricardo; Mauricio Herrera, Victor] Univ Autonoma Bucaramanga UNAB Hosp Local Norte I, Bucaramanga, Colombia.
   [Soria, Carmen; Dimitrakis, Lady] Univ Catolica Santiago Guayaquil, SOSECALI C Ltda, Guayaquil, Ecuador.
   [Paola Salgado, Silvia; Regato Arrata, Mary] Inst Nacl Invest Salud Publ Dr Leopoldo Izquieta, Guayaquil, Ecuador.
   [Gotuzzo, Eduardo; Guerra Allison, Humberto; Talledo, Michael] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander Humboldt, Humboldt, Germany.
   [Saba Villarroel, Paola Mariela] Ctr Nacl Enfermedades Trop CENETROP, Santa Cruz, CA, Bolivia.
   [Torres, Eric Martinez; Guzman, Maria G.; Martinez Rodriguez, Pedro A.; Alvarez Vera, Mayling; Galindo Santana, Belkis; Reyes, Alicia; Serrano Alvarez, Silvia] Pedro Kouri Trop Med Inst IPK, Havana, Cuba.
   [Ferriol Dorticos, Diana] MINSAP, Secc Materno Infantil, Cienfuegos, Cuba.
   [Hegewisch-Taylor, Jennifer; Alpuche-Aranda, Celia; Lopez-Gatell, Hugo] Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas Inst, Cuernavaca, Morelos, Mexico.
   [Gonzalez-Diaz, Esteban] Hosp Civil Guadalajara, Unidad Vigilancia Epidemiol Hosp Med Prevent, Fray Antonio Alcalde O P, Mexico.
   [Pavia-Ruz, Norma] Univ Autonoma Yucatan, Ctr Invest Reg Dr Hideyo Noguchi, Mexico City, DF, Mexico.
   [Gonzalez, Cesar; Grajales, Concepcion; Rojas, Teresita; Arriaga, Lumumba; Vallejos, Alfonso; Tynevez, Dominique] INSERM, Concepcion, Chile.
   [de Lamballerie, Xavier; Thirion, Laurence] AixMarseille Univ, Inserm 1207, INSERM Gouadelo, IRD 190,Unite Virus Emergents, Marseille, France.
   [Drexler, Jan Felix] Charite Univ Med Berlin, Berlin, Germany.
   [Drexler, Jan Felix] Free Univ Berlin, Berlin, Germany.
   [Drexler, Jan Felix] Berlin Inst Hlth, Inst Virol, Berlin, Germany.
   [Rockx, Barry; van Gorp, Eric; Koopmans, Marion] Erasmus MC, Rotterdam, Netherlands.
   [Avelino-Silva, Vivian I.; Segurado, Aluisio] Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian I.; Segurado, Aluisio] Univ Sao Paulo, Fac Med, Inst Med Trop, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian I.] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Mayaud, Philippe; Alexander, Neal; Nacul, Luis] London Sch Hyg & Trop Med, London, England.
   [Tami, Adriana] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol, Groningen, Netherlands.
   [Tami, Adriana; Bethencourt, Sarah] Univ Carabobo, Fac Ciencias Salud, Valencia, Venezuela.
   [Miranda, Maria C.; Villar, Luis A.] Univ Ind Santander, Bucaramanga, Colombia.
   [Rosenberger, Kerstin D.; Jaenisch, Thomas] Heidelberg Univ Hosp, Sect Clin Trop Med, Dept Infect Dis, INF 324, D-69120 Heidelberg, Germany.
   [Rosenberger, Kerstin D.; Jaenisch, Thomas] German Ctr Infect Res DZIF, Heidelberg Site, Cologne, Germany.
   [Pohl, Moritz] Heidelberg Univ Hosp, Inst Med Biometry & Informat, Heidelberg, Germany.
   [Viana, Isabelle F. T.] Fundacao Oswaldo Cruz, FIOCRUZ, Aggeu Magalhaes Inst, Recife, PE, Brazil.
   [Rabello, Renata; Brasil, Patricia] Fundacao Oswaldo Cruz, FIOCRUZ, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil.
   [Soria, Carmen] Univ Catolic Santiago Guayaquil, Guayaquil, Ecuador.
   [Soria, Carmen] SOSECALI C Ltda, Guayaquil, Ecuador.
   [Salgado, Silvia P.] Inst Nacl Invest Salud Publ Dr Leopold Izquieta P, Guayaquil, Ecuador.
   [Gotuzzo, Eduardo] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru.
   [Guzman, Maria G.; Martinez, Pedro A.] Pedro Kouri Trop Med Inst IPK, Havana, Cuba.
   [Lopez-Gatell, Hugo; Hegewisch-Taylor, Jennifer] Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca, Morelos, Mexico.
   [Borja-Aburto, Victor H.; Gonzalez, Cesar] Mexican Inst Social Secur, Mexico City, Mexico.
   [Netto, Eduardo M.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Villarroel, Paola M. Saba] Ctr Nacl Enfermedades Trop CENETROP, Santa Cruzde SierraBoliv, Bolivia.
   [Hoen, Bruno] Ctr Hosp Univ Pointe A Pitre, Ctr Invest Clin 1424, INSERM, Pointe A Pitre, France.
   [Hoen, Bruno] Ctr Hosp Univ Pointe A Pitre, Serv Malad Infect & Trop, Dermatol, Med Interne, Pointe A Pitre, France.
   [Hoen, Bruno] Univ Antilles Guyane, Fac Med Hyacinthe Bastaraud, F-4537 Pointe A Pitre, EA, France.
   [Rockx, Barry; Koopmans, Marion] Erasmus MC, WHO CC Arbovirus & Hemorrhag Fever Viruses Refere, Dept Virosci, Rotterdam, Netherlands.
   [de Lamballerie, Xavier] Aix Marseille Univ, Marseille, France.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
RP Jaenisch, T (corresponding author), Heidelberg Univ Hosp, Sect Clin Trop Med, Dept Infect Dis, INF 324, D-69120 Heidelberg, Germany.; Jaenisch, T (corresponding author), German Ctr Infect Res DZIF, Heidelberg Site, Cologne, Germany.
EM thomas.jaenisch@urz.uni-heidelberg.de
RI Uhlmann, Lorenz/AAL-9839-2020; Herrera, Victor/ABB-4480-2020;
   Avelino-Silva, Vivian I/L-2640-2013; Segurado, Aluisio C/K-2229-2012
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Segurado, Aluisio
   C/0000-0002-6311-8036; Tami, Adriana/0000-0002-1918-9144; Martinez,
   Pedro A./0000-0002-9886-6448
FU European Union's Horizon 2020 Research and Innovation Program under
   ZIKAlliance [734548]; Deutsche ForschungsgemeinschaftGerman Research
   Foundation (DFG); Ruprecht-Karls-Universitat Heidelberg;
   Baden-Wurttemberg Ministry of Science, Research and the Arts; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR001863, UL1TR001863, UL1TR001863, UL1TR001863, UL1TR001863]
   Funding Source: NIH RePORTER
FX This work is supported by the European Union's Horizon 2020 Research and
   Innovation Program under ZIKAlliance Grant Agreement no. 734548; the
   study also received partial funding from Deutsche Forschungsgemeinschaft
   funding programme Open Access Publishing, Baden-Wurttemberg Ministry of
   Science, Research and the Arts and by Ruprecht-Karls-Universitat
   Heidelberg. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Anaya JM, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0601-y
   Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Bayley N., 2006, BAYLEY SCALES INFANT
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Broutet N, 2016, NEW ENGL J MED, V374, P1506, DOI 10.1056/NEJMp1602708
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Cauchemez S, 2016, LANCET, V387, P2125, DOI 10.1016/S0140-6736(16)00651-6
   Cavalheiro S, 2016, CHILD NERV SYST, V32, P1057, DOI 10.1007/s00381-016-3074-6
   Charrel R, 2017, J CLIN MICROBIOL, V55, P3219, DOI 10.1128/JCM.00987-17
   Charrel RN, 2016, B WORLD HEALTH ORGAN, V94, P574, DOI 10.2471/BLT.16.171207
   Cleton NB, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003580
   Corman VM, 2016, B WORLD HEALTH ORGAN, V94, P880, DOI 10.2471/BLT.16.175950
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   Culjat M, 2016, CLIN INFECT DIS, V63, P805, DOI 10.1093/cid/ciw324
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   de Oliveira WK, 2017, NEW ENGL J MED, V376, P1591, DOI 10.1056/NEJMc1608612
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   DICK GWA, 1953, T ROY SOC TROP MED H, V47, P13, DOI 10.1016/0035-9203(53)90021-2
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Dudley DM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12204
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   ECLAMC, 2015, FREQ MICR AO NASC BR
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Ferguson NM, 2016, SCIENCE, V353, P353, DOI 10.1126/science.aag0219
   Fischer C, 2018, EMERG INFECT DIS, V24, P888, DOI 10.3201/eid2405.171747
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Frank C, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.23.30252
   Freour T, 2016, EUROSURVEILLANCE, V21, P10, DOI 10.2807/1560-7917.ES.2016.21.23.30254
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Hoen B, 2018, NEW ENGL J MED, V378, P985, DOI 10.1056/NEJMoa1709481
   Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006
   ICMJE, DEF ROL AUTH CONTR
   Jaenisch T, 2017, B WORLD HEALTH ORGAN, V95, P191, DOI [10.2471/BLT.16.178608, 10.2471/blt.16.178608]
   Jaenisch T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1440-3
   Jaenisch T, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002320
   Krauer F, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002203
   L'Huillier AG, 2017, J CLIN MICROBIOL, V55, P2462, DOI 10.1128/JCM.00442-17
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanteri MC, 2016, TRANSFUSION, V56, P1907, DOI 10.1111/trf.13677
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   Cuevas EL, 2016, MMWR-MORBID MORTAL W, V65, P1409, DOI 10.15585/mmwr.mm6549e1
   Magalhaes T, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006055
   Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2
   Matheron S, 2016, CLIN INFECT DIS, V63, DOI 10.1093/cid/ciw509
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i720
   Meaney-Delman D, 2016, OBSTET GYNECOL, V128, P724, DOI 10.1097/AOG.0000000000001625
   Mecharles S, 2016, LANCET, V387, P1481, DOI 10.1016/S0140-6736(16)00644-9
   Mehrjardi MZ, 2017, JPN J RADIOL, V35, P341, DOI 10.1007/s11604-017-0641-z
   Messina JP, 2016, ELIFE, V5, DOI 10.7554/eLife.15272
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Mogling R, 2017, EUROSURVEILLANCE, V22, P18, DOI 10.2807/1560-7917.ES.2017.22.36.30609
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
   Netto EM, 2017, MBIO, V8, DOI [10.1128/mBio.01390-17, 10.1128/mbio.01390-17]
   O'Reilly KM, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1158-8
   Oehler E, 2014, EUROSURVEILLANCE, V19, P4
   Olagnier D, 2016, DNA CELL BIOL, V35, P367, DOI 10.1089/dna.2016.3404
   Organization W. H., 2016, WHO DIR GEN SUMM OUT
   Pacheco O, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMoa1604037
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Shapiro-Mendoza CK, 2017, MMWR-MORBID MORTAL W, V66, P615, DOI 10.15585/mmwr.mm6623e1
   Sheridan MA, 2017, P NATL ACAD SCI USA, V114, pE1587, DOI 10.1073/pnas.1616097114
   Squires J, 2009, AGES STAGES QUESTION
   Swaminathan S, 2016, NEW ENGL J MED, V375, P1907, DOI 10.1056/NEJMc1610613
   Tappe D, 2016, MED MICROBIOL IMMUN, V205, P269, DOI 10.1007/s00430-015-0445-7
   Teixeira MG, 2016, AM J PUBLIC HEALTH, V106, P601, DOI 10.2105/AJPH.2016.303113
   Turmel JM, 2016, LANCET, V387, P2501, DOI 10.1016/S0140-6736(16)30775-9
   van der Linden V, 2016, MMWR-MORBID MORTAL W, V65, P1343, DOI 10.15585/mmwr.mm6547e2
   Van Kerkhove MD, 2016, LANCET GLOB HEALTH, V4, pE911, DOI 10.1016/S2214-109X(16)30255-8
   Ventura CV, 2016, LANCET, V387, P2502, DOI 10.1016/S0140-6736(16)30776-0
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   Venturi G, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.8.30148
   Villarroel PMS, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006239
   Wong SJ, 2017, EBIOMEDICINE, V16, P136, DOI 10.1016/j.ebiom.2017.01.008
   World Health Organization, 2016, ZIK VIR DIS INT CAS
   World Health Organization, 2016, ZIK VIR INF UPD EV C
NR 85
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD DEC 26
PY 2019
VL 19
IS 1
AR 1081
DI 10.1186/s12879-019-4685-9
PG 14
WC Infectious Diseases
SC Infectious Diseases
GA KI2EP
UT WOS:000511160500003
PM 31878895
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Pereira, IO
   Pascom, ARP
   Mosimann, G
   Perini, FB
   Coelho, R
   Rick, F
   Benzaken, A
   Avelino-Silva, VI
AF Pereira, I. O.
   Pascom, A. R. P.
   Mosimann, G.
   Barros Perini, F.
   Coelho, R. A.
   Rick, F.
   Benzaken, A.
   Avelino-Silva, V. I.
TI Post-exposure prophylaxis following consented sexual exposure: impact of
   national recommendations on user profile, drug regimens and estimates of
   averted HIV infections
SO HIV MEDICINE
LA English
DT Article
DE antiretroviral; averted infections; HIV; post-exposure prophylaxis;
   sexual exposure
ID MEN; PREVENTION; ACCESS
AB Objectives The aim of the study was to describe the characteristics, impact and outreach of post-exposure prophylaxis (PEP) for sexual exposure in Brazil. Methods We used secondary data from the Brazilian Ministry of Health to describe the impact of national guidelines on the frequency of prescription, user profile and antiretroviral regimens. We also estimated the number of potentially averted HIV infections attributable to PEP for consented sexual exposure between 2009 and 2017. Results A total of 260 457 PEP regimens were prescribed to individuals >= 14 years old; 104 613 (40.2%) were prescribed for consented sexual exposure, with an increasing frequency since 2011. Drugs used in PEP regimens underwent significant modifications during the period, reflecting national recommendations. We estimated that there were up to 3138 potentially averted HIV infections attributable to PEP for consented sexual exposure between 2009 and 2017. Conclusions In the context of a combined HIV prevention strategy, PEP is still an essential tool for individuals for whom other methods are contraindicated or fail to be applied.
C1 [Pereira, I. O.; Pascom, A. R. P.; Mosimann, G.; Barros Perini, F.; Coelho, R. A.; Rick, F.] Minist Hlth Brazil, Dept Chron Condit & Sexually Transmitted Infect, Brasilia, DF, Brazil.
   [Rick, F.; Benzaken, A.] Aids Hlth Care Fdn, Global Programm, Sao Paulo, Brazil.
   [Benzaken, A.] Trop Med Fdn Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Avelino-Silva, V. I.] Univ Sao Paulo, Med Sch, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Av Dr Eneas Carvalho Aguiar, BR-05403000 Sao Paulo, SP, Brazil.
EM viviansil-va87@gmail.com
RI Avelino-Silva, Vivian I/L-2640-2013; Rick, Fernanda/AAR-5551-2020
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Rick,
   Fernanda/0000-0002-0817-094X
FU Organizacao Panamericana de Saude (OPAS)
FX We thank the colleagues at the Strategic Information unit for sharing
   valuable information for this analysis. This study was partially funded
   by Organizacao Panamericana de Saude (OPAS).
CR Australian Society for HIV Medicine, 2016, POSTEXPOSURE PROPHYL
   Bourry O, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-78
   Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101
   Cresswell F, 2016, INT J STD AIDS, V27, P713, DOI 10.1177/0956462416641813
   Jain S, 2015, CLIN INFECT DIS, V60, pS200, DOI 10.1093/cid/civ094
   Kerr L, 2018, MEDICINE, V97, pS9, DOI [10.1097/MD.0000000000010573, 10.1097/md.0000000000010573]
   Martin JN, 2004, AIDS, V18, P787, DOI 10.1097/00002030-200403260-00010
   McFaul K, 2015, INT J STD AIDS, V26, P521, DOI 10.1177/0956462414547525
   Ministerio da Saude Secretaria de Vigilancia em Saude, 2017, B EP HIV AIDS
   Ministerio da Saude Secretaria de Vigilancia em Saude, 2017, REL MON CLIN HIV
   Ministerio da Saude Secretaria de Vigilancia em Saude Departamento de DST Aids e Hepatites Virais, 2010, REC TER ANT AD INF H
   Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia Prevencao e Controle das Infeccoes Sexualmente Transmissiveis do HIV/Aids e das Hepatites Virais, 2018, CLIN PROT THER GUID
   Morrison SA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197998
   Otten RA, 2000, J VIROL, V74, P9771, DOI 10.1128/JVI.74.20.9771-9775.2000
   Richens J, 2005, SEX TRANSM INFECT, V81, P190, DOI 10.1136/sti.2005.014886
   Roedling S, 2008, INT J STD AIDS, V19, P241, DOI 10.1258/ijsa.2007.007216
   Schechter M, 2004, JAIDS-J ACQ IMM DEF, V35, P519, DOI 10.1097/00126334-200404150-00010
   Tsai CC, 1998, J VIROL, V72, P4265, DOI 10.1128/JVI.72.5.4265-4273.1998
   Waldo CR, 2000, AIDS, V14, P1035, DOI 10.1097/00002030-200005260-00016
NR 19
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
EI 1468-1293
J9 HIV MED
JI HIV Med.
PD APR
PY 2020
VL 21
IS 4
BP 240
EP 245
DI 10.1111/hiv.12825
EA NOV 2019
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA KT4UY
UT WOS:000496602500001
PM 31730296
DA 2020-12-01
ER

PT J
AU Pascom, AR
   Pinho, REGG
   Rick, F
   Veras, NMC
   Perini, FD
   Meireles, MV
   Pereira, GF
   Benzaken, AS
   Avelino-Silva, VI
AF Pascom, Ana R.
   Pinho, Rosana E. G. G.
   Rick, Fernanda
   Veras, Nazle M. C.
   Perini, Filipe de Barros
   Meireles, Mariana V.
   Pereira, Gerson F.
   Benzaken, Adele S.
   Avelino-Silva, Vivian I.
TI Comparison of cumulative viraemia following treatment initiation with
   different antiretroviral regimens: a real-life study in Brazil
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE HIV; antiretroviral treatment; cumulative viremia; efficacy;
   antiretroviral regimen; real-life
ID HIV-1-INFECTED ADOLESCENTS; EFFICACY; DOLUTEGRAVIR; SAFETY
AB Introduction The relative efficacy of different antiretroviral (ART) regimens has been extensively evaluated in the context of clinical trials, using HIV viral load (VL) measurements at pre-specified timepoints after ART onset. However, data from real-life studies using combined longitudinal measurements of cumulative viraemia are scarce. This study aimed to address the independent effect of different ART regimens on HIV cumulative viraemia over the first 12 months after treatment initiation, using programmatic data from the Ministry of Health of Brazil. Methods Retrospective cohort study analysing cumulative viraemia under the most frequently used ART regimens in Brazil (tenofovir, lamivudine and dolutegravir (regimen 1); tenofovir, lamivudine and efavirenz (regimen 2); tenofovir, lamivudine and ritonavir-boosted atazanavir (regimen 3)). Results and Discussion We included 112,243 patients >12 years old who received their first ART prescription between January 2014 and August 2017. Univariate analysis indicated that cumulative viraemia was significantly lower in patients receiving regimen 1 as compared with those receiving regimens 2 or 3 (p<0.0001 for both pairwise comparisons). In a multivariable analysis adjusted for age, sex, baseline T CD4+ counts and baseline HIV VL, ART regimen persisted with statistically significant effect on 12-month cumulative viraemia. The model predicted a 45-unit increase in log(10) copy-days/mL cumulative viraemia for regimen 2 as compared with regimen 1, and a 70-unit increase in log(10) copy-days/mL cumulative viraemia for regimen 3 as compared with regimen 1 (95%CI 41 to 49 and 61 to 79 respectively; p<0.001 for both comparisons). In models restricted to youths (13 to 24 years old) and female patients, ART regimen had similar effects. ART regimen with dolutegravir in association with a tenofovir-lamivudine backbone was superior to regimens containing efavirenz or boosted atazanavir in reducing HIV VL, as shown by cumulative viraemia over the first 12 months after treatment initiation. The superiority persisted even after adjusting the analysis for potential confounders. Conclusions Our findings could bring direct benefits to patients as suggested by lower viral replication during treatment, lower risk of HIV transmission, and a potential reduction in resistance mutations in the initial 12 months under ART.
C1 [Pascom, Ana R.; Pinho, Rosana E. G. G.; Rick, Fernanda; Veras, Nazle M. C.; Perini, Filipe de Barros; Meireles, Mariana V.; Pereira, Gerson F.] Minist Hlth Brazil, HIV AIDS & Viral Hepatitis, Dept Surveillance Prevent & Control STIs, Brasilia, DF, Brazil.
   [Benzaken, Adele S.] Trop Med Fdn Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Avelino-Silva, Vivian I.] Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Ave Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
EM viviansilva87@gmail.com
RI Avelino-Silva, Vivian I/L-2640-2013; Rick, Fernanda/AAR-5551-2020
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Rick,
   Fernanda/0000-0002-0817-094X; Meireles, Mariana/0000-0002-2243-7145
FU OPAS - Organizacao Panamericana de Saude
FX OPAS - Organizacao Panamericana de Saude partially funded this study.
CR Batista CJB, 2018, C RETR OPP DIS BOST
   Briand C, 2017, J ANTIMICROB CHEMOTH, V72, P837, DOI 10.1093/jac/dkw464
   Davy-Mendez T, 2018, AIDS, V32, P2593, DOI [10.1097/qad.0000000000001990, 10.1097/QAD.0000000000001990]
   Delaney JA, 2019, EPIDEMIOLOGY, V30, P69, DOI 10.1097/EDE.0000000000000930
   Gianotti N, 2018, INT J ANTIMICROB AG, V52, P492, DOI 10.1016/j.ijantimicag.2018.07.001
   Hughes AJ, 2018, AIDS, V32, P1881, DOI 10.1097/QAD.0000000000001914
   Kandel CE, 2015, DRUG DES DEV THER, V9, P3547, DOI 10.2147/DDDT.S84850
   Kanters S, 2016, LANCET HIV, V3, pE510, DOI 10.1016/S2352-3018(16)30091-1
   le Roux SM, 2019, PEDIATR INFECT DIS J, V38, P70, DOI 10.1097/INF.0000000000002193
   Lima V, 2009, JAIDS-J ACQ IMM DEF, V51, P3, DOI 10.1097/QAI.0b013e31819e721b
   Lima VD, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18617
   Lima VD, 2008, AIDS, V22, P2371, DOI 10.1097/QAD.0b013e328315cdd3
   Meireles MV, 2019, AIDS, V33, P1663, DOI 10.1097/QAD.0000000000002254
   Meireles MV, 2018, C RETR OPP DIS BOST
   Modjarrad K, 2010, LANCET INFECT DIS, V10, P455, DOI 10.1016/S1473-3099(10)70093-1
   Patel DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105653
   Robertson MM, 2019, JAIDS-J ACQ IMM DEF, V80, P46, DOI 10.1097/QAI.0000000000001877
   Rutherford GW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162775
   Tasker SA, 1999, ANN INTERN MED, V131, P430, DOI 10.7326/0003-4819-131-6-199909210-00006
   Viani RM, 2015, PEDIATR INFECT DIS J, V34, P1207, DOI 10.1097/INF.0000000000000848
NR 20
TC 1
Z9 1
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD NOV
PY 2019
VL 22
IS 11
AR e25397
DI 10.1002/jia2.25397
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA JS3DW
UT WOS:000500190400007
PM 31743620
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Nisida, IVV
   Boulos, MIC
   Da Silva, LMB
   Mayaud, P
   Avelino-Silva, VI
   Segurado, AC
AF Vichr Nisida, Isabelle Vera
   Castro Boulos, Maria-Ivete
   Britto Da Silva, Lia Maria
   Mayaud, Philippe
   Avelino-Silva, Vivian Iida
   Segurado, Aluisio Cotrim
TI Predictors of Adherence to HIV Post-Exposure Prophylaxis and Retention
   in Care After an Episode of Sexual Violence in Brazil
SO INTERNATIONAL JOURNAL OF SEXUAL HEALTH
LA English
DT Meeting Abstract
DE sexual violence; sexually transmitted infections (STI); retention in
   care
C1 [Vichr Nisida, Isabelle Vera] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Castro Boulos, Maria-Ivete; Britto Da Silva, Lia Maria; Mayaud, Philippe; Avelino-Silva, Vivian Iida; Segurado, Aluisio Cotrim] Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Mayaud, Philippe] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England.
RI Segurado, Aluisio C/K-2229-2012; Avelino-Silva, Vivian I/L-2640-2013
OI Segurado, Aluisio C/0000-0002-6311-8036; Avelino-Silva, Vivian
   I/0000-0002-6660-3088
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1931-7611
EI 1931-762X
J9 INT J SEX HEALTH
JI Int. J. Sex. Health
PD SEP 23
PY 2019
VL 31
SU 1
BP A377
EP A377
PG 1
WC Psychology, Clinical; Public, Environmental & Occupational Health;
   Social Sciences, Interdisciplinary
SC Psychology; Public, Environmental & Occupational Health; Social Sciences
   - Other Topics
GA JC5RK
UT WOS:000489340402119
DA 2020-12-01
ER

PT J
AU Freitas, AC
   Avelino-Silva, VI
   Gutierrez, EB
   Marques, HHD
   Durigon, GS
   Segurado, AC
AF Freitas, Angela Carvalho
   Avelino-Silva, Vivian Iida
   Gutierrez, Eliana Battaggia
   de Souza Marques, Heloisa Helena
   Durigon, Giuliana Stravinskas
   Segurado, Aluisio Cotrim
TI HIV-infected youths transitioning from pediatric to adult outpatient
   care in a teaching tertiary care hospital in Sao Paulo city, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Adolescent; Young adult; Pediatric HIV; Transition-to-care; Adult care
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; VIROLOGICAL
   FAILURE; PERINATAL HIV; YOUNG-ADULTS; US YOUTH; CHILDREN; ADOLESCENTS;
   NONADHERENCE; MORTALITY
AB Background: HIV-infected children surviving until adulthood have been transitioning to adult outpatient health care service in Brazil since the late 2000's. Deterioration of clinical condition is expected during this period, as reported among youths with non-communicable chronic diseases. Despite their young age, they are long-term hosts of the virus, have prolonged exposure to antiretroviral therapy and have suffered from the social determinants and stigma of HIV infection since early childhood.
   Objectives: This study aimed to (1) describe demographic and clinical characteristics at the first appointment at adult care service following pediatric care of a cohort of Brazilian youths living with HIV since childhood; and (2) retrospectively address adherence and clinical variables in the last two years of pediatric follow-up.
   Methods: Descriptive study.
   Results: 41 consecutive patients referred to adult outpatient care from a pediatric HIV unit were enrolled, median age 19 years, and median lifetime CD4+ nadir 117 cell/mm(3); 89% reported previous AIDS-defining conditions. At first laboratory assessment in adult care, only 46% had undetectable (<400 copies/ml) HIV viral load and the median CD4+ count was 250 cell/mm(3).
   Conclusion: Youths living with HIV at the transition from pediatric to adult care had poor treatment adherence, low lifetime CD4+ cell nadir, low CD4 cell count and detectable HIV viral load. Health care providers should closely monitor these adolescents in a youth friendly environment, prepared for open communication about all aspects of their health. (C) 2019 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Freitas, Angela Carvalho; Avelino-Silva, Vivian Iida; Segurado, Aluisio Cotrim] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, SP, Brazil.
   [Gutierrez, Eliana Battaggia] Serv Atendimento Especializado DST & AIDS, Secretaria Saude Prefeitura Municipio Sao Paulo, Sao Paulo, SP, Brazil.
   [de Souza Marques, Heloisa Helena; Durigon, Giuliana Stravinskas] Univ Sao Paulo, Fac Med, Inst Crianca, Sao Paulo, SP, Brazil.
RP Freitas, AC (corresponding author), Rua Ferreira de Araujo,789 SEAP HCFMUSP, BR-05428002 Sao Paulo, SP, Brazil.
EM angela.freitas@hc.fm.usp.br
RI Avelino-Silva, Vivian I/L-2640-2013; Segurado, Aluisio C/K-2229-2012
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Segurado, Aluisio
   C/0000-0002-6311-8036
CR Acree ME, 2017, PEDIATR ANN, V46, pE198, DOI 10.3928/19382359-20170424-02
   Agwu AL, 2015, J ADOLESCENT HEALTH, V56, P345, DOI 10.1016/j.jadohealth.2014.11.009
   Agwu AL, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18579
   [Anonymous], 1994, MMWR Recomm Rep, V43, P1
   Badell Martina L, 2013, Infect Dis Obstet Gynecol, V2013, P301763, DOI 10.1155/2013/301763
   Barlow-Mosha L, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18600
   Blazquez D, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0853-8
   Buchanan AL, 2012, PEDIATRICS, V129, pE1244, DOI 10.1542/peds.2011-1740
   Byrne L, 2014, J INT AIDS SOC, V17, P130, DOI 10.7448/IAS.17.4.19693
   Campbell F, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009794.pub2
   Casseb J, 2012, REV INST MED TROP SP, V54, P257, DOI 10.1590/S0036-46652012000500004
   Coelho L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098666
   Cohen S, 2016, NEUROLOGY, V86, P19, DOI 10.1212/WNL.0000000000002209
   Cordova E, 2015, ENFERM INFEC MICR CL, V33, P134, DOI 10.1016/j.eimc.2014.05.005
   de Mulder M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052155
   de Paula CC, 2011, REV BRAS ENFERM, V64, P658, DOI 10.1590/S0034-71672011000400005
   Favarato G, 2017, J INT AIDS SOC, V20, P75
   Fortuny C, 2015, PEDIATR INFECT DIS J, V34, pS36, DOI 10.1097/INF.0000000000000663
   Judd A, 2017, HIV MED, V18, P171, DOI 10.1111/hiv.12411
   Kacanek D, 2015, AIDS, V29, P1227, DOI 10.1097/QAD.0000000000000697
   Kakkar F, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0644-4
   Kim SH, 2014, AIDS, V28, P1945, DOI 10.1097/QAD.0000000000000316
   Lipshultz SE, 2013, JAMA PEDIATR, V167, P520, DOI 10.1001/jamapediatrics.2013.1206
   Machado DM, 2016, BRAZ J INFECT DIS, V20, P229, DOI 10.1016/j.bjid.2015.12.009
   Ministerio da Sande Secretaria de Acoes Basicas de Sande, 1987, REC PREV CONTR INF P
   Ministerio da Sande Secretaria de Politicas de Sande, 2001, COORD NAC DST AIDS G
   Ministerio da Sande Secretaria de Vigilancia em n Sande Programa Nacional de DST e AIDS, 2009, REC TER ANT CRIANC I
   Mirani G, 2015, CLIN INFECT DIS, V61, P1850, DOI 10.1093/cid/civ687
   Nichols SL, 2016, PEDIATR INFECT DIS J, V35, P649, DOI 10.1097/INF.0000000000001131
   Rudy BJ, 2010, AIDS PATIENT CARE ST, V24, P97, DOI 10.1089/apc.2009.0198
   Ryscavage P, 2016, AIDS CARE, V28, P561, DOI 10.1080/09540121.2015.1131967
   Cruz MLS, 2015, AIDS CARE, V27, P6, DOI 10.1080/09540121.2014.940270
   Schtscherbyna A, 2012, INT J INFECT DIS, V16, pE872, DOI 10.1016/j.ijid.2012.07.019
   Sheth SS, 2015, AIDS CARE, V27, P350, DOI 10.1080/09540121.2014.998610
   Slogrove A, 2017, J INT AIDS SOC, V20, P9
   Tanaka Luana Fiengo, 2015, Rev Paul Pediatr, V33, P327, DOI 10.1016/j.rpped.2014.12.003
   Tanaka LF, 2015, J PEDIAT-BRAZIL, V91, P152, DOI 10.1016/j.jped.2014.06.007
   Van der Linden D, 2013, J PEDIATR INFECT DIS, V2, P382, DOI 10.1093/jpids/pis106
   Westling K, 2016, INFECT DIS-NOR, V48, P449, DOI 10.3109/23744235.2016.1143964
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2019
VL 23
IS 5
BP 291
EP 297
DI 10.1016/j.bjid.2019.07.004
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA JW6UT
UT WOS:000503185200002
PM 31479628
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Nisida, IVV
   Boulos, MIC
   da Silva, LMB
   Mayaud, P
   Avelino-Silva, VI
   Segurado, AC
AF Vichr Nisida, Isabelle Vera
   Boulos, Maria-Ivete Castro
   Britto da Silva, Lia Maria
   Mayaud, Philippe
   Avelino-Silva, Vivian Iida
   Segurado, Aluisio Cotrim
TI Predictors of Adherence to HIV Post-Exposure Prophylaxis and Retention
   in Care After an Episode of Sexual Violence in Brazil
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
DE sexual violence; HIV post-exposure prophylaxis; adherence; retention in
   care; sexually transmitted infections (STI)
ID ASSAULT; VICTIMS; SURVIVORS; HEALTH; RISK; EXPERIENCES; PREVALENCE;
   ABUSE; DRUG
AB Adherence to nonoccupational post-exposure prophylaxis (nPEP) among sexual violence (SV) victims and their retention in care after SV represent significant challenges. This study aimed at identifying predictors of adherence to nPEP and retention in clinical-laboratory follow-up among SV victims in Sao Paulo, Brazil. We conducted a retrospective cohort study of SV victims admitted to care and follow-up at the SV unit of the main reference hospital in Sao Paulo within 72 h following the SV episode. Eligible patients were submitted to a standardized protocol that included nPEP, screening, and management for other sexually transmitted infection as well as emergency contraception. Predictors of adherence to nPEP for 28 days and retention in care until discharge at 180 days after admission were analyzed. A total of 199 SV episodes in 197 victims were recorded from January 2001 to December 2013 (156 months). Of those episodes, 167 were eligible to receive nPEP and 160 (96%) actually received a prescription. Overall 104/160 [65%, 95% confidence interval (CI) 57-72] SV victims, who received nPEP, were fully adherent to nPEP up to 28 days, whereas 89/199 (45%, 95% CI 38-52) were retained in care for 180 days following admission. In multi-variate analysis, patients undergoing at least one psychological consultation (n = 126) were more likely to adhere to nPEP (adjusted odds ratio [adjOR] 8.32; 95% CI 3.0-23.3) and be retained in care for 6 months (adjOR 40.33; 95% CI 8.33-195.30) compared to patients not receiving psychological support. In contrast, study outcomes were not associated with victims' age and sex and with type of perpetrator. In our cohort, provision of psychological care was shown to be associated with enhanced adherence to nPEP and retention in care.
C1 [Vichr Nisida, Isabelle Vera; Boulos, Maria-Ivete Castro; Britto da Silva, Lia Maria; Mayaud, Philippe; Avelino-Silva, Vivian Iida; Segurado, Aluisio Cotrim] Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Ave Dr Eneas de Carvalho Aguiar 470, BR-05430000 Sao Paulo, SP, Brazil.
   [Mayaud, Philippe] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England.
RP Segurado, AC (corresponding author), Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Ave Dr Eneas de Carvalho Aguiar 470, BR-05430000 Sao Paulo, SP, Brazil.
EM segurado@usp.br
RI Segurado, Aluisio C/K-2229-2012; Nisida, Isabelle V. V./H-7903-2013;
   Avelino-Silva, Vivian I/L-2640-2013
OI Segurado, Aluisio C/0000-0002-6311-8036; Avelino-Silva, Vivian
   I/0000-0002-6660-3088
CR Arend E, 2013, J ASSOC NURSE AIDS C, V24, P154, DOI 10.1016/j.jana.2012.02.007
   Basile KC, 2016, AM J PUBLIC HEALTH, V18, P1
   Bass JK, 2013, NEW ENGL J MED, V368, P2182, DOI 10.1056/NEJMoa1211853
   Black M. C., 2010, NATL INTIMATE PARTNE
   BOWNES IT, 1991, ACTA PSYCHIAT SCAND, V83, P27, DOI 10.1111/j.1600-0447.1991.tb05507.x
   Brasil . Ministerio da Saude. Secretaria de AtencAo a Saude, 2012, DEP AC PROGR ESTR PR
   Campbell R, 2008, AM PSYCHOL, V63, P702, DOI 10.1037/0003-066X.63.8.702
   CERQUEIRA D., 2018, ATLAS VIOLENCIA 2018
   Chacko L, 2012, SEX TRANSM INFECT, V88, P335, DOI 10.1136/sextrans-2011-050371
   Draughon JE, 2012, PSYCHOL HEALTH MED, V17, P235, DOI 10.1080/13548506.2011.579984
   DREZETT J, 1999, REV BRAS GINECOL OBS, V21, P539
   Du Mont Janice, 2011, Open AIDS J, V5, P102, DOI 10.2174/1874613601105010102
   Ford N, 2015, CLIN INFECT DIS, V60, pS182, DOI 10.1093/cid/civ093
   Ford N, 2014, AIDS, V28, P2721, DOI 10.1097/QAD.0000000000000505
   Garcia MT, 2005, SEX TRANSM DIS, V32, P214, DOI 10.1097/01.olq.0000149785.48574.3e
   Garcia-Moreno C., 2005, WHO MULTICOUNTRY STU
   Gilles C, 2010, EUR J OBSTET GYN R B, V151, P185, DOI 10.1016/j.ejogrb.2010.03.014
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Humphrey JA, 2000, J ADOLESCENT HEALTH, V27, P419, DOI 10.1016/S1054-139X(00)00168-3
   JENNY C, 1990, NEW ENGL J MED, V322, P713, DOI 10.1056/NEJM199003153221101
   Jewkes R., 2002, WORLD REPORT VIOLENC, P147
   Johnson CF, 2004, LANCET, V364, P462, DOI 10.1016/S0140-6736(04)16771-8
   Larsen ML, 2015, BJOG-INT J OBSTET GY, V122, P577, DOI 10.1111/1471-0528.13093
   Latimer J, 2017, AIDS PATIENT CARE ST, V31, P237, DOI 10.1089/apc.2016.0265
   Mason F, 2013, BEST PRACT RES CL OB, V27, P27, DOI 10.1016/j.bpobgyn.2012.08.015
   Mittendorfer-Rutz E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099869
   Muriuki EM, 2017, AIDS PATIENT CARE ST, V31, P255, DOI 10.1089/apc.2016.0274
   Patel A, 2013, INT J GYNECOL OBSTET, V123, P24, DOI 10.1016/j.ijgo.2013.04.014
   Raj A, 2000, Matern Child Health J, V4, P125, DOI 10.1023/A:1009526422148
   Roland ME, 2012, AIDS BEHAV, V16, P990, DOI 10.1007/s10461-011-9892-3
   Senn TE, 2006, J CONSULT CLIN PSYCH, V74, P720, DOI 10.1037/0022-006X.74.4.720
   Smith Dawn K., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Ullman SE, 2001, J TRAUMA STRESS, V14, P369, DOI 10.1023/A:1011125220522
   von Sternberg K, 2012, WOMEN HEALTH ISS, V22, pE283, DOI 10.1016/j.whi.2012.01.004
   Walsh K, 2016, J INTERPERS VIOLENCE, V31, P2475, DOI 10.1177/0886260515576968
   World Health Organisation, 2017, RESP CHILDR AD WHO H
   ZIERLER S, 1991, AM J PUBLIC HEALTH, V81, P572, DOI 10.2105/AJPH.81.5.572
   Zinzow HM, 2012, SOC PSYCH PSYCH EPID, V47, P893, DOI 10.1007/s00127-011-0397-1
NR 38
TC 2
Z9 2
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD SEP 1
PY 2019
VL 33
IS 9
BP 399
EP 405
DI 10.1089/apc.2019.0080
EA AUG 2019
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA IX8JR
UT WOS:000480128900001
PM 31386552
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Kallas, EG
   Zanella, LGFABD
   Moreira, CHV
   Buccheri, R
   Diniz, GBF
   Castineiras, ACP
   Costa, PR
   Dias, JZC
   Marmorato, MP
   Song, ATW
   Maestri, A
   Borges, IC
   Joelsons, D
   Cerqueira, NB
   Souza, NCSE
   Claro, IM
   Sabino, EC
   Levi, JE
   Avelino-Silva, VI
   Ho, YL
AF Kallas, Esper G.
   D'Elia Zanella, Luiz Gonzaga F. A. B.
   Moreira, Carlos Henrique, V
   Buccheri, Renata
   Diniz, Gabriela B. F.
   Castineiras, Anna Carla P.
   Costa, Priscilla R.
   Dias, Juliana Z. C.
   Marmorato, Mariana P.
   Song, Alice T. W.
   Maestri, Alvino
   Borges, Igor C.
   Joelsons, Daniel
   Cerqueira, Natalia B.
   Santiago e Souza, Nathalia C.
   Claro, Ingra Morales
   Sabino, Ester C.
   Levi, Jose Eduardo
   Avelino-Silva, Vivian, I
   Ho, Yeh-Li
TI Predictors of mortality in patients with yellow fever: an observational
   cohort study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID VIRUS OUTBREAK; ZIKA VIRUS; PCR; RESURGENCE; SPREAD; ANGOLA
AB Background Yellow fever virus infection results in death in around 30% of symptomatic individuals. The aim of this study was to identify predictors of death measured at hospital admission in a cohort of patients admitted to hospital during the 2018 outbreak of yellow fever in the outskirts of Sao Paulo city, Brazil.
   Methods In this observational cohort study, we enrolled patients with yellow fever virus from two hospitals in Sao Paolo-the Hospital das Clinicas, University of Sao Paulo and the Infectious Diseases Institute "Emilio Ribas". Patients older than 18 years admitted to hospital with fever or myalgia, headache, arthralgia, oedema, rash, or conjunctivitis were consecutively screened for inclusion in the present study. Consenting patients were included if they had travelled to geographical areas in which yellow fever virus cases had been previously confirmed. Yellow fever infection was confirmed by real-time PCR in blood collected at admission or tissues at autopsy. We sequenced the complete genomes of yellow fever virus from infected individuals and evaluated demographic, clinical, and laboratory findings at admission and investigated whether any of these measurements correlated with patient outcome (death).
   Findings Between Jan 11, 2018, and May 10, 2018, 118 patients with suspected yellow fever were admitted to Hospital das Clinicas, and 113 patients with suspected yellow fever were admitted to Infectious Diseases Institute "Emilio Ribas". 95 patients with suspected yellow fever were included in the study, and 136 patients were excluded. Three (3%) of 95 patients with suspected yellow fever who were included in the study were excluded because they received a different diagnosis, and 16 patients with undetectable yellow fever virus RNA were excluded. Therefore, 76 patients with confirmed yellow fever virus infection, based on detectable yellow fever virus RNA in blood (74 patients) or yellow fever virus confirmed only at the autopsy report (two patients), were included in our analysis. 27 (36%) of 76 patients died during the 60 day period after hospital admission. We generated 14 complete yellow fever virus genomes from the first 15 viral load-detectable samples. The genomes belonged to a single monophyletic clade of the South America I genotype, sub-genotype E. Older age, male sex, higher leukocyte and neutrophil counts, higher alanine aminotransferase, aspartate transaminase (AST), bilirubin, and creatinine, prolonged prothrombin time, and higher yellow fever virus RNA plasma viral load were associated with higher mortality. In a multivariate regression model, older age, elevated neutrophil count, increased AST, and higher viral load remained independently associated with death. All 11 (100%) patients with neutrophil counts of 4000 cells per mL or greater and viral loads of 5.1 log(10) copies/mL or greater died (95% CI 72-100), compared with only three (11%) of 27 (95% CI 2-29) among patients with neutrophil counts of less than 4000 cells per mL and viral loads of less than 5.1 log(10) copies/mL.
   Interpretation We identified clinical and laboratory predictors of mortality at hospital admission that could aid in the care of patients with yellow fever virus. Identification of these prognostic markers in patients could help clinicians prioritise admission to the intensive care unit, as patients often deteriorate rapidly. Moreover, resource allocation could be improved to prioritise key laboratory examinations that might be more useful in determining whether a patient could have a better outcome. Our findings support the important role of the virus in disease pathogenesis, suggesting that an effective antiviral could alter the clinical course for patients with the most severe forms of yellow fever.
C1 [Kallas, Esper G.; D'Elia Zanella, Luiz Gonzaga F. A. B.; Moreira, Carlos Henrique, V; Costa, Priscilla R.; Dias, Juliana Z. C.; Marmorato, Mariana P.; Song, Alice T. W.; Maestri, Alvino; Borges, Igor C.; Joelsons, Daniel; Cerqueira, Natalia B.; Claro, Ingra Morales; Sabino, Ester C.; Avelino-Silva, Vivian, I; Ho, Yeh-Li] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, BR-01246903 Sao Paulo, Brazil.
   [D'Elia Zanella, Luiz Gonzaga F. A. B.; Moreira, Carlos Henrique, V; Buccheri, Renata; Diniz, Gabriela B. F.; Castineiras, Anna Carla P.] Infect Dis Inst Emilio Ribas, Sao Paulo, Brazil.
   [Santiago e Souza, Nathalia C.; Levi, Jose Eduardo] Univ Sao Paulo, Trop Med Inst, Sao Paulo, Brazil.
RP Kallas, EG (corresponding author), Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, BR-01246903 Sao Paulo, Brazil.
EM esper.kallas@usp.br
RI Marmorato, Mariana/V-5375-2018; Avelino-Silva, Vivian I/L-2640-2013;
   Castineiras, Anna/AAB-6754-2019; Sabino, Ester Cerdeira/F-7750-2010;
   Borges, Igor Carmo/AAG-8531-2019
OI Marmorato, Mariana/0000-0002-0644-0862; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Castineiras, Anna/0000-0003-2503-9414; Sabino,
   Ester Cerdeira/0000-0003-2623-5126; Carmo Borges,
   Igor/0000-0003-2749-0313; Kallas, Esper/0000-0003-2026-6925; Moreira,
   Carlos Henrique Valente/0000-0002-4187-5482; Barros D'Elia Zanella, Luiz
   Gonzaga Francisco de Assis/0000-0002-3166-5633
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP)
FX Sao Paulo Research Foundation (FAPESP).
CR Aguiar BS, 2018, INT J INFECT DIS, V70, P20, DOI 10.1016/j.ijid.2018.02.007
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P442
   Bae HG, 2003, J VIROL METHODS, V110, P185, DOI 10.1016/S0166-0934(03)00129-0
   BEEUWKES Henry, 1936, Transactions of the Royal Society of Tropical Medicine and Hygiene, V30, P61, DOI 10.1016/S0035-9203(36)90014-7
   Blake LE, 2014, MBIO, V5, DOI 10.1128/mBio.01253-14
   de Rezende IM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006538
   Dick OB, 2012, AM J TROP MED HYG, V87, P584, DOI 10.4269/ajtmh.2012.11-0770
   Engelmann F, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003295
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Fernandes-Monteiro AG, 2015, HUM VACC IMMUNOTHER, V11, P1865, DOI 10.4161/21645515.2014.990854
   Fischer C, 2017, EMERG INFECT DIS, V23, P1867, DOI 10.3201/eid2311.171131
   Gomez MM, 2018, J GEN VIROL, V99, P536, DOI 10.1099/jgv.0.001033
   Grobbelaar AA, 2016, EMERG INFECT DIS, V22, P1854, DOI 10.3201/eid2210.160818
   Halai UA, 2017, CLIN INFECT DIS, V65, P877, DOI 10.1093/cid/cix472
   Hughes HR, 2018, EMERG INFECT DIS, V24, P1598, DOI 10.3201/eid2408.180588
   Julander JG, 2014, ANTIVIR RES, V103, P32, DOI 10.1016/j.antiviral.2013.12.011
   Kraemer MUG, 2017, LANCET INFECT DIS, V17, P330, DOI [10.1016/s1473-3099(16)30513-8, 10.1016/S1473-3099(16)30513-8]
   Lindsey NP, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay108
   Massad E, 2018, EPIDEMIOL INFECT, V146, P1219, DOI [10.1017/S0950268818001334, 10.1017/s0950268818001334]
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Monath TP, 2005, EXPERT REV VACCINES, V4, P553, DOI 10.1586/14760584.4.4.553
   Monath TP, 2003, ADV VIRUS RES, V60, P343, DOI 10.1016/S0065-3527(03)60009-6
   Nunes PCG, 2018, VIRUSES, V10, pE236
   Plotkin SA, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay130
   Quaresma JAS, 2013, REV MED VIROL, V23, P305, DOI 10.1002/rmv.1752
   Quick J, 2017, NAT PROTOC, V12, P1261, DOI 10.1038/nprot.2017.066
   Rowe EK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002777
   Secretary of Health State of Sao Paulo, 2018, B EP FEBR AM
   Shearer FM, 2017, LANCET INFECT DIS, V17, P1209, DOI 10.1016/S1473-3099(17)30419-X
   Song ATW, 2019, HEPATOLOGY, V69, P1349, DOI 10.1002/hep.30273
   ter Meulen J, 2004, J INFECT DIS, V190, P1821, DOI 10.1086/425016
   Tuboi SH, 2007, T ROY SOC TROP MED H, V101, P169, DOI 10.1016/j.trstmh.2006.04.001
   van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
   Weaver SC, 2015, NEW ENGL J MED, V372, P1231, DOI 10.1056/NEJMra1406035
   Wilder-Smith A, 2017, J TRAVEL MED, V24, P1
NR 35
TC 13
Z9 13
U1 3
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUL
PY 2019
VL 19
IS 7
BP 750
EP 758
DI 10.1016/S1473-3099(19)30125-2
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA IF1DQ
UT WOS:000472818900035
PM 31104909
DA 2020-12-01
ER

PT J
AU Koopmans, M
   de Lamballerie, X
   Jaenisch, T
   Rosenberger, KD
   Morales, I
   Marques, ETA
   Viana, IFT
   Brasil, P
   Rabello, R
   Avelino-Silva, VI
   Segurado, A
   Alexander, N
   Mayaud, P
   Netto, EM
   Tami, A
   Bethencourt, S
   Miranda, MC
   Lozano, A
   Soria, C
   Cisneros, SPS
   Gotuzzo, E
   Guzman, MG
   Rodriguez, PAM
   Lopez-Gatell, H
   Hegewisch-Taylor, J
   Borja-Aburto, VH
   Bonilla, CRG
   Hoen, B
   van Roode, M
   Rockx, B
AF Koopmans, Marion
   de lamballerie, Xavier
   Jaenisch, Thomas
   Rosenberger, Kerstin D.
   Morales, Ivonne
   Marques, Ernesto T. A.
   Viana, Isabelle F. T.
   Brasil, Patricia
   Rabello, Renata
   Avelino-Silva, Vivian I.
   Segurado, Aluisio
   Alexander, Neal
   Mayaud, Philippe
   Netto, Eduardo Martins
   Tami, Adriana
   Bethencourt, Sarah
   Consuelo Miranda, Maria
   Lozano, Anyela
   Soria, Carmen
   Salgado Cisneros, Silvia P.
   Gotuzzo, Eduardo
   Guzman, Maria G.
   Rodriguez, Pedro A. M.
   Lopez-Gatell, Hugo
   Hegewisch-Taylor, Jennifer
   Hugo Borja-Aburto, Victor
   Gonzalez Bonilla, Cesar R.
   Hoen, Bruno
   van Roode, Martine
   Rockx, Barry
CA ZIKAlliance Consortium
TI Familiar barriers still unresolved-a perspective on the Zika virus
   outbreak research response
SO LANCET INFECTIOUS DISEASES
LA English
DT Review
AB Research is an important component of an effective response to the increasing frequency of widespread infectious disease outbreaks. In turn, the ability to do such studies relies on willingness of partners in different regions to collaborate and the capacity to mount a rapid research response. The EU-funded ZIKAlliance Consortium has initiated a multicountry epidemiological, clinical, and laboratory research agenda to determine the incidence, risk factors, and outcomes of Zika virus infection in pregnant women and their children. We reviewed the timeline of patient cohort initiation in relation to the Zika virus epidemic and mapped key events regarding funding, regulatory approvals, and site preparation during this timeline. We then assessed barriers and delays that the international research team experienced through a systematic telephone interview. We have identified three major bottlenecks in the implementation of a swift response: the absence of a timeline for the funding process, delays in regulatory and ethical approval, and the challenging logistics of laboratory support, including diagnostics. These bottlenecks illustrate the clear and urgent need for implementing a strong and permanent global emerging infectious diseases research capacity that has structured funding, enables long-term partnerships, and develops basic clinical and laboratorial research and a response infrastructure that is ready to deploy.
C1 [Koopmans, Marion; van Roode, Martine; Rockx, Barry] Erasmus MC, Rotterdam, Netherlands.
   [de lamballerie, Xavier] Aix Marseille Univ, Unite Virus Emergents, Marseille, France.
   [Jaenisch, Thomas] Heidelberg Univ Hosp, Dept Infect Dis, Sect Clin Trop Med, Heidelberg, Germany.
   [Rosenberger, Kerstin D.; Morales, Ivonne] Heidelberg Univ Hosp, Dept Infect Dis, Heidelberg, Germany.
   [Marques, Ernesto T. A.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA.
   [Viana, Isabelle F. T.; Brasil, Patricia; Rabello, Renata] Fundacao Oswaldo Cruz, Aggeu Magalhaes Inst, Recife, PE, Brazil.
   [Avelino-Silva, Vivian I.; Segurado, Aluisio] Univ Sao Paulo, Sao Paulo, Brazil.
   [Alexander, Neal; Mayaud, Philippe] London Sch Hyg & Trop Med, London, England.
   [Netto, Eduardo Martins] Univ Fed Bahia, Salvador, BA, Brazil.
   [Tami, Adriana; Bethencourt, Sarah] Univ Med Ctr Groningen, Dept Med Microbiol, Groningen, Netherlands.
   [Tami, Adriana; Bethencourt, Sarah] Univ Carabobo, Fac Ciencias Salud, Valencia, Venezuela.
   [Consuelo Miranda, Maria; Lozano, Anyela] Univ Ind Santander, Bucaramanga, Colombia.
   [Soria, Carmen] Univ Catolica, Santiago De Guayaquil, Guayaqil, Ecuador.
   [Salgado Cisneros, Silvia P.] Inst Nacl Invest Salud Publ Dr Leopoldo Izquieta, Guayaquil, Ecuador.
   [Gotuzzo, Eduardo] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, San Martin De Porres, Peru.
   [Guzman, Maria G.; Rodriguez, Pedro A. M.] Inst Trop Med Pedro Kouri, Havana, Cuba.
   [Lopez-Gatell, Hugo; Hegewisch-Taylor, Jennifer] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico.
   [Hugo Borja-Aburto, Victor; Gonzalez Bonilla, Cesar R.] Mexican Inst Social Secur, Mexico City, DF, Mexico.
   [Hoen, Bruno] INSERM, Paris, France.
RP Koopmans, M (corresponding author), Erasmus MC, Virosci, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.
EM m.koopmans@erasmusmc.nl
RI Segurado, Aluisio C/K-2229-2012; Marques, Ernesto T. A/L-4967-2013;
   Avelino-Silva, Vivian I/L-2640-2013; Netto, Eduardo/D-1432-2013;
   Koopmans, Marion/Y-9170-2019; Viana, Isabelle/M-4435-2017
OI Segurado, Aluisio C/0000-0002-6311-8036; Marques, Ernesto T.
   A/0000-0003-3826-9358; Avelino-Silva, Vivian I/0000-0002-6660-3088;
   Netto, Eduardo/0000-0003-1691-6761; Koopmans,
   Marion/0000-0002-5204-2312; Martinez, Pedro A./0000-0002-9886-6448;
   Hegewisch Taylor, Jennifer/0000-0002-1057-2921; Viana,
   Isabelle/0000-0003-4648-6635; Miranda Montoya, Maria
   Consuelo/0000-0001-5730-0723
FU EU Directorate General for Research [734548]
FX The work described in the manuscript was funded by the EU Directorate
   General for Research grant number 734548 (ZIKAlliance). The sponsor of
   the study had no role in study design, data collection, data analysis,
   data interpretation, or writing of the report. We thank Sandra Kamga for
   her support in collecting information from the questionnaires. We also
   thank Martine van Roode and Barry Rockx that assisted MK in drafting an
   interview with a list of questions for the cohort initiation part of the
   study and, with the help of Sandra Kamga, created interviews to assess
   the list of possible barriers encountered.
CR Alirol E, 2017, BMC MED ETHICS, V18, DOI 10.1186/s12910-017-0201-1
   Braga JU, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179725
   Charrel R, 2017, J CLIN MICROBIOL, V55, P3219, DOI 10.1128/JCM.00987-17
   de Oliveira WK, 2017, LANCET, V390, P861, DOI 10.1016/S0140-6736(17)31368-5
   Granger D, 2017, J CLIN MICROBIOL, V55, P2127, DOI [10.1128/JCM.00580-17, 10.1128/jcm.00580-17]
   Heymann DL, 2016, LANCET, V387, P719, DOI 10.1016/S0140-6736(16)00320-2
   Jaenisch T, 2017, B WORLD HEALTH ORGAN, V95, P191, DOI [10.2471/BLT.16.178608, 10.2471/blt.16.178608]
   Jaenisch T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1440-3
   Lee WT, 2017, J CLIN MICROBIOL, V22, P56
   Ministerio de Saude (MS), 2015, B EPIDEMIOL, V46, P1
   Paules CI, 2017, ANN INTERN MED, V167, P805, DOI 10.7326/M17-2496
   Perkins MD, 2017, LANCET, V390, P2111, DOI 10.1016/S0140-6736(17)31224-2
   Reusken CB, 2018, CLIN MICROBIOL INFEC, V24, P221, DOI 10.1016/j.cmi.2017.12.010
   Reveiz L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180220
   Ribeiro CD, 2018, SCIENCE, V362, P404, DOI 10.1126/science.aau5229
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Van Kerkhove MD, 2016, LANCET GLOB HEALTH, V4, pE911, DOI 10.1016/S2214-109X(16)30255-8
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 18
TC 5
Z9 5
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD FEB
PY 2019
VL 19
IS 2
BP E59
EP E62
DI 10.1016/S1473-3099(18)30497-3
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA HJ6LD
UT WOS:000457299500006
PM 30420230
DA 2020-12-01
ER

PT J
AU Antonio, MB
   Cuba, GT
   Vasconcelos, RP
   Alves, APPS
   da Silva, BO
   Avelino-Silva, VI
AF Antonio, Marilia B.
   Cuba, Gabriel T.
   Vasconcelos, Ricardo P.
   Alves, Ana Paula P. S.
   da Silva, Bruna Oliveira
   Avelino-Silva, Vivian Iida
TI Natural experiment of syphilis treatment with doxycycline or benzathine
   penicillin in HIV-infected patients
SO AIDS
LA English
DT Article
DE doxycycline; HIV; natural experiment; penicillin; serology; syphilis;
   treatment
AB Background: Although doxycycline is widely used as an alternative to benzathine penicillin for the treatment of early and late latent syphilis, data on serological response following treatment with doxycycline among HIV-infected patients are limited. Methods: In this study, we analysed serological response to syphilis treatment with doxycycline among HIV-infected patients treated during a benzathine penicillin shortage period and compared with treatment response among patients treated with benzathine penicillin. Cases with neurosyphilis and those treated with suboptimal doses or with concurrent medications in association with benzathine penicillin or doxycycline were excluded. Results: Fifty patients treated with doxycycline from September 2014 to December 2016 were compared with 115 patients treated with benzathine penicillin for early, late latent or latent syphilis of unknown duration. Patients treated with doxycycline were slightly older [(median 49 years old, 95% confidence interval (95% CI) 43-56] than those in the penicillin group (median 44 years old, 95% CI 37-50; P = 0.007). Groups had no statistically significant differences regarding sex, HIV suppression under treatment and syphilis stages. Serological response to treatment, defined as a nonreagent Venereal Disease Research Laboratory (VDRL) or at least a four-fold reduction in VDRL titres measured 6-12 months after treatment, was seen in 72% (95% CI 58-84) of patients treated with doxycycline and 70% (95% CI 60-78) of patients treated with penicillin (P = 0.753). Conclusion: We found no statistically significant differences in serological response to treatment with doxycycline or benzathine penicillin among HIV-infected patients with early, late latent or latent syphilis of unknown duration. Our findings suggest that doxycycline is an acceptable treatment to HIV-infected patients with nontertiary stages of syphilis. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Antonio, Marilia B.; Cuba, Gabriel T.; Vasconcelos, Ricardo P.; Avelino-Silva, Vivian Iida] Univ Sao Paulo, Dept Infect & Parasit Dis, Fac Med, Sao Paulo, Brazil.
   [Cuba, Gabriel T.] Univ Fed Sao Paulo, Lab Especial, Escola Paulista Med, Microbiol Clin, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian Iida] Hosp Sirio Libanes, Sao Paulo, Brazil.
RP Antonio, MB (corresponding author), Univ Sao Paulo, Dept Infect & Parasit Dis, Fac Med, Sao Paulo, Brazil.; Antonio, MB (corresponding author), Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
EM bordignon.mba@gmail.com
RI Avelino-Silva, Vivian I/L-2640-2013; Vasconcelos, Ricardo/AAL-4634-2020
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Vasconcelos,
   Ricardo/0000-0002-9753-0563
CR Centers for Disease Control and Prevention, 2017, PEN G BENZ SHORT 201
   Centers for Disease Control and Prevention, 2015, MMWR-MORBID MORTAL W, V64, P38
   Centers for Disease Control and Prevention, 2017, SEX TRANSM DIS SURV
   Cousins DE, 2012, INT J STD AIDS, V23, P632, DOI 10.1258/ijsa.2012.011395
   Liu HY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180001
   Luo ZZ, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2715-z
   Nurse-Findlay S, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002473
   Rolfs RT, 1997, NEW ENGL J MED, V337, P307, DOI 10.1056/NEJM199707313370504
   Salado-Rasmussen K, 2016, ACTA DERM-VENEREOL, V96, P807, DOI 10.2340/00015555-2289
   Shockman S, 2014, CLIN DERMATOL, V32, P213, DOI 10.1016/j.clindermatol.2013.08.005
   Tsai JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109813
NR 11
TC 2
Z9 2
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JAN 2
PY 2019
VL 33
IS 1
BP 77
EP 81
DI 10.1097/QAD.0000000000001975
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA HO5AY
UT WOS:000460936300008
PM 30102654
DA 2020-12-01
ER

PT J
AU Tozetto-Mendoza, TR
   Avelino-Silva, VI
   Fonseca, S
   Claro, IM
   de Paula, AV
   Levin, AS
   Sabino, EC
   Mendes-Correa, MC
   Figueiredo, WM
   Felix, AC
   Souza, NCS
   Costa, AA
   Inenami, M
   da Silva, RMG
   Levi, JE
   Romano, CM
   Paranhos-BaccalA, G
   Segurado, AC
   Mayaud, P
AF Tozetto-Mendoza, Tania Regina
   Avelino-Silva, Vivian Iida
   Fonseca, Silvia
   Claro, Ingra Morales
   de Paula, Anderson Vicente
   Levin, Anna Sara
   Sabino, Ester Cerdeira
   Mendes-Correa, Maria Cassia
   Figueiredo, Walter Manso
   Felix, Alvina Clara
   Santiago Souza, Nathalia C.
   Costa, Angela Aparecida
   Inenami, Maria
   Gasparetto da Silva, Rosangela M.
   Levi, Jose Eduardo
   Romano, Camila Malta
   Paranhos-BaccalA, Glaucia
   Segurado, Aluisio Cotrim
   Mayaud, Philippe
TI Zika virus infection among symptomatic patients from two healthcare
   centers in Sao Paulo State, Brazil: prevalence, clinical
   characteristics, viral detection in body fluids and serodynamics
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE Zika virus; Differential diagnosis; Kinetics; Body fluids; Polymerase
   chain reaction; Real-Time Polymerase Chain Reaction; Serology; Brazil
ID MALE SEXUAL TRANSMISSION; TIME RT-PCR; DENGUE; EPIDEMIC
AB Zika virus (ZIKV) clinical presentation and frequency/duration of shedding need further clarification. Symptomatic ZIKV-infected individuals identified in two hospitals in Sao Paulo State, Brazil, were investigated regarding clinical characteristics, shedding in body fluids, and serodynamics. Ninety-four of 235 symptomatic patients (Site A: 58%; Site B: 16%) had Real-Time PCR-confirmed ZIKV infection; fever, headache and gastrointestinal symptoms were less frequent, and rash was more frequent compared to ZIKV-negative patients. Real-Time PCR in serum had worse performance compared to plasma, while urine had the highest sensitivity. Shedding in genital fluids and saliva was rare. IgM positivity was the highest <14 days after the symptoms onset (86%), decreasing >28 days (24%); IgG positivity increased >14 days (96%) remaining positive in 94% of patients >28 days. ZIKV prevalence varied importantly in two neighboring cities during the same transmission season. Urine Real-Time PCR can improve diagnostic sensitivity; serum testing is less useful. Accurate serological tests are needed to improve diagnosis and surveillance.
C1 [Tozetto-Mendoza, Tania Regina; de Paula, Anderson Vicente; Levin, Anna Sara; Sabino, Ester Cerdeira; Mendes-Correa, Maria Cassia; Felix, Alvina Clara; Santiago Souza, Nathalia C.; Levi, Jose Eduardo; Romano, Camila Malta; Paranhos-BaccalA, Glaucia; Segurado, Aluisio Cotrim; Mayaud, Philippe] Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, SP, Brazil.
   [Avelino-Silva, Vivian Iida; Claro, Ingra Morales; Levin, Anna Sara; Sabino, Ester Cerdeira; Mendes-Correa, Maria Cassia; Segurado, Aluisio Cotrim] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, SP, Brazil.
   [Fonseca, Silvia] Hosp Sao Francisco, Ribeirao Preto, SP, Brazil.
   [Figueiredo, Walter Manso; Costa, Angela Aparecida; Inenami, Maria; Gasparetto da Silva, Rosangela M.] Univ Sao Paulo, Fac Saude Publ, Serv Especial Saude Araraquara, Araraquara, SP, Brazil.
   [Paranhos-BaccalA, Glaucia] BioMerieux SA, Med Diagnost Discovery Dept MD3, Marcy Letoile, France.
   [Mayaud, Philippe] Fac Infect & Trop Dis, London Sch Hyg & Trop Med, London, England.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Inst Med Trop Sao Paulo, Av Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
EM viviansilva87@gmail.com
RI Romano, Camila/ABC-2883-2020; Levin, Anna S/C-8831-2012; Avelino-Silva,
   Vivian I/L-2640-2013; Sabino, Ester Cerdeira/F-7750-2010; Romano, Camila
   M/C-8185-2013; Segurado, Aluisio C/K-2229-2012
OI Romano, Camila/0000-0003-4550-1987; Levin, Anna S/0000-0003-2427-8368;
   Avelino-Silva, Vivian I/0000-0002-6660-3088; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Segurado, Aluisio C/0000-0002-6311-8036
FU European Union's Horizon 2020 Research and Innovation Programme under
   ZIKAlliance [734548]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES -Ministry of Education, Brazil)CAPES
   [CSF-PVE-S-88887.122640/2016-00, CSF-PVE-S-88881.068160/2014-01];
   bioMerieux Corporation
FX This work was supported by the European Union's Horizon 2020 Research
   and Innovation Programme under ZIKAlliance Grant Agreement No 734548,
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES
   -Ministry of Education, Brazil, grants No CSF-PVE-S-88887.122640/2016-00
   [VAS support] and CSF-PVE-S-88881.068160/2014-01 [ASL, ACS and PM
   support]) and bioMerieux Corporation. The funders had no role in the
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Avelino-Silva VL, 2018, REV INST MED TROP SP, V60, DOI [10.1590/S1678-9946201860064, 10.1590/s1678-9946201860064]
   Bogoch II, 2016, LANCET, V387, P335, DOI 10.1016/S0140-6736(16)00080-5
   Bonaldo MC, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004816
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Calvet GA, 2016, J CLIN VIROL, V74, P1, DOI 10.1016/j.jcv.2015.11.014
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Cecilia D, 2015, ARCH VIROL, V160, P323, DOI 10.1007/s00705-014-2217-x
   Colombo TE, 2017, J CLIN VIROL, V96, P20, DOI 10.1016/j.jcv.2017.09.002
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   Deckard DT, 2016, MMWR-MORBID MORTAL W, V65, P372, DOI 10.15585/mmwr.mm6514a3
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Faye O, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-311
   Felix AC, 2017, J MED VIROL, V89, P1477, DOI 10.1002/jmv.24789
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Frank C, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.23.30252
   Freour T, 2016, EUROSURVEILLANCE, V21, P10, DOI 10.2807/1560-7917.ES.2016.21.23.30254
   Huhtamo E, 2010, J CLIN VIROL, V47, P49, DOI 10.1016/j.jcv.2009.11.001
   Huzly D, 2016, EUROSURVEILLANCE, V21, P9, DOI 10.2807/1560-7917.ES.2016.21.16.30203
   Joguet G, 2017, LANCET INFECT DIS, V17, P1200, DOI 10.1016/S1473-3099(17)30444-9
   Kim CR, 2018, LANCET GLOB HEALTH, V6, pE24, DOI 10.1016/S2214-109X(17)30419-9
   L'Huillier AG, 2017, J CLIN MICROBIOL, V55, P2462, DOI 10.1128/JCM.00442-17
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Li Jiandong, 2016, Zhonghua Liu Xing Bing Xue Za Zhi, V37, P329, DOI 10.3760/cma.j.issn.0254-6450.2016.03.007
   Mecharles S, 2016, LANCET, V387, P1481, DOI 10.1016/S0140-6736(16)00644-9
   Pasquier C, 2018, DIAGN MICR INFEC DIS, V90, P26, DOI 10.1016/j.diagmicrobio.2017.09.001
   Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108
   Prisant N, 2017, CLIN INFECT DIS, V64, P107, DOI 10.1093/cid/ciw669
   Prisant N, 2016, LANCET INFECT DIS, V16, P1000, DOI 10.1016/S1473-3099(16)30193-1
   Safronetz D, 2017, EMERG INFECT DIS, V23, P1577, DOI 10.3201/eid2309.162043
   Sanchez-Montalva A, 2018, TROP MED INT HEALTH, V23, P92, DOI 10.1111/tmi.13019
   Teixeira MG, 2016, AM J PUBLIC HEALTH, V106, P601, DOI 10.2105/AJPH.2016.303113
   Turmel JM, 2016, LANCET, V387, P2501, DOI 10.1016/S0140-6736(16)30775-9
   Venturi G, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.8.30148
   Visseaux B, 2016, LANCET INFECT DIS, V16, P1220, DOI 10.1016/S1473-3099(16)30387-5
   Vranjac Alexandre, 2016, DISTRIBUICAO CASOS C
   Vranjac Alexandre, 2016, DISTRIBUICAO CASOS D
   Vranjac Alexandre, 2016, DISTRIBUICAO CASOS Z
   World Health Organization, WHO DIR GEN SUMM OUT
NR 40
TC 4
Z9 4
U1 0
U2 2
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PY 2019
VL 61
AR e19
DI 10.1590/S1678-9946201961019
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA HS4BZ
UT WOS:000463808000002
PM 30970110
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Kallas, EG
AF Avelino-Silva, Vivian I.
   Kallas, Esper G.
TI Untold stories of the Zika virus epidemic in Brazil
SO REVIEWS IN MEDICAL VIROLOGY
LA English
DT Review
DE congenital Zika syndrome; Guillain-Barre syndrome; microcephaly;
   outbreak; Zika virus
ID GUILLAIN-BARRE-SYNDROME; FDA-APPROVED DRUG; AEDES-AEGYPTI; SEXUAL
   TRANSMISSION; DENGUE VIRUS; CULEX-QUINQUEFASCIATUS; BORNE TRANSMISSION;
   ANTIVIRAL ACTIVITY; CROSS-REACTIVITY; BIRTH-DEFECTS
AB The Zika virus infection outbreak in Brazil in 2014 to 2015 resulted in the identification of previously unknown consequences of the disease, including the notorious microcephaly among many defects in fetuses born to women infected during pregnancy. A number of individuals were involved in this remarkable discovery, from the detection of viral circulation in the country to the studies on the causal link with congenital abnormalities and the provision of awareness and social support to families affected by the disease. In this article, we review the background to this experience, describing aspects of the epidemiology, medical research, and scientific response to the Zika virus outbreak in Brazil.
C1 [Avelino-Silva, Vivian I.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian I.] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Avelino-Silva, Vivian I/L-2640-2013
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Kallas,
   Esper/0000-0003-2026-6925
CR Abrao EP, 2016, VECTOR-BORNE ZOONOT, V16, P124, DOI 10.1089/vbz.2015.1804
   Acosta LJ, 2016, HUFFINGTON POST
   Aiken ARA, 2016, NEW ENGL J MED, V375, P396, DOI 10.1056/NEJMc1605389
   Malta JMAS, 2017, EPIDEMIOL SERV SAUDE, V26, P9, DOI [10.5123/s1679-49742017000100002, 10.5123/S1679-49742017000100002]
   [Anonymous], MON CAS OB FEBR AM B
   de Brito CAA, 2016, REV SOC BRAS MED TRO, V49, P537, DOI 10.1590/0037-8682-0328-2016
   Arsuaga M, 2016, LANCET INFECT DIS, V16, P1107, DOI 10.1016/S1473-3099(16)30320-6
   Avelino-Silva A.C, 2017, 53 C SOC BRAS MED TR
   Avelino-Silva VI, 2016, LANCET, V387, P2599, DOI 10.1016/S0140-6736(16)30843-1
   Ayres CFJ, 2016, LANCET INFECT DIS, V16, P278, DOI 10.1016/S1473-3099(16)00073-6
   Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   Barreto ML, 2016, LANCET, V387, P919, DOI 10.1016/S0140-6736(16)00545-6
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Besnard M., 2014, EURO SURVEILL, V19
   Blitvich BJ, 2015, VIRUSES-BASEL, V7, P1927, DOI 10.3390/v7041927
   Brasil Ministerio da Saude, PORT N 1 813 11 NOV
   Brasil Ministerio da Saude, 2015, PROT VIG RESP OC MIC
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Ferreira MLB, 2017, AM J TROP MED HYG, V97, P1405, DOI 10.4269/ajtmh.17-0106
   Brito MB, 2016, REV BRAS GINECOL OBS, V38, P583, DOI 10.1055/s-0036-1593411
   Broutet N, 2016, NEW ENGL J MED, V374, P1506, DOI 10.1056/NEJMp1602708
   Bullard-Feibelman KM, 2017, ANTIVIR RES, V137, P134, DOI 10.1016/j.antiviral.2016.11.023
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cardoso CW, 2015, EMERG INFECT DIS, V21, P2274, DOI 10.3201/eid2112.151167
   Carrington CVF, 2013, INFECT GENET EVOL, V13, P198, DOI 10.1016/j.meegid.2012.08.015
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   Cordeiro MT, 2016, LANCET, V387, P1811, DOI 10.1016/S0140-6736(16)30253-7
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   Darney BG, 2017, OBSTET GYNECOL, V129, P638, DOI [10.1097/AOG.0000000000001914, 10.1097/aog.0000000000001914]
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   de Oliveira WK, 2017, NEW ENGL J MED, V376, P1591, DOI 10.1056/NEJMc1608612
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Diallo D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109442
   Diaz-Quijano FA, 2017, ANN EPIDEMIOL, V27, P616, DOI 10.1016/j.annepidem.2017.08.009
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   Diniz D, 2017, J FAM PLAN REPROD H, V43, P80, DOI 10.1136/jfprhc-2016-101678
   Diniz D, 2016, DEV WORLD BIOETH, V16, P62, DOI 10.1111/dewb.12119
   Dodson BL, 2017, PEERJ, V5, DOI 10.7717/peerj.3096
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Dupont-Rouzeyrol M, 2015, EMERG INFECT DIS, V21, P381, DOI 10.3201/eid2102.141553
   Dyer O, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i383
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   FENTON TR, 2013, BMC PEDIATR, V13
   Fernandes RS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004993
   Ferreira AC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09797-8
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Franca RFO, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004760
   Frank C, 2016, EUROPEAN COMMUNICABL, V2016, P21, DOI DOI 10.2807/1560-7917
   Freour T., 2016, EURO SURVEILL, V21
   Goertz GP, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005654
   Govero J, 2016, NATURE, V540, P438, DOI 10.1038/nature20556
   Grubaugh ND, 2017, NATURE, V546, P401, DOI 10.1038/nature22400
   Guo XX, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.102
   Hazin AN, 2016, NEW ENGL J MED, V374, P2193, DOI 10.1056/NEJMc1603617
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Jaenisch T, 2017, B WORLD HEALTH ORGAN, V95, P191, DOI [10.2471/BLT.16.178608, 10.2471/blt.16.178608]
   Joguet G, 2017, LANCET INFECT DIS, V17, P1200, DOI 10.1016/S1473-3099(17)30444-9
   Kallas EG, 2016, JAMA PEDIATR, V170, P633, DOI 10.1001/jamapediatrics.2016.0857
   Kam YW, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92428
   Kenney JL, 2017, AM J TROP MED HYG, V96, P1235, DOI 10.4269/ajtmh.16-0865
   Kindhauser MK, 2016, B WORLD HEALTH ORGAN, V94, P675, DOI 10.2471/BLT.16.171082
   Lanteri MC, 2016, TRANSFUSION, V56, P1907, DOI 10.1111/trf.13677
   Leite RD, 2015, EMERG INFECT DIS, V21, P1681, DOI 10.3201/eid2109.150391
   Li CF, 2017, EBIOMEDICINE, V24, P189, DOI 10.1016/j.ebiom.2017.09.034
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   Likos A, 2016, MMWR-MORBID MORTAL W, V65, P1032, DOI 10.15585/mmwr.mm6538e1
   Liu Y, 2017, NATURE, V545, P482, DOI 10.1038/nature22365
   Liu ZZ, 2017, EMERG INFECT DIS, V23, P1085, DOI 10.3201/eid2307.161528
   Liuzzi G, 2016, NEW MICROBIOL, V39, P83
   Magnani DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan8184
   Magnani DM, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005655
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P1106, DOI 10.1016/S1473-3099(16)30336-X
   MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411
   Matheron S, 2016, CLIN INFECT DIS, V63, DOI 10.1093/cid/ciw509
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI DOI 10.1136/BMJ
   Mecharles S, 2016, LANCET, V387, P1481, DOI 10.1016/S0140-6736(16)00644-9
   Mehrjardi MZ, 2017, JPN J RADIOL, V35, P341, DOI 10.1007/s11604-017-0641-z
   Metsky HC, 2017, NATURE, V546, P411, DOI 10.1038/nature22402
   Ministerio da Saude . Secretaria de Vigilancia em Saude, 2018, B EP, V11
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Moore CA, 2016, JAMA PEDIAT
   Mumtaz N, 2017, ANTIVIR RES, V146, P161, DOI 10.1016/j.antiviral.2017.09.004
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2014, EURO SURVEILL, V19
   Muturi EJ, 2017, TROP MED INT HEALTH, V22, P399, DOI 10.1111/tmi.12846
   Netto EM, 2017, MBIO, V8, DOI [10.1128/mBio.01390-17, 10.1128/mbio.01390-17]
   Oehler E, 2013, EUROSURVEILLANCE, V2014, P19, DOI DOI 10.2807/1560-7917.ES2014.19.9.20720
   Organization W. H., 2016, WHO DIR GEN SUMM OUT
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Paploski IAD, 2016, EMERG INFECT DIS, V22, P1438, DOI 10.3201/eid2208.160496
   Partlow J, 2016, WASHINGTON POST
   Paul LM, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.72
   Paz-Bailey G., 2017, N ENGL J MED
   Pires de Mello CP, 2017, ANTIMICROB AGENTS CH, V62
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Quintero-Gil DC, 2014, J INFECT DEV COUNTR, V8, P876, DOI 10.3855/jidc.3978
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   Reynolds MR, 2017, MMWR-MORBID MORTAL W, V66, P366, DOI 10.15585/mmwr.mm6613e1
   Rossetto EV, 2017, REV INST MED TROP SP, V59, DOI [10.1590/S1678-9946201759017, 10.1590/s1678-9946201759017]
   Ruckert C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15412
   SACRAMENTO CQ, 2017, SCI REP UK, V7
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Shan C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00737-8
   Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322
   Shapiro-Mendoza CK, 2017, MMWR-MORBID MORTAL W, V66, P615, DOI 10.15585/mmwr.mm6623e1
   Shiryaev SA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15467-6
   Silva AA, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-0589
   Silveira M., 2015, NAO ENGRAVIDEM AGORA
   Snyder B, 2018, J MED VIROL, V90, P8, DOI 10.1002/jmv.24932
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tebas P, 2017, N ENGL J MED
   Terradas G, 2017, CURR OPIN INSECT SCI, V22, P37, DOI 10.1016/j.cois.2017.05.005
   Tetro JA, 2016, MICROBES INFECT, V18, P167, DOI 10.1016/j.micinf.2015.12.010
   Tognarelli J, 2016, ARCH VIROL, V161, P665, DOI 10.1007/s00705-015-2695-5
   Turmel JM, 2016, LANCET, V387, P2501, DOI 10.1016/S0140-6736(16)30775-9
   van der Linden V, 2016, MMWR-MORBID MORTAL W, V65, P1343, DOI 10.15585/mmwr.mm6547e2
   Ventura CV, 2016, LANCET, V387, P2502, DOI 10.1016/S0140-6736(16)30776-0
   Venturi G, 2016, EURO SURVEILL, V21
   Victora CG, 2016, LANCET, V387, P621, DOI 10.1016/S0140-6736(16)00273-7
   Vinhaes ES, 2017, CLIN INFECT DIS, V64, P675, DOI 10.1093/cid/ciw770
   World Health Organization, 2017, SIT REP ZIK VIR MICR
   Xu L, 2017, P NATL ACAD SCI USA, V114, P113, DOI 10.1073/pnas.1618558114
   Yuan L, 2017, SCIENCE, V358, P933, DOI 10.1126/science.aam7120
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 131
TC 2
Z9 2
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1052-9276
EI 1099-1654
J9 REV MED VIROL
JI Rev. Med. Virol.
PD NOV
PY 2018
VL 28
IS 6
AR e2000
DI 10.1002/rmv.2000
PG 9
WC Virology
SC Virology
GA HA2NV
UT WOS:000450076600006
PM 30074287
OA Bronze
DA 2020-12-01
ER

PT J
AU Vasconcelos, R
   Avelino-Silva, V
   Alves, AP
   Noronha, N
   Picone, C
   Silva, B
   Segurado, A
AF Vasconcelos, Ricardo
   Avelino-Silva, Vivian
   Alves, Ana Paula
   Noronha, Nicole
   Picone, Camila
   Silva, Bruna
   Segurado, Aluisio
TI Number of Sexual Partners Does Not Predict HIV Status in a Brazilian STI
   Clinic
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT HIV Research for Prevention Meeting (HIVR4P) - AIDS Vaccine, Microbicide
   and ARV-Based Prevention Science
CY OCT 21-25, 2018
CL Madrid, SPAIN
C1 [Vasconcelos, Ricardo; Avelino-Silva, Vivian; Alves, Ana Paula; Noronha, Nicole; Picone, Camila; Silva, Bruna; Segurado, Aluisio] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian] Hosp Sirio Libanes, Sao Paulo, Brazil.
RI Vasconcelos, Ricardo/AAL-4634-2020; Segurado, Aluisio C/K-2229-2012;
   Avelino-Silva, Vivian I/L-2640-2013
OI Vasconcelos, Ricardo/0000-0002-9753-0563; Segurado, Aluisio
   C/0000-0002-6311-8036; Avelino-Silva, Vivian I/0000-0002-6660-3088
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2018
VL 34
SU 1
MA P11.24
BP 243
EP 243
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA GY2KM
UT WOS:000448371600441
DA 2020-12-01
ER

PT J
AU Cerqueira, N
   Vasconcelos, R
   Hojilla, C
   Kallas, E
   Avelino-Silva, V
AF Cerqueira, Natalia
   Vasconcelos, Ricardo
   Hojilla, Carlo
   Kallas, Esper
   Avelino-Silva, Vivian
TI Attitudes and Knowledge About HIV PrEP Among Infectious Diseases
   Physicians in Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Meeting Abstract
CT HIV Research for Prevention Meeting (HIVR4P) - AIDS Vaccine, Microbicide
   and ARV-Based Prevention Science
CY OCT 21-25, 2018
CL Madrid, SPAIN
C1 [Cerqueira, Natalia; Vasconcelos, Ricardo; Kallas, Esper; Avelino-Silva, Vivian] Univ Sao Paulo, Sao Paulo, Brazil.
   [Hojilla, Carlo] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Avelino-Silva, Vivian] Hosp Sirio Libanes, Sao Paulo, Brazil.
RI Avelino-Silva, Vivian I/L-2640-2013; Vasconcelos, Ricardo/AAL-4634-2020
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Vasconcelos,
   Ricardo/0000-0002-9753-0563
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD OCT
PY 2018
VL 34
SU 1
MA P14.47
BP 275
EP 275
PG 1
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA GY2KM
UT WOS:000448371600502
DA 2020-12-01
ER

PT J
AU Freitas, A
   Avelino-Silva, V
   Gutierrez, E
   Durigon, G
   Pereira, MF
   Litivinoc, N
   Marques, HH
   Segurado, A
AF Freitas, A.
   Avelino-Silva, V.
   Gutierrez, E.
   Durigon, G.
   Pereira, M. F.
   Litivinoc, N.
   Marques, H. H.
   Segurado, A.
TI Predictors of treatment adherence and HIV viral load among youths
   transitioning from pediatric to adult HIV outpatient care in Sao Paulo,
   Brazil
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Freitas, A.; Avelino-Silva, V.; Gutierrez, E.; Segurado, A.] Univ Sao Paulo, Fac Med, Molestias Infecciosas & Parasitarias, Sao Paulo, Brazil.
   [Durigon, G.; Pereira, M. F.; Litivinoc, N.; Marques, H. H.] HCFMUSP, Inst Crianca, Infectol, Sao Paulo, Brazil.
RI Segurado, Aluisio C/K-2229-2012; Avelino-Silva, Vivian I/L-2640-2013
OI Segurado, Aluisio C/0000-0002-6311-8036; Avelino-Silva, Vivian
   I/0000-0002-6660-3088
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD AUG
PY 2018
VL 73
SU S
MA UMP. 371
BP 239
EP 240
DI 10.1016/j.ijid.2018.04.3960
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA GO8MP
UT WOS:000440345100526
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
AF Avelino-Silva, Vivian Iida
TI Is Zika virus outbreak a solved issue in Brazil?
SO EINSTEIN-SAO PAULO
LA English
DT Editorial Material
ID SEXUAL TRANSMISSION; CONTACT; STATES
C1 [Avelino-Silva, Vivian Iida] Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
   [Avelino-Silva, Vivian Iida] Hosp Sirio Libanes, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Rua Dona Adma Jafet 74,3rd Andar Bela Vista, BR-01308050 Sao Paulo, SP, Brazil.
EM viviansilva87@gmail.com
RI Avelino-Silva, Vivian I/L-2640-2013
OI Avelino-Silva, Vivian I/0000-0002-6660-3088
CR Atkinson B, 2016, EMERG INFECT DIS, V22, P940, DOI 10.3201/eid2205.160107
   Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   BEARCROFT W. G. C., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P442, DOI 10.1016/0035-9203(56)90090-6
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Cancian N, 2017, BRASIL REGISTRA QUED
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   Diaz-Quijano FA, 2017, ANN EPIDEMIOL, V27, P616, DOI 10.1016/j.annepidem.2017.08.009
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P521, DOI 10.1016/0035-9203(52)90043-6
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Fields BN, 2007, FIELDS VIROLOGY, V1
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Frank C, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.23.30252
   Freour T, 2016, EUROSURVEILLANCE, V21, P10, DOI 10.2807/1560-7917.ES.2016.21.23.30254
   Hancock W. T., 2014, EMERG INFECT DIS, V20, P1085
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanteri MC, 2016, TRANSFUSION, V56, P1907, DOI 10.1111/trf.13677
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i720
   Messina JP, 2016, ELIFE, V5, DOI 10.7554/eLife.15272
   Ministerio~ da Saude do Brasil, 2017, B EPIDEMIOLOGICO, V48, P1
   Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Organization W. H., 2016, WHO DIR GEN SUMM OUT
   Silveira M., 2015, NAO ENGRAVIDEM AGORA
   STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994
   Tappe D, 2016, MED MICROBIOL IMMUN, V205, P269, DOI 10.1007/s00430-015-0445-7
   Turmel JM, 2016, LANCET, V387, P2501, DOI 10.1016/S0140-6736(16)30775-9
   Venturi G, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.8.30148
   Watts AG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178211
NR 32
TC 1
Z9 1
U1 0
U2 2
PU INST ISRAELITA ENSINO & PESQUISA ALBERT EINSTEIN
PI SAO PAULO SP
PA AVENIDA ALBERT EINSTEIN, 627 701, SAO PAULO SP, 05651-901, BRAZIL
SN 1679-4508
EI 2317-6385
J9 EINSTEIN-SAO PAULO
JI Einstein
PD JAN-MAR
PY 2018
VL 16
IS 1
AR UNSP eED4325
DI 10.1590/S1679-45082018ED4325
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA GD6GC
UT WOS:000430606100017
PM 29694613
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Paquin-Proulx, D
   Avelino-Silva, VI
   Santos, BAN
   Barsotti, NS
   Siroma, F
   Ramos, JF
   Tonacio, AC
   Song, A
   Maestri, A
   Cerqueira, NB
   Felix, AC
   Levi, JE
   Greenspun, BC
   Rougvie, MD
   Rosenberg, MG
   Nixon, DF
   Kallas, EG
AF Paquin-Proulx, Dominic
   Avelino-Silva, Vivian I.
   Santos, Bianca A. N.
   Barsotti, Nathalia Silveira
   Siroma, Fabiana
   Ramos, Jessica Fernandes
   Tonacio, Adriana Coracini
   Song, Alice
   Maestri, Alvino
   Cerqueira, Natalia Barros
   Felix, Alvina Clara
   Levi, Jose Eduardo
   Greenspun, Benjamin C.
   Rougvie, Miguel de Mulder
   Rosenberg, Michael G.
   Nixon, Douglas F.
   Kallas, Esper G.
TI MAIT cells are activated in acute Dengue virus infection and after in
   vitro Zika virus infection
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID INVARIANT T-CELLS; TRANSMISSION; POPULATION; IMMUNITY
AB Dengue virus (DENV) and Zika virus (ZIKV) are members of the Flaviviridae and are pre-dominantly transmitted via mosquito bites. Both viruses are responsible for a growing number of infections in tropical and subtropical regions. DENV infection can cause lethargy with severe morbidity and dengue shock syndrome leading to death in some cases. ZIKV is now linked with Guillain-Barre A syndrome and fetal malformations including microcephaly and developmental disorders (congenital Zika syndrome). The protective and pathogenic roles played by the immune response in these infections is unknown. Mucosal-associated invariant T (MAIT) cells are a population of innate T cells with potent anti-bacterial activity. MAIT cells have also been postulated to play a role in the immune response to viral infections. In this study, we evaluated MAIT cell frequency, phenotype, and function in samples from subjects with acute and convalescent DENV infection. We found that in acute DENV infection, MAIT cells had elevated co-expression of the activation markers CD38 and HLA-DR and had a poor IFN gamma response following bacterial stimulation. Furthermore, we found that MAIT cells can produce IFN gamma in response to in vitro infection with ZIKV. This MAIT cell response was independent of MR1, but dependent on IL-12 and IL-18. Our results suggest that MAIT cells may play an important role in the immune response to Flavivirus infections.
C1 [Paquin-Proulx, Dominic; Greenspun, Benjamin C.; Rougvie, Miguel de Mulder; Nixon, Douglas F.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.
   [Avelino-Silva, Vivian I.; Santos, Bianca A. N.; Barsotti, Nathalia Silveira; Ramos, Jessica Fernandes; Tonacio, Adriana Coracini; Song, Alice; Maestri, Alvino; Cerqueira, Natalia Barros; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian I.; Siroma, Fabiana; Ramos, Jessica Fernandes; Tonacio, Adriana Coracini; Song, Alice] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Felix, Alvina Clara; Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop Sao Paulo, Dept Molestias Infecciosas & Parasitarias LIM 52, Sao Paulo, Brazil.
   [Felix, Alvina Clara; Levi, Jose Eduardo] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Rosenberg, Michael G.] Jacobi Med Ctr, Pediat Infect Dis Dept, Bronx, NY USA.
RP Paquin-Proulx, D (corresponding author), George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.
EM dpaquin_proulx@gwu.edu
RI Song, Alice Tung Wan/F-2494-2014; Avelino-Silva, Vivian I/L-2640-2013;
   de Mulder Rougvie, Miguel/AAG-6224-2020; Nixon, Douglas/AAU-5734-2020
OI Song, Alice Tung Wan/0000-0001-6992-9326; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; de Mulder Rougvie, Miguel/0000-0002-8026-7076;
   Nixon, Douglas/0000-0002-2801-1786; Paquin Proulx,
   Dominic/0000-0003-1407-3414; Silveira Barsotti,
   Nathalia/0000-0003-3513-5258; Kallas, Esper/0000-0003-2026-6925
FU District of Columbia Center for AIDS Research, an NIH [AI117970]; GWU
   SMHS Office of International Medicine Programs
FX This research was funded in part by a pilot award, and facilities and
   services, from the District of Columbia Center for AIDS Research, an NIH
   funded program (AI117970), and from the GWU SMHS Office of International
   Medicine Programs. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Calvet GA, 2016, J CLIN VIROL, V74, P1, DOI 10.1016/j.jcv.2015.11.014
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cosgrove C, 2013, BLOOD, V121, P951, DOI 10.1182/blood-2012-06-436436
   de Matos AM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003520
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   Dias J, 2017, P NATL ACAD SCI US
   Dias J, 2016, J LEUKOCYTE BIOL, V100, P233, DOI 10.1189/jlb.4TA0815-391RR
   Fagundes CT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001449
   Gold MC, 2014, J EXP MED, V211, P1601, DOI 10.1084/jem.20140507
   Hengst J, 2016, EUR J IMMUNOL, V46, P2204, DOI 10.1002/eji.201646447
   Joao Esau Custodio, 2017, Pediatr Infect Dis J, V36, P500, DOI 10.1097/INF.0000000000001482
   Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605
   Le Bourhis L, 2010, NAT IMMUNOL, V11, P701, DOI 10.1038/ni.1890
   Leeansyah E, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005072
   Leeansyah E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4143
   Leeansyah E, 2013, BLOOD, V121, P1124, DOI 10.1182/blood-2012-07-445429
   Leeansyah E, 2013, CURR OPIN HIV AIDS, V8, P117, DOI 10.1097/COH.0b013e32835c7134
   Li J, 2016, AUSTRALAS J DERMATOL
   Loh L, 2016, P NATL ACAD SCI USA, V113, P10133, DOI 10.1073/pnas.1610750113
   Messina JP, 2016, ELIFE, V5, DOI 10.7554/eLife.15272
   Mustafa AS, 2001, FEMS IMMUNOL MED MIC, V30, P229, DOI 10.1111/j.1574-695X.2001.tb01575.x
   Pacsa AS, 2000, FEMS IMMUNOL MED MIC, V28, P151, DOI 10.1111/j.1574-695X.2000.tb01470.x
   Pal T, 2014, J CLIN VIROL, V61, P365, DOI 10.1016/j.jcv.2014.09.003
   Pang JX, 2015, AM J TROP MED HYG, V92, P1156, DOI 10.4269/ajtmh.15-0031
   Paquin-Proulx D, 2017, IMMUNOHORIZON, V1, P141
   Paquin-Proulx D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175345
   Penot P, 2017, EURO SURVEILL, V22
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Reantragoon R, 2013, J EXP MED, V210, P2305, DOI 10.1084/jem.20130958
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Salou M, 2017, CURR OPIN IMMUNOL, V48, P7, DOI 10.1016/j.coi.2017.07.009
   Tang XZ, 2013, J IMMUNOL, V190, P3142, DOI 10.4049/jimmunol.1203218
   Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2898, DOI 10.1038/jid.2014.261
   Treiner E, 2003, NATURE, V422, P164, DOI 10.1038/nature01433
   Ussher JE, 2014, EUR J IMMUNOL, V44, P195, DOI 10.1002/eji.201343509
   van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
   van de Weg CAM, 2012, J CLIN VIROL, V53, P38, DOI 10.1016/j.jcv.2011.09.028
   van Wilgenburg B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11653
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
NR 40
TC 17
Z9 17
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JAN
PY 2018
VL 12
IS 1
AR e0006154
DI 10.1371/journal.pntd.0006154
PG 15
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FU7HJ
UT WOS:000424022700027
PM 29357366
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VL
   Alvarenga, C
   Abreu, C
   Tozetto-Mendoza, TR
   do Canto, CLM
   Manuli, ER
   Mendes-Correa, MC
   Sabino, EC
   Figueiredo, WM
   Segurado, AC
   Mayaud, P
AF Avelino-Silva, Vivian Lida
   Alvarenga, Conrado
   Abreu, Carolina
   Tozetto-Mendoza, Tania Regina
   Motta do Canto, Cynthia Liliane
   Manuli, Erika Regina
   Mendes-Correa, Maria Cassia
   Sabino, Ester Cerdeira
   Figueiredo, Walter Manso
   Segurado, Aluisio Cotrim
   Mayaud, Philippe
TI Potential effect of Zika virus infection on human male fertility?
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE Zika virus; exual transmission; Shedding; Semen; Spermogram; Fertility;
   Brazil
ID SEXUAL TRANSMISSION
AB Background: Zika virus (ZIKV) sexual transmission and prolonged viral shedding in semen have been previously reported, suggesting a strong viral affinity for genital tissues. A transient impact of ZIKV on male fertility was shown in animal and human studies. Methods: Adult male patients with confirmed ZIKV infection diagnosed in the city of Araraquara, Brazil during the epidemic season of 2016 were invited one year after the acute infection to respond to a questionnaire of genital symptoms and to provide a semen sample for molecular ZIKV testing and spermogram analysis, as well as a serum sample for hormonal testing. Results: 101 of 187 tested patients had positive ZIKV RT-PCR in plasma and/or urine samples (54%. 72 women and 29 men). Of 15 adult male participants for whom telephone contact was successful, 14 responded to the questionnaire of genital symptoms and six consented to provide a semen sample at a median of 12 months after the acute infection. We report abnormal spermogram results from patients one year after confirmed ZIKV infection. Conclusions: Our findings suggest a possible long-term detrimental effect of ZIKV infection on human male fertility that has to be further explored in well-characterized samples from cohort studies conducted in ZIKV-endemic areas.
C1 [Avelino-Silva, Vivian Lida; Segurado, Aluisio Cotrim] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Av Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
   [Alvarenga, Conrado; Abreu, Carolina] Lab Med Masculina, Sao Paulo, SP, Brazil.
   [Tozetto-Mendoza, Tania Regina; Motta do Canto, Cynthia Liliane; Manuli, Erika Regina; Mendes-Correa, Maria Cassia; Sabino, Ester Cerdeira] Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, SP, Brazil.
   [Figueiredo, Walter Manso] Serv Especial Saude Araraquara, Sao Paulo, Brazil.
   [Mayaud, Philippe] London Sch Hyg & Trop Med, London, England.
RP Avelino-Silva, VL (corresponding author), Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Av Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
EM viviansilva87@gmail.com
RI Segurado, Aluisio C/K-2229-2012; Avelino-Silva, Vivian I/L-2640-2013;
   Sabino, Ester Cerdeira/F-7750-2010
OI Segurado, Aluisio C/0000-0002-6311-8036; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Sabino, Ester Cerdeira/0000-0003-2623-5126
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - CAPESCAPES
   [CSF-PVE-S-88887.122640/2016-00]; Ministry of Education, Brazil;
   European Union's Horizon 2020 Research and Innovation Program under the
   ZIKAlliance Grant [734548]
FX This work was partially supported by Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - CAPES, process
   CSF-PVE-S-88887.122640/2016-00, Ministry of Education, Brazil; and the
   European Union's Horizon 2020 Research and Innovation Program under the
   ZIKAlliance Grant Agreement No 734548.
CR Arsuaga M, 2016, LANCET INFECT DIS, V16, P1107, DOI 10.1016/S1473-3099(16)30320-6
   Brasil. Ministerio da Saude, 2015, PROT VIG RESP OC MIC
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Govero J, 2016, NATURE, V540, P438, DOI 10.1038/nature20556
   Joguet G, 2017, LANCET INFECT DIS, V17, P1200, DOI 10.1016/S1473-3099(17)30444-9
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P1106, DOI 10.1016/S1473-3099(16)30336-X
   Matheron S, 2016, CLIN INFECT DIS, V63, DOI 10.1093/cid/ciw509
   Ministerio da Saude Monitoramento dos casos de dengue, 2018, B EPIDEMIOLOGICO, V49, P1
   Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
   Nicastri E, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.32.30314
   Sherley M, 2018, SEX HEALTH, V15, P183, DOI 10.1071/SH17046
   Turmel JM, 2016, LANCET, V387, P2501, DOI 10.1016/S0140-6736(16)30775-9
   Uraki R, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602899
   World Health Organization, 2010, WHO LAB MAN EX PROC
NR 16
TC 9
Z9 9
U1 0
U2 3
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PY 2018
VL 60
AR e64
DI 10.1590/S1678-9946201860064
PG 4
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA GY8FT
UT WOS:000448858700004
PM 30379231
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-01
ER

PT J
AU Braz-Silva, PH
   Tozetto-Mendoza, TR
   Sumita, LM
   Freire, W
   Palmieri, M
   do Canto, AM
   Avelino-Silva, VI
   Gallottini, M
   Mayaud, P
   Pannuti, CS
AF Braz-Silva, Paulo H.
   Tozetto-mendoza, Tania R.
   Sumita, Laura M.
   Freire, Wilton
   Palmieri, Michelle
   do Canto, Alan M.
   Avelino-Silva, Vivian I.
   Gallottini, Marina
   Mayaud, Philippe
   Pannuti, Claudio S.
TI Prospective study of human herpesvirus 8 oral shedding, viremia, and
   serological status among human immunodeficiency virus seropositive and
   seronegative individuals in Sao Paulo, Brazil
SO JOURNAL OF ORAL MICROBIOLOGY
LA English
DT Article
DE HHV-8; oral shedding; Kaposi sarcoma; HIV
ID MEN; INFECTION; WOMEN; SEROPREVALENCE; SARCOMA; RISK; SEX
AB Human herpesvirus 8 (HHV-8) is a gamma-herpesvirus and etiological agent of all forms of Kaposi sarcoma (KS). Saliva may play an important role in HHV-8 transmission in specific populations. Little is known about HHV-8 oral shedding pattern and the possible correlation with the HHV-8 serological profile and viremia. A prospective study was conducted of HHV-8 salivary excretion among human immunodeficiency virus HIV-seronegative (n = 47) and -seropositive (n = 44) homosexual men and HIV-seropositive women (n = 32) over a 6-month period with monthly HHV-8 serologies (immunofluorescence assays to identify antibodies to latent and lytic HHV-8 viral proteins, and a whole-virus HHV-8 enzyme-linked immunosorbent assay [ELISA]), monthly HHV-8 DNA serum/plasma detection, and daily self-collected oral rinses for HHV-8-DNA detection using real-time polymerase chain reaction. HHV-8 seropositivity was 51.1%, 63.6%, and 37.5%, in the three studied groups. There was no case of HHV-8 DNA detection in serum/plasma. Intermittent detection of oral HHV-8 DNA was observed during 5.1% (110/2,160) of visits among 28% (18/64) of HHV-8-seropositive individuals, all of whom were males and HHV-8 ELISA seropositive. In immunologically controlled populations of Brazil, HHV-8 oral shedding was limited to HHV-8-seropositive men, occurred infrequently and intermittently, and was not linked to HHV-8 viremia, suggesting a limited potential for oral or blood transmission.
C1 [Braz-Silva, Paulo H.; Tozetto-mendoza, Tania R.; Sumita, Laura M.; Freire, Wilton; Pannuti, Claudio S.] Univ Sao Paulo, IMTSP, Lab Virol LIM 52, Sao Paulo, Brazil.
   [Braz-Silva, Paulo H.; Palmieri, Michelle; do Canto, Alan M.] Univ Sao Paulo, Fac Odontol FOUSP, Disciplina Patol Geral, Dept Estomatol, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian I.] Univ Sao Paulo, Fac Med FMUSP, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, Brazil.
   [Gallottini, Marina] Univ Sao Paulo, Dept Estomatol, Disciplina Patol Oral & Maxilofacial, Sao Paulo, Brazil.
   [Mayaud, Philippe] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London, England.
RP Braz-Silva, PH (corresponding author), Univ Sao Paulo, IMTSP, Lab Virol LIM 52, Sao Paulo, Brazil.; Braz-Silva, PH (corresponding author), Univ Sao Paulo, Fac Odontol FOUSP, Disciplina Patol Geral, Dept Estomatol, Sao Paulo, Brazil.
EM pbraz@usp.br
RI Avelino-Silva, Vivian I/L-2640-2013; Braz-Silva, Paulo
   Henrique/O-4344-2014
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Braz-Silva, Paulo
   Henrique/0000-0002-1842-9521
FU FAPESP-Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/04223-1,
   2012/04303-5]
FX Supported by FAPESP-Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   Grant numbers: 2012/04223-1 and 2012/04303-5.
CR Casper C, 2004, JAIDS-J ACQ IMM DEF, V35, P233, DOI 10.1097/00126334-200403010-00003
   Casper C, 2007, J INFECT DIS, V195, P30, DOI 10.1086/509621
   de Souza VAUF, 2007, J INFECT DIS, V196, P844, DOI 10.1086/520549
   Del Mistro A, 2012, SEX TRANSM DIS, V39, P894, DOI 10.1097/OLQ.0b013e31826ef2da
   Ignacio RAB, 2016, INFECT AGENTS CANCER, V11, DOI 10.1186/s13027-016-0052-2
   Johnston C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004222
   Levi JE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023546
   Nascimento MC, 2007, J CLIN MICROBIOL, V45, P715, DOI 10.1128/JCM.01264-06
   Pauk J, 2000, NEW ENGL J MED, V343, P1369, DOI 10.1056/NEJM200011093431904
   Phipps W, 2014, J MED VIROL, V86, P1759, DOI 10.1002/jmv.23941
   Pierrotti LC, 2005, SEX TRANSM DIS, V32, P57, DOI 10.1097/01.olq.0000148300.33428.6e
   Qu LR, 2010, TRANSFUSION, V50, P1050, DOI 10.1111/j.1537-2995.2009.02559.x
   Souza VAUF, 2004, BRAZ J MED BIOL RES, V37, P123, DOI 10.1590/S0100-879X2004000100017
   Taylor MM, 2004, J INFECT DIS, V190, P484, DOI 10.1086/421466
   Tozetto-Mendoza TR, 2018, J INVESTIG CLIN DENT, V9, DOI 10.1111/jicd.12278
   Vamvakas EC, 2011, TRANSFUS MED REV, V25, P47, DOI 10.1016/j.tmrv.2010.08.006
   Vitale F, 2000, EPIDEMIOL INFECT, V125, P671, DOI 10.1017/S0950268800004726
   Widmer IC, 2006, JAIDS-J ACQ IMM DEF, V42, P420, DOI 10.1097/01.qai.0000226790.31463.e6
NR 18
TC 5
Z9 6
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2000-2297
J9 J ORAL MICROBIOL
JI J. Oral Microbiology
PD OCT 15
PY 2017
VL 9
AR 1384287
DI 10.1080/20002297.2017.1384287
PG 6
WC Microbiology
SC Microbiology
GA FO6NH
UT WOS:000416980300001
PM 29081916
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-01
ER

PT J
AU Vieira, VA
   Avelino-Silva, VI
   Cerqueira, NB
   Costa, DA
   Costa, PR
   Vasconcelos, RP
   Madruga, VR
   Moreira, RI
   Hoagland, B
   Veloso, VG
   Grinsztejn, B
   Kallas, EG
AF Vieira, Vinicius A.
   Avelino-Silva, Vivian I.
   Cerqueira, Natalia B.
   Costa, Dayane A.
   Costa, Priscilla R.
   Vasconcelos, Ricardo P.
   Madruga, Valdez R.
   Moreira, Ronaldo I.
   Hoagland, Brenda
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Kallas, Esper G.
CA PrEP Brasil Study Team
TI Asymptomatic anorectal Chlamydia trachomatis and Neisseria gonorrhoeae
   infections are associated with systemic CD8(+) T-cell activation
SO AIDS
LA English
DT Article
DE cellular immunity; Chlamydia trachomatis; HIV; immune activation;
   Neisseria gonorrhoeae; preexposure prophylaxis; T lymphocyte
ID HIV PREEXPOSURE PROPHYLAXIS; SEXUALLY-TRANSMITTED INFECTIONS; IMMUNE
   ACTIVATION; HIGH-RISK; TRANSGENDER WOMEN; RECTAL GONORRHEA;
   GENITAL-TRACT; UNITED-STATES; MEN; SEX
AB Background: Oral preexposure prophylaxis (PrEP) has been established as a pivotal strategy in HIV prevention. However, bacterial sexually transmitted infections (STIs), such as Chlamydia trachomatis and Neisseria gonorrhoeae, are also highly prevalent. Although the presence of STI-related mucosal lesions is a known risk factor for HIV acquisition, the potential increase in risk associated with asymptomatic STIs is not completely understood. Recent data demonstrated higher T-cell activation is a risk factor for sexually acquired HIV-1 infection. We examined the effect of asymptomatic C. trachomatis and N. gonorrhoeae anorectal infection on systemic immune activation, potentially increasing the risk of HIV acquisition.
   Methods: We analyzed samples from participants of PrEP Brasil, a demonstration study of daily oral emtricitabine/tenofovir disoproxil fumarate HIV PrEP among healthy MSM, for T-cell activation by flow cytometry. We included 34 asymptomatic participants with anorectal swab for C. trachomatis and/or N. gonorrhoeae infection, whereas negative for other STIs, and 35 controls.
   Results: We found a higher frequency of human leukocyte antigen DR(+)CD3(+)CD8(+)T cells (1.5 vs. 0.9%, P<0.005) and with memory phenotype in the group with asymptomatic C. trachomatis and/or N. gonorrhoeae infection. Exhaustion and senescence markers were also significant higher in this group. No difference was observed in the soluble CD14 levels.
   Conclusion: Our findings suggest asymptomatic anorectal C. trachomatis and/or N. gonorrhoeae increase systemic immune activation, potentially increasing the risk of HIV acquisition. Regular screening and treatment of asymptomatic STIs should be explored as adjuvant tools for HIV prevention. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Vieira, Vinicius A.; Cerqueira, Natalia B.; Costa, Dayane A.; Costa, Priscilla R.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, SP, Brazil.
   [Vasconcelos, Ricardo P.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, SP, Brazil.
   [Avelino-Silva, Vivian I.] Hosp Sirio Libanes, Inst Ensino & Pesquisa, Sao Paulo, SP, Brazil.
   [Madruga, Valdez R.] Ctr Referencia & Treinamento DST AIDS, Sao Paulo, SP, Brazil.
   [Moreira, Ronaldo I.; Hoagland, Brenda; Veloso, Valdilea G.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil.
RP Kallas, EG (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil.
EM esper.kallas@usp.br
RI Vasconcelos, Ricardo/AAL-4634-2020; Avelino-Silva, Vivian I/L-2640-2013
OI Vasconcelos, Ricardo/0000-0002-9753-0563; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Kallas, Esper/0000-0003-2026-6925
FU Brazilian Ministry of Health [01/2013 BRA/K57]; National Counsel of
   Technological and Scientific Development - CNPqNational Council for
   Scientific and Technological Development (CNPq) [402004/2012-4,
   454931/2014-0]; SVS [281/2013]; Fundacao de Amparo a Pesquisa do Estado
   do Rio de Janeiro - FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ) [E-26/110.261/2014];
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/51743-0];
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Programa de Excelencia Academica - PROEX Program, Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - CAPES
FX The current work and PrEP Brasil study was supported by the Brazilian
   Ministry of Health (#01/2013 BRA/K57), National Counsel of Technological
   and Scientific Development - CNPq (#402004/2012-4, #454931/2014-0) SVS
   (#281/2013), Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro -
   FAPERJ (#E-26/110.261/2014) and Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo - FAPESP (#2012/51743-0). Gilead Sciences donated the study
   drug and covered the costs related to drug level assessment. D.A.C.'s
   scholarship was funded by FAPESP; P.R.C.'s scholarship was funded by
   Programa de Excelencia Academica - PROEX Program, Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - CAPES.
CR Avelino-Silva VI, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005219
   Baker J, 2009, AIDS PATIENT CARE ST, V23, P585, DOI 10.1089/apc.2008.0277
   Begaud E, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-35
   Bernstein KT, 2010, JAIDS-J ACQ IMM DEF, V53, P537, DOI 10.1097/QAI.0b013e3181c3ef29
   Blumenthal Jill, 2014, Virtual Mentor, V16, P909, DOI 10.1001/virtualmentor.2014.16.11.stas1-1411
   Buchbinder SP, 2014, LANCET INFECT DIS, V14, P468, DOI 10.1016/S1473-3099(14)70025-8
   Card CM, 2009, J INFECT DIS, V199, P1318, DOI 10.1086/597801
   Centers for Disease Control and Prevention, SEX TRANSM DIS SURV
   Cohen MS, 1998, LANCET, V351, P5
   Cohen Myron S, 2004, Top HIV Med, V12, P104
   CRAIB KJP, 1995, GENITOURIN MED, V71, P150, DOI 10.1136/sti.71.3.150
   Cunha CB, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2002-0
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Fichorova RN, 2001, INFECT IMMUN, V69, P5840, DOI 10.1128/IAI.69.9.5840-5848.2001
   Fonner VA, 2016, AIDS, V30, P1973, DOI 10.1097/QAD.0000000000001145
   Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   HAHN T, 1989, CLIN IMMUNOL IMMUNOP, V50, P53, DOI 10.1016/0090-1229(89)90221-3
   Horton RE, 2010, J INFECT DIS, V202, pS377, DOI 10.1086/655971
   Hunt PW, 2012, CURR HIV-AIDS REP, V9, P139, DOI 10.1007/s11904-012-0118-8
   Kaech SM, 2001, NAT IMMUNOL, V2, P415
   Kahle EM, 2015, J INFECT DIS, V211, P1451, DOI 10.1093/infdis/jiu621
   Koning FA, 2005, J IMMUNOL, V175, P6117, DOI 10.4049/jimmunol.175.9.6117
   Kuebler PJ, 2016, J INFECT DIS, V213, P569, DOI 10.1093/infdis/jiv425
   Lee HSW, 2008, J IMMUNOL, V180, P6827, DOI 10.4049/jimmunol.180.10.6827
   Liu AY, 2013, JAIDS-J ACQ IMM DEF, V64, P87, DOI 10.1097/QAI.0b013e31828f097a
   Masson L, 2015, CLIN INFECT DIS, V61, P260, DOI 10.1093/cid/civ298
   Masson L, 2014, SEX TRANSM INFECT, V90, P580, DOI 10.1136/sextrans-2014-051601
   McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2
   McLaren PJ, 2010, J INFECT DIS, V202, pS339, DOI 10.1086/655968
   Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273
   Murali-Krishna K, 2000, J IMMUNOL, V165, P1733, DOI 10.4049/jimmunol.165.4.1733
   Pathela P, 2015, CLIN INFECT DIS, V61, P281, DOI 10.1093/cid/civ289
   Pathela P, 2013, CLIN INFECT DIS, V57, P1203, DOI 10.1093/cid/cit437
   Pattacini L, 2016, JAIDS-J ACQ IMM DEF, V72, P119, DOI 10.1097/QAI.0000000000000919
   Reddy BS, 2004, CLIN EXP IMMUNOL, V137, P552, DOI 10.1111/j.1365-2249.2004.02564.x
   Redgrove KA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00534
   Restrepo C, 2010, J IMMUNOL, V185, P982, DOI 10.4049/jimmunol.1000221
   Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015
   Scott HM, 2016, AIDS RES THER, V13, DOI 10.1186/s12981-016-0089-8
   Sheth PM, 2008, J INFECT DIS, V197, P1394, DOI 10.1086/587697
   Solomon MM, 2014, CLIN INFECT DIS, V59, P1020, DOI 10.1093/cid/ciu450
   Tao GY, 2016, CLIN INFECT DIS, V63, P1325, DOI 10.1093/cid/ciw594
   Volk JE, 2015, CLIN INFECT DIS, V61, P1601, DOI 10.1093/cid/civ778
   Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862
NR 45
TC 1
Z9 1
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD SEP 24
PY 2017
VL 31
IS 15
BP 2069
EP 2076
DI 10.1097/QAD.0000000000001580
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA FG8ZM
UT WOS:000410727600004
PM 28692536
DA 2020-12-01
ER

PT J
AU Magnani, DM
   Silveira, CGT
   Rosen, BC
   Ricciardi, MJ
   Pedreno-Lopez, N
   Gutman, MJ
   Bailey, VK
   Maxwell, HS
   Domingues, A
   Gonzalez-Nieto, L
   Avelino-Silva, VI
   Trindade, M
   Nogueira, J
   Oliveira, CS
   Maestri, A
   Felix, AC
   Levi, JE
   Nogueira, ML
   Martins, MA
   Martinez-Navio, JM
   Fuchs, SP
   Whitehead, SS
   Burton, DR
   Desrosiers, RC
   Kallas, EG
   Watkins, DI
AF Magnani, Diogo M.
   Silveira, Cassia G. T.
   Rosen, Brandon C.
   Ricciardi, Michael J.
   Pedreno-Lopez, Nuria
   Gutman, Martin J.
   Bailey, Varian K.
   Maxwell, Helen S.
   Domingues, Aline
   Gonzalez-Nieto, Lucas
   Avelino-Silva, Vivian I.
   Trindade, Mateus
   Nogueira, Juliana
   Oliveira, Consuelo S.
   Maestri, Alvino
   Felix, Alvina Clara
   Levi, Jose Eduardo
   Nogueira, Mauricio L.
   Martins, Mauricio A.
   Martinez-Navio, Jose M.
   Fuchs, Sebastian P.
   Whitehead, Stephen S.
   Burton, Dennis R.
   Desrosiers, Ronald C.
   Kallas, Esper G.
   Watkins, David I.
TI A human inferred germline antibody binds to an immunodominant epitope
   and neutralizes Zika virus
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID MEMORY B-CELLS; DENGUE VIRUS; INTERIM GUIDELINES; UNITED-STATES;
   MONOCLONAL-ANTIBODIES; SOMATIC HYPERMUTATION; PREGNANT-WOMEN; HIV-1
   VACCINE; INFECTION; RESPONSES
AB The isolation of neutralizing monoclonal antibodies (nmAbs) against the Zika virus (ZIKV) might lead to novel preventative strategies for infections in at-risk individuals, primarily pregnant women. Here we describe the characterization of human mAbs from the plasmablasts of an acutely infected patient. One of the 18 mAbs had the unusual feature of binding to and neutralizing ZIKV despite not appearing to have been diversified by affinity maturation. This mAb neutralized ZIKV (Neut(50) similar to 2 mu g/ml) but did not react with any of the four dengue virus serotypes. Except for the expected junctional diversity created by the joining of the V-(D)-J genes, there was no deviation from immunoglobulin germline genes. This is a rare example of a human mAb with neutralizing activity in the absence of detectable somatic hypermutation. Importantly, binding of this mAb to ZIKV was specifically inhibited by human plasma from ZIKV-exposed individuals, suggesting that it may be of value in a diagnostic setting.
C1 [Magnani, Diogo M.; Rosen, Brandon C.; Ricciardi, Michael J.; Pedreno-Lopez, Nuria; Gutman, Martin J.; Bailey, Varian K.; Maxwell, Helen S.; Domingues, Aline; Gonzalez-Nieto, Lucas; Martins, Mauricio A.; Martinez-Navio, Jose M.; Fuchs, Sebastian P.; Desrosiers, Ronald C.; Watkins, David I.] Univ Miami, Dept Pathol, Miami, FL 33136 USA.
   [Silveira, Cassia G. T.; Maestri, Alvino; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, SP, Brazil.
   [Avelino-Silva, Vivian I.; Trindade, Mateus] Hosp Sirio Libanes, Sao Paulo, SP, Brazil.
   [Trindade, Mateus] Univ Sao Paulo, Sch Med, Neurol Dept, Sao Paulo, SP, Brazil.
   [Nogueira, Juliana] Adolfo Lutz Inst, Sao Paulo, SP, Brazil.
   [Oliveira, Consuelo S.] Inst Evandro Chagas, Belem, Para, Brazil.
   [Felix, Alvina Clara; Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop Sao Paulo, Dept Molestias Infecciosas & Parasitarias LIM 52, Sao Paulo, SP, Brazil.
   [Felix, Alvina Clara; Levi, Jose Eduardo] Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
   [Nogueira, Mauricio L.] Fac Med Sao Jose do Rio Preto, Dept Doencas Dermatol Infecciosas & Parasitarias, Lab Pesquisas Virol, Sao Jose Do Rio Preto, SP, Brazil.
   [Whitehead, Stephen S.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
   [Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA 92037 USA.
   [Burton, Dennis R.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Cambridge, MA USA.
RP Watkins, DI (corresponding author), Univ Miami, Dept Pathol, Miami, FL 33136 USA.
EM dwatkins@med.miami.edu
RI Avelino-Silva, Vivian I/L-2640-2013; Martins, Mauricio/AAU-9226-2020;
   Whitehead, Stephen/AAG-2787-2019; Nogueira, Mauricio L/B-7599-2012;
   amsalu, ribka/G-8780-2019; Terrassani Silveira, Cassia/M-8057-2017
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Martins,
   Mauricio/0000-0001-8336-216X; Nogueira, Mauricio L/0000-0003-1102-2419;
   Terrassani Silveira, Cassia/0000-0002-0932-7769; Kallas,
   Esper/0000-0003-2026-6925; Magnani, Diogo/0000-0002-1773-2406
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [4P01AI094420-05]; Wallace H. Coulter
   Center for Translational Research at University of Miami; Miami Clinical
   and Translational Science Institute (CTSI); NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460,
   UL1TR000460, UL1TR000460, UL1TR000460, UL1TR000460, UL1TR000460] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [ZIAAI000891, ZIAAI000891, ZIAAI000891,
   ZIAAI000891, ZIAAI000891, ZIAAI000891, ZIAAI000891, ZIAAI000891,
   ZIAAI000891, ZIAAI000891, ZIAAI000891] Funding Source: NIH RePORTER
FX This work was supported by the NIH grant 4P01AI094420-05, the Wallace H.
   Coulter Center for Translational Research at the University of Miami
   [http://www.miami.edu/index.php/u innovation/about_us/whcc/], and the
   Miami Clinical and Translational Science Institute (CTSI) [http://
   miamictsi.org].The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Bonsignori M, 2016, CELL, V165, P449, DOI 10.1016/j.cell.2016.02.022
   BOORMAN J. P. T., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P238, DOI 10.1016/0035-9203(56)90029-3
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Corti D, 2016, SCIENCE, V351, P1339, DOI 10.1126/science.aad5224
   Davidson E, 2014, IMMUNOLOGY, V143, P13, DOI 10.1111/imm.12323
   de Alwis R, 2014, METHODS MOL BIOL, V1138, P27, DOI 10.1007/978-1-4939-0348-1_3
   de Paula Freitas B, 2016, JAMA OPHTHALMOL
   Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   Dyer O, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6983
   Eisen HN, 2014, CANCER IMMUNOL RES, V2, P381, DOI 10.1158/2326-6066.CIR-14-0029
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Fields BN, 2007, FIELDS VIROLOGY, Vxix, P3091
   Fink K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00078
   Gatherer D, 2016, J GEN VIROL, V97, P269, DOI 10.1099/jgv.0.000381
   Giudicelli Veronique, 2011, Cold Spring Harb Protoc, V2011, P695, DOI 10.1101/pdb.prot5633
   Godoy-Lozano EE, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0276-1
   HADDOW AJ, 1964, B WORLD HEALTH ORGAN, V31, P57
   Hangartner L, 2006, NAT REV IMMUNOL, V6, P231, DOI 10.1038/nri1783
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Hennessey M, 2016, MMWR-MORBID MORTAL W, V65, P55, DOI 10.15585/mmwr.mm6503e1
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   Honein MA, 2016, JAMA J AM MED ASS
   Huzly D, 2016, EURO SURVEILL, V21
   Kalinke U, 2000, P NATL ACAD SCI USA, V97, P10126, DOI 10.1073/pnas.97.18.10126
   Kalinke U, 1996, IMMUNITY, V5, P639, DOI 10.1016/S1074-7613(00)80277-0
   Kato M, 2015, J VIROL, V89, P1468, DOI 10.1128/JVI.02293-14
   KAVERI SV, 1991, CLIN EXP IMMUNOL, V86, P192
   Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144
   Klein F, 2013, CELL, V153, P126, DOI 10.1016/j.cell.2013.03.018
   Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lefranc MP, 2003, DEV COMP IMMUNOL, V27, P55, DOI 10.1016/S0145-305X(02)00039-3
   Likos A, 2016, MMWR-MORBID MORTAL W, V65, P1032, DOI 10.15585/mmwr.mm6538e1
   Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1180
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i720
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Mor G, 2016, AM J REPROD IMMUNOL, V75, P421, DOI 10.1111/aji.12505
   Oduyebo T, 2016, MMWR-MORBID MORTAL W, V65, P122, DOI 10.15585/mmwr.mm6505e2
   Oster AM, 2016, MMWR-MORBID MORTAL W, V65, P120, DOI 10.15585/mmwr.mm6505e1
   Petersen EE, 2016, MMWR-MORBID MORTAL W, V65, P30, DOI 10.15585/mmwr.mm6502e1
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   ROOST HP, 1995, P NATL ACAD SCI USA, V92, P1257, DOI 10.1073/pnas.92.5.1257
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Sok D, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003754
   Speer SD, 2016, SCIENCE, V353, P750, DOI 10.1126/science.aah6187
   Staples JE, 2016, MMWR-MORBID MORTAL W, V65, P63, DOI 10.15585/mmwr.mm6503e3
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Sukupolvi-Petty S, 2010, J VIROL, V84, P9227, DOI 10.1128/JVI.01087-10
   Takemori T, 2014, EUR J IMMUNOL, V44, P1258, DOI 10.1002/eji.201343716
   Thornburg NJ, 2016, J CLIN INVEST, V126, P1482, DOI 10.1172/JCI85317
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Tiller T, 2007, IMMUNITY, V26, P205, DOI 10.1016/j.immuni.2007.01.009
   Wakerley BR, 2014, NAT REV NEUROL, V10, P537, DOI 10.1038/nrneurol.2014.138
   Wang QH, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aai8336
   West AP, 2014, CELL, V156, P633, DOI 10.1016/j.cell.2014.01.052
   Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11
   Xiao XD, 2009, BIOCHEM BIOPH RES CO, V390, P404, DOI 10.1016/j.bbrc.2009.09.029
   Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382
NR 72
TC 10
Z9 10
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2017
VL 11
IS 6
AR e0005655
DI 10.1371/journal.pntd.0005655
PG 17
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EZ9WL
UT WOS:000405080700038
PM 28604797
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Miyaji, KT
   Avelino-Silva, VI
   Simoes, M
   Freire, MD
   de Medeiros, CR
   Braga, PE
   Neves, MAA
   Lopes, MH
   Kallas, EG
   Sartori, AMC
AF Miyaji, Karina Takesaki
   Avelino-Silva, Vivian Iida
   Simoes, Marisol
   Freire, Marcos da Silva
   de Medeiros, Carlos Roberto
   Braga, Patricia Emilia
   Acala Neves, Maria Angelica
   Lopes, Marta Heloisa
   Kallas, Esper Georges
   Christovam Sartori, Ana Marli
TI Prevalence and titers of yellow fever virus neutralizing antibodies in
   previously vaccinated adults
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE Elderly; Immunization; Neutralizing antibody; Seroprevalence; Yellow
   fever vaccine
ID 17D; IMMUNOSENESCENCE; IMMUNOGENICITY
AB Introduction: The World Health Organization (WHO) recommends one single dose of the Yellow Fever (YF) vaccine based on studies of antibody persistency in healthy adults. We assessed the prevalence and titers of YF virus neutralizing antibodies in previously vaccinated persons aged >= 60 years, in comparison to younger adults. We also evaluated the correlation between antibody titers and the time since vaccination among participants who received one vaccine dose, and the seropositivity among participants vaccinated prior to or within the past 10 years. Methods: previously vaccinated healthy persons aged >= 18 years were included. YF virus neutralizing antibody titers were determined by means of the 50% Plaque Reduction Neutralization Test. Results: 46 persons aged >= 60 years and 48 persons aged 18 to 59 years were enrolled. There was no significant difference in the prevalence of YF virus neutralizing antibodies between the two groups (p = 0.263). However, titers were significantly lower in the elderly (p = 0.022). There was no correlation between YF virus neutralizing antibody titers and the time since vaccination. There was no significant difference in seropositivity among participants vaccinated prior to or within the past 10 years. Conclusions: the clinical relevance of the observed difference in YF virus neutralizing antibody titers between the two groups is not clear.
C1 [Miyaji, Karina Takesaki; Avelino-Silva, Vivian Iida; Lopes, Marta Heloisa; Christovam Sartori, Ana Marli] Univ Sao Paulo, Dept Molestias Infecciosas & Parasitarias, Fac Med, Av Dr Eneas de Carvalho Aguiar 155, BR-05403000 Sao Paulo, SP, Brazil.
   [Simoes, Marisol; Freire, Marcos da Silva] Fundacao Oswaldo Cruz, Lab Tecnol Virol Biomanguinhos, Rio De Janeiro, RJ, Brazil.
   [de Medeiros, Carlos Roberto] Hosp Vital Brazil, Inst Butantan, Sao Paulo, SP, Brazil.
   [Braga, Patricia Emilia] Univ Sao Paulo, Dept Med Prevent, Fac Med, Sao Paulo, SP, Brazil.
   [Acala Neves, Maria Angelica; Kallas, Esper Georges] Univ Sao Paulo, Div Imunol Clin & Alergia, Fac Med, Sao Paulo, SP, Brazil.
RP Miyaji, KT (corresponding author), Univ Sao Paulo, Dept Molestias Infecciosas & Parasitarias, Fac Med, Av Dr Eneas de Carvalho Aguiar 155, BR-05403000 Sao Paulo, SP, Brazil.
EM karinamiyaji@gmail.com
RI Braga, Patricia/B-7806-2018; Sartori, Ana Marli Christovam/I-6663-2012;
   Lopes, Marta H/J-3285-2012; Avelino-Silva, Vivian I/L-2640-2013; Miyaji,
   Karina T/B-1319-2016; Medeiros, Carlos Roberto de/F-6513-2015
OI Sartori, Ana Marli Christovam/0000-0003-3777-0757; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Miyaji, Karina T/0000-0003-2653-3975; Lopes,
   Marta Heloisa/0000-0001-5236-6248; Kallas, Esper/0000-0003-2026-6925
CR [Anonymous], 2013, Wkly Epidemiol Rec, V88, P269
   Brasil. Ministerio da Saude, REC VAC FEBR AM AP D
   Brasil. Ministerio da Saude, 2014, ASP EP FEBR AM SILV, V45, P1
   Caldas IR, 2014, VACCINE, V32, P4977, DOI 10.1016/j.vaccine.2014.07.021
   Camacho LAB, 2004, REV SAUDE PUBL, V38, P671, DOI 10.1590/S0034-89102004000500009
   Coulange Bodilis H, 2011, Bull Soc Pathol Exot, V104, P260, DOI 10.1007/s13149-011-0135-7
   Gómez Sergio Y, 2008, Rev. salud pública, V10, P796
   Goronzy JJ, 2013, NAT IMMUNOL, V14, P428, DOI 10.1038/ni.2588
   Gotuzzo E, 2013, AM J TROP MED HYG, V89, P434, DOI 10.4269/ajtmh.13-0264
   Grubeck-Loebenstein B, 2009, AGING CLIN EXP RES, V21, P201, DOI 10.1007/BF03324904
   Mascheretti M, 2013, REV SAUDE PUBL, V47, DOI 10.1590/S0034-8910.2013047004341
   Monath TP, 2005, HUM VACCINES, V1, P207, DOI 10.4161/hv.1.5.2221
   Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
   Monath TP, 2013, VACCINES, P870
   Niedrig M, 1999, TROP MED INT HEALTH, V4, P867, DOI 10.1046/j.1365-3156.1999.00496.x
   POLAND JD, 1981, B WORLD HEALTH ORGAN, V59, P895
   Roukens AH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027753
   Simoes M, 2012, BIOLOGICALS, V40, P399, DOI 10.1016/j.biologicals.2012.09.005
   Tuboi SH, 2007, T ROY SOC TROP MED H, V101, P169, DOI 10.1016/j.trstmh.2006.04.001
NR 19
TC 9
Z9 9
U1 0
U2 4
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PY 2017
VL 59
AR e2
DI 10.1590/S1678-9946201759002
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA ER3ZT
UT WOS:000398739500002
PM 28380113
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Miyaji, KT
   Hunt, PW
   Huang, Y
   Simoes, M
   Lima, SB
   Freire, MS
   Caiaffa, HH
   Hong, MA
   Costa, DA
   Dias, JZC
   Cerqueira, NB
   Nishiya, AS
   Sabino, EC
   Sartori, AM
   Kallas, EG
AF Avelino-Silva, Vivian I.
   Miyaji, Karina T.
   Hunt, Peter W.
   Huang, Yong
   Simoes, Marisol
   Lima, Sheila B.
   Freire, Marcos S.
   Caiaffa-Filho, Helio H.
   Hong, Marisa A.
   Costa, Dayane Alves
   Dias, Juliana Zanatta C.
   Cerqueira, Natalia B.
   Nishiya, Anna Shoko
   Sabino, Ester Cerdeira
   Sartori, Ana M.
   Kallas, Esper G.
TI CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity
   in HIV-Infected Patients
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID T-CELL-ACTIVATION; ANTIRETROVIRAL THERAPY; TRYPTOPHAN CATABOLISM; C
   INFECTION; MORTALITY; IMMUNIZATION; EVENTS; NORMALIZATION; INFLAMMATION;
   INDIVIDUALS
AB Background
   HIV-infected individuals have deficient responses to Yellow Fever vaccine (YFV) and may be at higher risk for adverse events (AE). Chronic immune activation-characterized by low CD4/CD8 ratio or high indoleamine 2,3-dioxygenase-1 (IDO) activity D may influence vaccine response in this population.
   Methods
   We prospectively assessed AE, viremia by the YFV virus and YF-specific neutralizing antibodies (NAb) in HIV-infected (CD4>350) and -uninfected adults through 1 year after vaccination. The effect of HIV status on initial antibody response to YFV was measured during the first 3 months following vaccination, while the effect on persistence of antibody response was measured one year following vaccination. We explored CD4/CD8 ratio, IDO activity (plasma kynurenine/tryptophan [KT] ratio) and viremia by Human Pegivirus as potential predictors of NAb response to YFV among HIV-infected participants with linear mixed models.
   Results
   12 HIV-infected and 45-uninfected participants were included in the final analysis. HIV was not significantly associated with AE, YFV viremia or NAb titers through the first 3 months following vaccination. However, HIV-infected participants had 0.32 times the NAb titers observed for HIV-uninfected participants at 1 year following YFV (95% CI 0.13 to 0.83, p = 0.021), independent of sex, age and prior vaccination. In HIV-infected participants, each 10% increase in CD4/CD8 ratio predicted a mean 21% higher post-baseline YFV Nab titer (p = 0.024). Similarly, each 10% increase in KT ratio predicted a mean 21% lower post-baseline YFV Nab titer (p = 0.009). Viremia by Human Pegivirus was not significantly associated with NAb titers.
   Conclusions
   HIV infection appears to decrease the durability of NAb responses to YFV, an effect that may be predicted by lower CD4/CD8 ratio or higher KT ratio.
C1 [Avelino-Silva, Vivian I.; Miyaji, Karina T.; Sabino, Ester Cerdeira; Sartori, Ana M.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian I.; Hunt, Peter W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Huang, Yong] Univ Calif San Francisco, Sch Pharm, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.
   [Simoes, Marisol; Lima, Sheila B.; Freire, Marcos S.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Caiaffa-Filho, Helio H.; Hong, Marisa A.] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Caiaffa-Filho, Helio H.] Univ Sao Paulo, Sch Med, Lab Med Invest LIM 3, Sao Paulo, Brazil.
   [Hong, Marisa A.; Costa, Dayane Alves; Dias, Juliana Zanatta C.; Cerqueira, Natalia B.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Nishiya, Anna Shoko; Sabino, Ester Cerdeira] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.; Avelino-Silva, VI (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
EM viviansilva87@gmail.com
RI Caiaffa-Filho, Helio H/H-6982-2012; Avelino-Silva, Vivian I/L-2640-2013;
   Sartori, Ana Marli Christovam/I-6663-2012; Sabino, Ester
   Cerdeira/F-7750-2010; Hunt, Peter W./P-2976-2017
OI Caiaffa-Filho, Helio H/0000-0001-6048-4527; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Sartori, Ana Marli
   Christovam/0000-0003-3777-0757; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Hunt, Peter W./0000-0002-4571-4870;
   Barbosa de Lima, Sheila Maria/0000-0001-9234-1678; Kallas,
   Esper/0000-0003-2026-6925
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Capes),
   Ministry of Education, BrazilCAPES; Fundacao de Amparo a Pesquisa do
   Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2013/05246-8]; NIH/NIAIDUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [1R01AI110271-01A1];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI110271, R01AI110271, R01AI110271, R01AI110271, R01AI110271]
   Funding Source: NIH RePORTER
FX This study was funded by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (Capes), Ministry of Education, Brazil; Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (2013/05246-8); and NIH/NIAID
   1R01AI110271-01A1. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Avelino-Silva VI, 2013, BONE MARROW TRANSPL, V48, P1008, DOI 10.1038/bmt.2012.277
   Avelino-Silva VI, 2015, J ACQ IMMUN DEF SYND, p[71, 189]
   Barte H, 2014, COCHRANE DB SYST REV, V1
   Bhaskaran K, 2008, JAMA-J AM MED ASSOC, V300, P51, DOI 10.1001/jama.300.1.51
   Bhattarai N, 2012, J INFECT DIS, V206, P1469, DOI 10.1093/infdis/jis515
   Boyer J RL., 2015, C RETR OPP DIS SEATT
   Byakwaga H, 2014, J INFECT DIS, V210, P383, DOI 10.1093/infdis/jiu115
   Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198
   Gaardbo JC, 2015, JAIDS-J ACQ IMM DEF, V70, P228, DOI 10.1097/QAI.0000000000000758
   GOUJON C, 1995, 4 INT C TRAV MED AC
   Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7
   Huang Y, 2013, BIOANALYSIS, V5, P1397, DOI [10.4155/bio.13.74, 10.4155/BIO.13.74]
   Hunt PW, 2014, J INFECT DIS, V210, P1228, DOI 10.1093/infdis/jiu238
   Hunt PW, 2012, CURR HIV-AIDS REP, V9, P139, DOI 10.1007/s11904-012-0118-8
   Hunt PW, 2011, AIDS, V25, P2123, DOI 10.1097/QAD.0b013e32834c4ac1
   Jain V, 2013, J INFECT DIS, V208, P1202, DOI 10.1093/infdis/jit311
   Lederman MM, 2013, ADV IMMUNOL, V119, P51, DOI 10.1016/B978-0-12-407707-2.00002-3
   Lindsey NP, 2008, VACCINE, V26, P6077, DOI 10.1016/j.vaccine.2008.09.009
   Lu W, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20052
   Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Mantel N, 2008, J VIROL METHODS, V151, P40, DOI 10.1016/j.jviromet.2008.03.026
   Martins RD, 2015, HUM VACC IMMUNOTHER, V11, P2183, DOI 10.1080/21645515.2015.1022700
   Milagres LG, 2013, AIDS, V27, P2697, DOI 10.1097/QAD.0000000000000007
   Mussini C, 2015, LANCET HIV, V2, pE98, DOI 10.1016/S2352-3018(15)00006-5
   Muyanja E, 2014, J CLIN INVEST, V124, P3147, DOI 10.1172/JCI75429
   Okulicz JF, 2015, JAMA INTERN MED, V175, P88, DOI 10.1001/jamainternmed.2014.4010
   Pacanowski J, 2012, JAIDS-J ACQ IMM DEF, V59, P360, DOI 10.1097/QAI.0b013e318249de59
   Parmigiani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079816
   Pistone T, 2010, CURR HIV RES, V8, P461, DOI 10.2174/157016210793499277
   Richardson K, 2011, AIDS, V25, P595, DOI 10.1097/QAD.0b013e32834411a8
   Schouten J, 2014, CROSS SECTIONAL COM
   Selvan SR, 2015, CURR CANC DRUG TARGE
   Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
   Sibailly TS, 1997, PEDIATR INFECT DIS J, V16, P1177, DOI 10.1097/00006454-199712000-00015
   Sidibe M, 2012, T ROY SOC TROP MED H, V106, P437, DOI 10.1016/j.trstmh.2012.04.002
   Simoes M, 2012, BIOLOGICALS, V40, P399, DOI 10.1016/j.biologicals.2012.09.005
   Staples JE, 2015, MMWR-MORBID MORTAL W, V64, P647
   Stapleton JT, 2013, AIDS, V27, P1829, DOI 10.1097/QAD.0b013e328363089f
   Tenorio AR, 2014, J INFECT DIS, V210, P1248, DOI 10.1093/infdis/jiu254
   U.S. Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases Division of AIDS, 2014, DIV AIDS DAIDS TABL
   Veit O, 2009, CLIN INFECT DIS, V48, P659, DOI 10.1086/597006
   Weinberg A, 2006, J INFECT DIS, V193, P302, DOI 10.1086/498979
NR 43
TC 11
Z9 12
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD DEC
PY 2016
VL 10
IS 12
AR e0005219
DI 10.1371/journal.pntd.0005219
PG 15
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EI0IX
UT WOS:000392158100070
PM 27941965
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Defechereux, PA
   Mehrotra, M
   Liu, AY
   McMahan, VM
   Glidden, DV
   Mayer, KH
   Vargas, L
   Amico, KR
   Chodacki, P
   Fernandez, T
   Avelino-Silva, VI
   Burns, D
   Grant, RM
AF Defechereux, Patricia A.
   Mehrotra, Megha
   Liu, Albert Y.
   McMahan, Vanessa M.
   Glidden, David V.
   Mayer, Kenneth H.
   Vargas, Lorena
   Amico, K. Rivet
   Chodacki, Piotr
   Fernandez, Telmo
   Avelino-Silva, Vivian I.
   Burns, David
   Grant, Robert M.
CA IPrEx Study Team
TI Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men
   and Transgender Women Who Have Sex With Men (MSM/TGW)
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Depression; Men who have sex with men; HIV prevention; PrEP; FTC/TDF;
   iPrEx
ID TENOFOVIR DISOPROXIL FUMARATE; NUTRITION EXAMINATION SURVEY; SUICIDAL
   IDEATION; BISEXUAL ADULTS; UNITED-STATES; HIV-INFECTION; RISK-TAKING;
   ANTIRETROVIRAL PROPHYLAXIS; ANGLO ADOLESCENTS; HISPANIC HEALTH
AB We conducted a longitudinal and cross-sectional analysis of depressive symptomology in iPrEx, a randomized, placebo-controlled trial of daily, oral FTC/TDF HIV pre-exposure prophylaxis (PrEP) in men and transgender women who have sex with men. Depression-related adverse events (AEs) were the most frequently reported severe or life-threatening AEs and were not associated with being randomized to the FTC/TDF arm (152 vs. 144 respectively OR 0.66 95 % CI 0.35-1.25). Center for Epidemiologic Studies Depression scale (CES-D) and a four questions suicidal ideation scale scores did not differ by arm. Participants reporting forced sex at anal sexual debut had higher CES-D scores (coeff: 3.23; 95 % CI 1.24-5.23) and were more likely to have suicidal ideation (OR 2.2; 95 % CI 1.09-4.26). CESD scores were higher among people reporting non-condom receptive anal intercourse (ncRAI) (OR 1.46; 95 % CI 1.09-1.94). We recommend continuing PrEP during periods of depression in conjunction with provision of mental health services.
C1 [Defechereux, Patricia A.; Mehrotra, Megha; McMahan, Vanessa M.; Grant, Robert M.] GIVI, J David Gladstone Inst, Grant Lab, 5th Floor,1650 Owens St, San Francisco, CA 94158 USA.
   [Liu, Albert Y.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA.
   [Liu, Albert Y.; Glidden, David V.; Grant, Robert M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Mayer, Kenneth H.] Fenway Community Hlth, Boston, MA USA.
   [Vargas, Lorena] Invest Med Salud, Lima, Peru.
   [Amico, K. Rivet] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
   [Amico, K. Rivet] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
   [Chodacki, Piotr] Univ Cape Town, Desmond Tutu HIV Fdn, ZA-7925 Cape Town, South Africa.
   [Fernandez, Telmo] Fdn Ecuatoriana Equidad, Guayaquil, Ecuador.
   [Avelino-Silva, Vivian I.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Burns, David] NIH, Bethesda, MD 20892 USA.
   [Grant, Robert M.] San Francisco AIDS Fdn, San Francisco, CA USA.
RP Grant, RM (corresponding author), GIVI, J David Gladstone Inst, Grant Lab, 5th Floor,1650 Owens St, San Francisco, CA 94158 USA.; Grant, RM (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.; Grant, RM (corresponding author), San Francisco AIDS Fdn, San Francisco, CA USA.
EM robert.grant@ucsf.edu
RI Glidden, David/AAD-4730-2020; /AAE-4700-2020; Avelino-Silva, Vivian
   I/L-2640-2013
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Glidden,
   David/0000-0001-5888-1419; Amico, K Rivet/0000-0002-4458-6934; Grant,
   Robert/0000-0002-0851-7085
FU Division of Acquired Immunodeficiency Syndrome (DAIDS), National
   Institute of Allergy and Infectious Diseases, National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [UO1 AI64002]; Bill and Melinda Gates
   FoundationBill & Melinda Gates Foundation; NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01
   AI64002]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01AI064002, R01AI118575, U01AI064002, U01AI064002,
   R01AI118575, U01AI064002, U01AI064002, U01AI064002, U01AI064002,
   R01AI118575, R01AI118575, R01AI118575, R01AI118575, U01AI064002,
   U01AI064002] Funding Source: NIH RePORTER
FX This paper is dedicated to the memory of James Jeff McConnell. The
   authors thank the iPrEx participants without whom none of these studies
   would have been possible. This work was supported by the Division of
   Acquired Immunodeficiency Syndrome (DAIDS), National Institute of
   Allergy and Infectious Diseases, National Institutes of Health, as a
   cooperative agreement (UO1 AI64002) and by the Bill and Melinda Gates
   Foundation. Study drugs were donated by Gilead Sciences. These agencies
   were not involved in the analysis of data or the preparation of this
   manuscript. Some of the data was presented as a poster, at the 6th
   International AIDS Society Conference on HIV Pathogenesis, Treatment,
   and Prevention, 2011, Rome. The authors also thank all study sites teams
   for their outstanding work in conducting the iPrEx trial. RG, DG, and
   VMM designed and coordinated the iPrEx and iPrEx OLE trials. AYL, PD and
   RG conceived the present depression study. RA provided consultancy. DB
   was the study sponsor Medical Officer and provided study oversight. AYL,
   LV, KM, PC, TF, VAS contributed to site leadership, procedural
   implementation and data collection. MM and DG performed the statistical
   analysis. PD and MM wrote the manuscript. All authors critically
   reviewed, revised, and approved the final manuscript. This work was
   supported by NIH U01 AI64002 and the Bill and Melinda Gates Foundation.
   Study drug was donated by Gilead Sciences. These agencies were not
   involved in the analysis of data or the preparation of this manuscript.
CR Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Arribas JR, 2008, JAIDS-J ACQ IMM DEF, V47, P74, DOI 10.1097/QAI.0b013e31815acab8
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Buchbinder SP, 2014, LANCET INFECT DIS, V14, P468, DOI 10.1016/S1473-3099(14)70025-8
   CHO MJ, 1993, SOC PSYCH PSYCH EPID, V28, P156, DOI 10.1007/BF00797317
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   Cochran SD, 2000, AM J PUBLIC HEALTH, V90, P573, DOI 10.2105/AJPH.90.4.573
   Cochran SD, 2003, J CONSULT CLIN PSYCH, V71, P53, DOI 10.1037/0022-006X.71.1.53
   Crockett LJ, 2005, J CONSULT CLIN PSYCH, V73, P47, DOI 10.1037/0022-006X.73.1.47
   Dunn EC, 2013, DEPRESS ANXIETY, V30, P955, DOI 10.1002/da.22102
   Fergusson DM, 2013, CHILD ABUSE NEGLECT, V37, P664, DOI 10.1016/j.chiabu.2013.03.013
   Ferrari AJ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001547
   Friedman MS, 2011, AM J PUBLIC HEALTH, V101, P1481, DOI 10.2105/AJPH.2009.190009
   Fumaz CR, 2005, JAIDS-J ACQ IMM DEF, V38, P560, DOI 10.1097/01.qai.0000147523.41993.47
   Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871
   Goldney RD, 2003, J AFFECT DISORDERS, V74, P267, DOI 10.1016/S0165-0327(02)00017-4
   Gonzalez JS, 2011, JAIDS-J ACQ IMM DEF, V58, P181, DOI [10.1097/QAI.0b013e31822d490a, 10.1097/QAI.0B013E31822D490A]
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   GUARNACCIA PJ, 1990, AM J PSYCHIAT, V147, P1449
   GUARNACCIA PJ, 1989, SOC SCI MED, V29, P85, DOI 10.1016/0277-9536(89)90131-7
   Haas AP, 2010, J HOMOSEXUAL, V58, P10, DOI 10.1080/00918369.2011.534038
   Herek GM, 1999, J CONSULT CLIN PSYCH, V67, P945, DOI 10.1037/0022-006X.67.6.945
   Herek GM, 2009, J INTERPERS VIOLENCE, V24, P54, DOI 10.1177/0886260508316477
   Horberg MA, 2008, JAIDS-J ACQ IMM DEF, V47, P384, DOI 10.1097/QAI.0b013e318160d53e
   Kim G, 2011, CULT DIVERS ETHN MIN, V17, P381, DOI 10.1037/a0025434
   Koblin BA, 2006, AIDS, V20, P731, DOI 10.1097/01.aids.0000216374.61442.55
   Lewinsohn PM, 1996, CLIN PSYCHOL-SCI PR, V3, P25, DOI 10.1111/j.1468-2850.1996.tb00056.x
   Liverpool Uo., 2013, DRUG INTERACTIONS CH
   Mays VM, 2001, AM J PUBLIC HEALTH, V91, P1869, DOI 10.2105/AJPH.91.11.1869
   Mills TC, 2004, AM J PSYCHIAT, V161, P278, DOI 10.1176/appi.ajp.161.2.278
   Mimiaga MJ, 2009, JAIDS-J ACQ IMM DEF, V51, P340, DOI 10.1097/QAI.0b013e3181a24b38
   Mollan KR, 2014, ANN INTERN MED, V161, P1, DOI 10.7326/M14-0293
   O'Leary A, 2003, AIDS CARE, V15, P17, DOI 10.1080/0954012021000039725
   Paul JP, 2001, CHILD ABUSE NEGLECT, V25, P557, DOI 10.1016/S0145-2134(01)00226-5
   Perdue T, 2003, AIDS EDUC PREV, V15, P81, DOI 10.1521/aeap.15.1.81.23842
   Pozniak AL, 2006, JAIDS-J ACQ IMM DEF, V43, P535
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Reisner SL, 2009, AIDS CARE, V21, P1481, DOI 10.1080/09540120902893258
   Reisner SL, 2009, AIDS BEHAV, V13, P798, DOI 10.1007/s10461-009-9571-9
   Reisner SL, 2009, AIDS PATIENT CARE ST, V23, P545, DOI 10.1089/apc.2008.0249
   Reuland DS, 2009, ANN FAM MED, V7, P455, DOI 10.1370/afm.981
   Rihs TA, 2006, HIV MED, V7, P544, DOI 10.1111/j.1468-1293.2006.00419.x
   ROBERTS RE, 1995, J AM ACAD CHILD PSY, V34, P81, DOI 10.1097/00004583-199501000-00018
   Ruiz-Grosso P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045413
   Salomon EA, 2009, AIDS BEHAV, V13, P811, DOI 10.1007/s10461-008-9439-4
   Sin NL, 2013, ANN BEHAV MED
   Stall R, 2003, AM J PUBLIC HEALTH, V93, P939, DOI 10.2105/AJPH.93.6.939
   Stansbury JP, 2006, J PERS ASSESS, V86, P10, DOI 10.1207/s15327752jpa8601_03
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Vatanasin D, 2012, J CHILD ADOL PS NURS, V25, P195, DOI 10.1111/jcap.12012
   Wagner GJ, 2011, ANN BEHAV MED, V42, P352, DOI 10.1007/s12160-011-9295-8
NR 51
TC 19
Z9 23
U1 0
U2 14
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD JUL
PY 2016
VL 20
IS 7
BP 1478
EP 1488
DI 10.1007/s10461-015-1082-2
PG 11
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA DQ1ZS
UT WOS:000379000500012
PM 26078115
OA Other Gold, Green Published
DA 2020-12-01
ER

PT J
AU Mehrotra, ML
   Glidden, DV
   McMahan, V
   Amico, KR
   Hosek, S
   Defechereux, P
   Mayer, KH
   Veloso, VG
   Bekker, LG
   Avelino-Silva, VI
   Schechter, M
   Grant, RM
AF Mehrotra, Megha L.
   Glidden, David V.
   McMahan, Vanessa
   Amico, K. Rivet
   Hosek, Sybil
   Defechereux, Patricia
   Mayer, Kenneth H.
   Veloso, Valdilea G.
   Bekker, Linda-Gail
   Avelino-Silva, Vivian I.
   Schechter, Mauro
   Grant, Robert M.
TI The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men
   who have Sex with Men and Transgender Women: A Marginal Structural Model
   Analysis of The iPrEx OLE Study
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Depression; Men who have sex with men; Transgender women; HIV
   prevention; Preexposure prophylaxis; PrEP; iPrEx OLE; Adherence;
   Marginal structural model
ID CES-D SCALE; PREEXPOSURE PROPHYLAXIS; HIV-INFECTION; ANTIRETROVIRAL
   PROPHYLAXIS; MEDICATION ADHERENCE; BISEXUAL ADULTS; AFRICAN WOMEN;
   UNITED-STATES; RISK-FACTORS; PREVENTION
AB We assessed the role of depressive symptoms on adherence to daily oral FTC/TDF for HIV PrEP in cis-gender men who have sex with men (MSM) and transgender women who have sex with men (TGW) using data from the iPrEx OLE study. A marginal structural logistic regression model was used to estimate the effect of time-varying CES-D scores on having protective levels of drug concentration, adjusting for confounding by sexual practices over time, prior adherence, and baseline demographic characteristics. We found a non-monotonic relationship between CES-D score and odds of protective FTC/TDF levels in MSM. We found evidence that the effect of depression on adherence varied between MSM and TGW, and that depressive symptoms did not contribute greatly to decreased adherence on a population scale. We recommend that depressive symptoms not preclude the prescription of PrEP, and that MSM and TGW be studied separately.
C1 [Mehrotra, Megha L.; McMahan, Vanessa; Defechereux, Patricia; Grant, Robert M.] GIVI, Grant Lab, J David Gladstone Inst, 5th Floor 1650 Owens St, San Francisco, CA 94158 USA.
   [Mehrotra, Megha L.; Glidden, David V.; Grant, Robert M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Amico, K. Rivet] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
   [Hosek, Sybil] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA.
   [Mayer, Kenneth H.] Fenway Community Hlth, Boston, MA USA.
   [Veloso, Valdilea G.] Fiocruz MS, Rio De Janeiro, Brazil.
   [Bekker, Linda-Gail] Desmond Tutu Hlth Fdn, Cape Town, South Africa.
   [Avelino-Silva, Vivian I.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Schechter, Mauro] Univ Fed Rio de Janeiro, Projeto Praca Onze, Hosp Escola Sao Francisco de Assis, Rio De Janeiro, Brazil.
RP Mehrotra, ML (corresponding author), GIVI, Grant Lab, J David Gladstone Inst, 5th Floor 1650 Owens St, San Francisco, CA 94158 USA.; Mehrotra, ML (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.
EM megha.mehrotra@gladstone.ucsf.edu
RI Glidden, David/AAD-4730-2020; /AAE-4700-2020; Avelino-Silva, Vivian
   I/L-2640-2013; Bekker, Linda-Gail/AAZ-8929-2020; Schechter,
   Mauro/AAG-7445-2020
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Glidden,
   David/0000-0001-5888-1419; Grant, Robert/0000-0002-0851-7085; Amico, K
   Rivet/0000-0002-4458-6934; BEKKER, LINDA-GAIL/0000-0002-0755-4386
FU US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [5U01AI064002];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI118575, U01AI064002, U01AI064002, R01AI118575, R01AI118575,
   U01AI064002, UM1AI069476, UM1AI069476, UM1AI069476, U01AI064002,
   UM1AI069476, UM1AI069476, UM1AI069476, U01AI064002, R01AI118575,
   UM1AI069476, R01AI118575, U01AI064002, R01AI118575, U01AI064002,
   UM1AI069476, UM1AI069476, U01AI064002, U01AI064002] Funding Source: NIH
   RePORTER
FX This study was funded by the US National Institutes of Health: Grant
   Number 5U01AI064002.
CR Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5
   Campos LN, 2010, AIDS BEHAV, V14, P289, DOI 10.1007/s10461-008-9435-8
   Castillo-Mancilla JR, 2013, AIDS RES HUM RETROV, V29, P384, DOI [10.1089/AID.2012.0089, 10.1089/aid.2012.0089]
   Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7
   Cochran SD, 2003, J CONSULT CLIN PSYCH, V71, P53, DOI 10.1037/0022-006X.71.1.53
   Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164
   Corneli AL, 2014, JAIDS-J ACQ IMM DEF, V66, P324, DOI 10.1097/QAI.0000000000000158
   Crockett LJ, 2005, J CONSULT CLIN PSYCH, V73, P47, DOI 10.1037/0022-006X.73.1.47
   Defechereux P, 2015, AIDS BEHAV, V16, P1
   Deutsch MB, 2015, LANCET HIV
   Fewell Z, 2004, STATA J, V4, P402, DOI 10.1177/1536867X0400400403
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008
   Haberer JE, 2015, AIDS, V29, P1277, DOI 10.1097/QAD.0000000000000647
   Hatzenbuehler ML, 2011, ANN BEHAV MED, V42, P227, DOI 10.1007/s12160-011-9275-z
   Hoffman B, 2014, DEPRESS RES TREAT, V13
   Koblin BA, 2006, AIDS, V20, P731, DOI 10.1097/01.aids.0000216374.61442.55
   Lewinsohn PM, 1996, CLIN PSYCHOL-SCI PR, V3, P25, DOI 10.1111/j.1468-2850.1996.tb00056.x
   Lin EHB, 2004, DIABETES CARE, V27, P2154, DOI 10.2337/diacare.27.9.2154
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   Mays VM, 2001, AM J PUBLIC HEALTH, V91, P1869, DOI 10.2105/AJPH.91.11.1869
   Nel A, 2013, AIDS CARE, V25, P948, DOI 10.1080/09540121.2012.748867
   O'Cleirigh C, 2009, J BEHAV MED, V32, P466, DOI 10.1007/s10865-009-9217-4
   ORME JG, 1986, J CLIN PSYCHOL, V42, P28, DOI 10.1002/1097-4679(198601)42:1<28::AID-JCLP2270420104>3.0.CO;2-T
   PRENTICE RL, 1986, BIOMETRIKA, V73, P1
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Reuland DS, 2009, ANN FAM MED, V7, P455, DOI 10.1370/afm.981
   ROBERTS RE, 1990, PSYCHIAT RES, V31, P69, DOI 10.1016/0165-1781(90)90110-Q
   Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011
   Ruiz-Grosso P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045413
   Safren SA, 2009, HEALTH PSYCHOL, V28, P1, DOI 10.1037/a0012715
   Salomon EA, 2009, AIDS BEHAV, V13, P811, DOI 10.1007/s10461-008-9439-4
   StataCorp, 2014, STATA STAT SOFTW REL
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   VanderWeele TJ, 2014, EPIDEMIOL METHODS, V3
   Vatanasin D, 2012, J CHILD ADOL PS NURS, V25, P195, DOI 10.1111/jcap.12012
NR 40
TC 15
Z9 14
U1 0
U2 9
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD JUL
PY 2016
VL 20
IS 7
BP 1527
EP 1534
DI 10.1007/s10461-016-1415-9
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA DQ1ZS
UT WOS:000379000500016
PM 27125241
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Amico, KR
   Mehrotra, M
   Avelino-Silva, VI
   McMahan, V
   Veloso, VG
   Anderson, P
   Guanira, J
   Grant, R
AF Amico, K. Rivet
   Mehrotra, Megha
   Avelino-Silva, Vivian I.
   McMahan, Vanessa
   Veloso, Valdilea G.
   Anderson, Peter
   Guanira, Juan
   Grant, Robert
CA IPrEx Study Team
TI Self-reported Recent PrEP Dosing and Drug Detection in an Open Label
   PrEP Study
SO AIDS AND BEHAVIOR
LA English
DT Article
DE PrEP adherence; Self-report; Drug levels; Open-label; Demonstration
   project; iPrEx; FTC/TDF
ID HIV PREEXPOSURE PROPHYLAXIS; TRANSGENDER WOMEN; AFRICAN WOMEN;
   ADHERENCE; MEN; PREVENTION; INFECTION; IPREX; SEX
AB Monitoring adherence to pre-exposure prophylaxis (PrEP) is part of the recommended package for PrEP prescribing, yet ongoing concerns about how to do so confidently are exacerbated by gross discrepancies in reported and actual use in clinical trials. We evaluated concordance between reports of recent PrEP dosing collected via neutral interviewing and drug quantitation in the iPrEx open-label extension, where participants (n = 1172) had the choice to receive or not receive PrEP. Self-report of recent dosing (at least one PrEP dose in the past 3-day) was the most common report (84 % of participants), and among these 83 % did have quantifiable levels of drug. The vast majority of those reporting no doses in the past 3-day (16 % of the sample) did not have quantifiable levels of drug (82 %). Predictors of over-report of dosing included younger age and lower educational attainment. Monitoring recent PrEP use through neutral interviewing may be a productive approach for clinicians to consider in implementation of real-world PrEP. Strategies to capture longer term or prevention-effective PrEP use, particularly for younger cohorts, are needed.
C1 [Amico, K. Rivet] Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA.
   [Mehrotra, Megha; McMahan, Vanessa; Grant, Robert] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA.
   [Avelino-Silva, Vivian I.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Rio De Janeiro, RJ, Brazil.
   [Anderson, Peter] Univ Colorado, Dept Pharmaceut Sci, Aurora, CO USA.
   [Guanira, Juan] Invest Med Salud, Lima, Peru.
   [Grant, Robert] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Amico, KR (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA.
EM ramico@umich.edu
RI Avelino-Silva, Vivian I/L-2640-2013; /AAE-4700-2020
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Guanira,
   Juan/0000-0002-2746-3086; Amico, K Rivet/0000-0002-4458-6934; Grant,
   Robert/0000-0002-0851-7085
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [A1064002]; FIH.NIH [A1068619];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476] Funding Source: NIH
   RePORTER
FX NIH A1064002 (Grant PI); FIH.NIH A1068619 (Sista, PI); Study drug was
   donated by Gilead Sciences.
CR Amico KR, 2012, AIDS BEHAV, V16, P1243, DOI 10.1007/s10461-012-0182-5
   Amico K Rivet, 2013, J Int Assoc Provid AIDS Care, V12, P79, DOI 10.1177/1545109712474844
   Amico KR, 2014, CLIN INFECT DIS, V59, pS55, DOI 10.1093/cid/ciu266
   Amico KR, 2012, CURR OPIN HIV AIDS, V7, P542, DOI 10.1097/COH.0b013e3283582d4a
   Amico KR, 2015, J ACQ IMMUN DEF SYND, V66, P530
   Amico KR, 2012, FOR COLL HIV RES 201
   Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524
   Corneli AL, 2015, JAIDS-J ACQ IMM DEF, V68, P578, DOI 10.1097/QAI.0000000000000525
   Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Grohskopf LA, 2013, JAIDS-J ACQ IMM DEF, V64, P79, DOI 10.1097/QAI.0b013e31828ece33
   Haberer JE, 2015, AIDS, V29, P1277, DOI 10.1097/QAD.0000000000000647
   Hosek SG, 2013, JAIDS-J ACQ IMM DEF, V62, P447, DOI 10.1097/QAI.0b013e3182801081
   Karris MY, 2014, CLIN INFECT DIS, V58, P704, DOI 10.1093/cid/cit796
   Liu A, 2014, JAIDS-J ACQ IMM DEF, V67, P528, DOI 10.1097/QAI.0000000000000351
   Lu M, 2008, AIDS BEHAV, V12, P86, DOI 10.1007/s10461-007-9261-4
   Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269
   Prevention CfDCa, 2014, PREEXP PROPH PREV HI, P67
   Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711
   Thompson MA, 2012, ANN INTERN MED, V156, P817, DOI 10.7326/0003-4819-156-11-201206050-00419
   Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614
   Williams AB, 2013, AIDS BEHAV, V17, P284, DOI 10.1007/s10461-012-0172-7
NR 22
TC 15
Z9 15
U1 0
U2 10
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD JUL
PY 2016
VL 20
IS 7
BP 1535
EP 1540
DI 10.1007/s10461-016-1360-7
PG 6
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA DQ1ZS
UT WOS:000379000500017
PM 26992393
OA Other Gold, Green Published
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Martin, JRN
AF Avelino-Silva, Vivian I.
   Martin, Jeff Rey N.
TI Association between Guillain-Barre syndrome and Zika virus infection
SO LANCET
LA English
DT Letter
C1 [Avelino-Silva, Vivian I.] Univ Sao Paulo, Sch Med, Hosp Sirio Libanes, Rua Prof Daher Cutait 69, BR-01308060 Sao Paulo, Brazil.
   [Avelino-Silva, Vivian I.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Rua Prof Daher Cutait 69, BR-01308060 Sao Paulo, Brazil.
   [Martin, Jeff Rey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Sch Med, Hosp Sirio Libanes, Rua Prof Daher Cutait 69, BR-01308060 Sao Paulo, Brazil.; Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Rua Prof Daher Cutait 69, BR-01308060 Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Avelino-Silva, Vivian I/L-2640-2013
OI Avelino-Silva, Vivian I/0000-0002-6660-3088
CR Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396
NR 2
TC 8
Z9 8
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUN 25
PY 2016
VL 387
IS 10038
BP 2599
EP 2599
DI 10.1016/S0140-6736(16)30843-1
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA DP3JX
UT WOS:000378390500019
PM 27353814
OA Bronze
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Miyaji, KT
   Mathias, A
   Costa, DA
   Dias, JZD
   Lima, SB
   Simoes, M
   Freire, MS
   Caiaffa, HH
   Hong, MA
   Lopes, MH
   Sartori, AM
   Kallas, EG
AF Avelino-Silva, Vivian Iida
   Miyaji, Karina Takesaki
   Mathias, Augusto
   Costa, Dayane Alves
   de Carvalho Dias, Juliana Zanatta
   Lima, Sheila Barbosa
   Simoes, Marisol
   Freire, Marcos S.
   Caiaffa-Filho, Helio H.
   Hong, Marisa A.
   Lopes, Marta H.
   Sartori, Ana M.
   Kallas, Esper G.
TI CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in
   Virologically Suppressed HIV-Infected Patients
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE yellow fever vaccine; yellow fever neutralizing antibodies; HIV; CD4(+);
   CD8(+) ratio; immune activation
ID GB-VIRUS-C; T-CELL-ACTIVATION; ANTIRETROVIRAL THERAPY;
   IMMUNOFLUORESCENCE ASSAY; PNEUMOCOCCAL CONJUGATE; NEUTRALIZATION TEST;
   IMMUNE ACTIVATION; IGG ANTIBODIES; IMMUNOGENICITY; SAFETY
AB Background:Yellow fever vaccine (YFV) induces weaker immune responses in HIV-infected individuals. However, little is known about YFV responses among antiretroviral-treated patients and potential immunological predictors of YFV response in this population.Methods:We enrolled 34 antiretroviral therapy (ART)-treated HIV-infected and 58 HIV-uninfected adults who received a single YFV dose to evaluate antibody levels and predictors of immunity, focusing on CD4(+) T-cell count, CD4(+)/CD8(+) ratio, and Human Pegivirus (GBV-C) viremia. Participants with other immunosuppressive conditions were excluded.Results:Median time since YFV was nonsignificantly shorter in HIV-infected participants than in HIV-uninfected participants (42 and 69 months, respectively, P = 0.16). Mean neutralizing antibody (NAb) titers was lower in HIV-infected participants than HIV-uninfected participants (3.3 vs. 3.6 log(10)mIU/mL, P = 0.044), a difference that remained significant after adjustment for age, sex, and time since vaccination (P = 0.024). In HIV-infected participants, lower NAb titers were associated with longer time since YFV (rho: -0.38, P = 0.027) and lower CD4(+)/CD8(+) ratio (rho: 0.42, P = 0.014), but not CD4(+) T-cell count (P = 0.52). None of these factors were associated with NAb titers in HIV-uninfected participant. GBV-C viremia was not associated with difference in NAb titers overall or among HIV-infected participants.Conclusions:ART-treated HIV-infected individuals seem to have impaired and/or less durable responses to YFV than HIV-uninfected individuals, which were associated with lower CD4(+)/CD8(+) ratio, but not with CD4(+) T-cell count. These results supports the notion that low CD4(+)/CD8(+) ratio, a marker linked to persistent immune activation, is a better indicator of functional immune disturbance than CD4(+) T-cell count in patients with successful ART.
C1 [Avelino-Silva, Vivian Iida; Miyaji, Karina Takesaki; Lopes, Marta H.; Sartori, Ana M.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Mathias, Augusto; Costa, Dayane Alves; de Carvalho Dias, Juliana Zanatta; Hong, Marisa A.; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Lima, Sheila Barbosa; Simoes, Marisol; Freire, Marcos S.] Fundacao Oswaldo Cruz Biomanguinhos, Rio De Janeiro, Brazil.
   [Caiaffa-Filho, Helio H.; Hong, Marisa A.] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Caiaffa-Filho, Helio H.] Univ Sao Paulo, Sch Med, Lab Med Invest LIM 3, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Av Dr Eneas Carvalho Aguiar 470,Sala 06, BR-05403000 Sao Paulo, SP, Brazil.
EM viviansilva87@gmail.com
RI Lopes, Marta H/J-3285-2012; Sartori, Ana Marli Christovam/I-6663-2012;
   Avelino-Silva, Vivian I/L-2640-2013; Mathias, Augusto/C-3247-2017;
   Caiaffa-Filho, Helio H/H-6982-2012; Miyaji, Karina T/B-1319-2016
OI Sartori, Ana Marli Christovam/0000-0003-3777-0757; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Caiaffa-Filho, Helio H/0000-0001-6048-4527;
   Miyaji, Karina T/0000-0003-2653-3975; Kallas, Esper/0000-0003-2026-6925;
   Mathias, Augusto/0000-0002-5896-9223; Barbosa de Lima, Sheila
   Maria/0000-0001-9234-1678; Lopes, Marta Heloisa/0000-0001-5236-6248
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (Capes)CAPES; Ministry of Education, Brazil; Fundacao de Amparo a
   Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [2013/05246-8]
FX This study has been partially funded by Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior (Capes), Ministry of Education, Brazil, and
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Grant Number
   2013/05246-8).
CR Abzug MJ, 2006, PEDIATR INFECT DIS J, V25, P920, DOI 10.1097/01.inf.0000237830.33228.c3
   [Anonymous], 2013, Wkly Epidemiol Rec, V88, P269
   Bamford A, 2014, AIDS, V28, P2033, DOI 10.1097/QAD.0000000000000385
   Bhaskaran K, 2008, JAMA-J AM MED ASSOC, V300, P51, DOI 10.1001/jama.300.1.51
   Bhattarai N, 2012, J INFECT DIS, V206, P1469, DOI 10.1093/infdis/jis515
   Boyer JRL, 2015, C RETR OPP DIS FEBR
   Caldas IR, 2014, VACCINE, V32, P4977, DOI 10.1016/j.vaccine.2014.07.021
   Camacho LAB, 2004, REV SAUDE PUBL, V38, P671, DOI 10.1590/S0034-89102004000500009
   Chen S, 2015, OBES RES CLIN PRACT, V9, P35, DOI 10.1016/j.orcp.2013.12.006
   Control. NIfBSa, 2008, WHO REF REAG 1 INT R
   Cook IF, 2008, VACCINE, V26, P3551, DOI 10.1016/j.vaccine.2008.04.054
   Crum-Cianflone NF, 2011, J INFECT DIS, V203, P1815, DOI 10.1093/infdis/jir180
   Dobler G, 1997, Wien Med Wochenschr, V147, P463
   Ernst D, 2014, HIV MED, V15, P245, DOI 10.1111/hiv.12094
   Goujon C, 1995, 4 INT C TRAV MED APR
   Heringlake S, 1998, J INFECT DIS, V177, P1723, DOI 10.1086/517431
   Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7
   Hunt PW, 2012, CURR HIV-AIDS REP, V9, P139, DOI 10.1007/s11904-012-0118-8
   Hunt PW, 2011, AIDS, V25, P2123, DOI 10.1097/QAD.0b013e32834c4ac1
   Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786
   Jain V, 2013, J INFECT DIS, V208, P1202, DOI 10.1093/infdis/jit311
   Klatt NR, 2013, IMMUNOL REV, V254, P326, DOI 10.1111/imr.12065
   Klein SL, 2015, T ROY SOC TROP MED H, V109, P9, DOI 10.1093/trstmh/tru167
   Lederman MM, 2013, ADV IMMUNOL, V119, P51, DOI 10.1016/B978-0-12-407707-2.00002-3
   Lefrere JJ, 1999, J INFECT DIS, V179, P783, DOI 10.1086/314671
   Lopes VB, 2013, VACCINE, V31, P1040, DOI 10.1016/j.vaccine.2012.12.047
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Milagres LG, 2013, AIDS, V27, P2697, DOI 10.1097/QAD.0000000000000007
   Ministerio da Saude-Secretaria de Vigilancia em Saude-Departamento de DST, 2014, B EP HIV AIDS
   Miraglia JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027214
   Monath TP, 2002, AM J TROP MED HYG, V66, P533, DOI 10.4269/ajtmh.2002.66.533
   Monath TP, 2008, VACCINES, P1748
   Mussini C, 2015, LANCET HIV, V2, pE98, DOI 10.1016/S2352-3018(15)00006-5
   Muyanja E, 2014, J CLIN INVEST, V124, P3147, DOI 10.1172/JCI75429
   Niedrig M, 1999, TROP MED INT HEALTH, V4, P867, DOI 10.1046/j.1365-3156.1999.00496.x
   Niedrig M, 2008, CLIN VACCINE IMMUNOL, V15, P177, DOI 10.1128/CVI.00078-07
   Okulicz JF, 2015, JAMA INTERN MED, V175, P88, DOI 10.1001/jamainternmed.2014.4010
   Pacanowski J, 2012, JAIDS-J ACQ IMM DEF, V59, P360, DOI 10.1097/QAI.0b013e318249de59
   Parmigiani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079816
   Pfister M, 2005, AM J TROP MED HYG, V72, P339, DOI 10.4269/ajtmh.2005.72.339
   Pistone T, 2010, CURR HIV RES, V8, P461, DOI 10.2174/157016210793499277
   POLAND JD, 1981, B WORLD HEALTH ORGAN, V59, P895
   Richardson K, 2011, AIDS, V25, P595, DOI 10.1097/QAD.0b013e32834411a8
   Rubin LG, 2014, CLIN INFECT DIS, V58, pE44, DOI 10.1093/cid/cit684
   Rydze RT, 2012, ANTIVIR THER, V17, P1271, DOI 10.3851/IMP2309
   Sahni H, 2014, J MED VIROL, V86, P426, DOI 10.1002/jmv.23845
   Schouten J, 2014, CLIN INFECT DIS, V59, P1787, DOI 10.1093/cid/ciu701
   Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
   Sibailly TS, 1997, PEDIATR INFECT DIS J, V16, P1177, DOI 10.1097/00006454-199712000-00015
   Sidibe M, 2012, T ROY SOC TROP MED H, V106, P437, DOI 10.1016/j.trstmh.2012.04.002
   Simoes M, 2012, BIOLOGICALS, V40, P399, DOI 10.1016/j.biologicals.2012.09.005
   Stapleton JT, 2013, AIDS, V27, P1829, DOI 10.1097/QAD.0b013e328363089f
   Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398
   Vahidnia F, 2012, CLIN INFECT DIS, V55, P1012, DOI 10.1093/cid/cis589
   Veit O, 2009, CLIN INFECT DIS, V48, P659, DOI 10.1086/597006
   Weinberg A, 2006, J INFECT DIS, V193, P302, DOI 10.1086/498979
   Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364
NR 57
TC 8
Z9 8
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD FEB 1
PY 2016
VL 71
IS 2
BP 189
EP 195
DI 10.1097/QAI.0000000000000845
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DB8YU
UT WOS:000368803900009
PM 26361176
OA Green Published
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Freire, MD
   Rocha, V
   Rodrigues, CA
   Novis, YS
   Sabino, EC
   Kallas, EG
AF Avelino-Silva, Vivian Iida
   Freire, Marcos da Silva
   Rocha, Vanderson
   Rodrigues, Celso Arrais
   Novis, Yana Sarkis
   Sabino, Ester C.
   Kallas, Esper Georges
TI Persistence of Yellow Fever vaccine-induced antibodies after cord blood
   stem cell transplant
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE cord blood stem cell transplant; immunosuppression; vaccine; yellow
   fever
ID INFECTION; IMMUNITY; VIREMIA
AB We report the case of a cord blood haematopoietic stem cell transplant recipient who was vaccinated for Yellow Fever (YF) 7days before initiating chemotherapy and had persistent YF antibodies more than 3years after vaccination. Since the stem cell donor was never exposed to wild YF or to the YF vaccine, and our patient was not exposed to YF or revaccinated, this finding strongly suggests the persistence of recipient immunity. We briefly discuss potential consequences of incomplete elimination of recipient's leukocytes following existing haematopoietic cancer treatments.
C1 [Avelino-Silva, Vivian Iida; Sabino, Ester C.; Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian Iida; Rocha, Vanderson; Rodrigues, Celso Arrais; Novis, Yana Sarkis; Kallas, Esper Georges] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Freire, Marcos da Silva] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Sabino, Ester C.] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Ave Dr Eneas de Carvalho Aguiar 470,Sala 6, BR-05403000 Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Rocha, Vanderson/AAO-1691-2020; Sabino, Ester Cerdeira/F-7750-2010;
   Avelino-Silva, Vivian I/L-2640-2013
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Kallas, Esper/0000-0003-2026-6925
CR Avelino-Silva VI, 2013, BONE MARROW TRANSPL, V48, P1008, DOI 10.1038/bmt.2012.277
   Barrett ADT, 2009, CURR OPIN IMMUNOL, V21, P308, DOI 10.1016/j.coi.2009.05.018
   Effros RB, 2008, CLIN INFECT DIS, V47, P542, DOI 10.1086/590150
   Ljungman P, 2009, BONE MARROW TRANSPL, V44, P521, DOI 10.1038/bmt.2009.263
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Monath TP., 2008, YELLOW FEVER VACCINE, P1748
   Parkkali T, 1997, BONE MARROW TRANSPL, V19, P933, DOI 10.1038/sj.bmt.1700768
   Parkkali T, 1996, APMIS, V104, P383, DOI 10.1111/j.1699-0463.1996.tb00731.x
   Reinhardt B, 1998, J MED VIROL, V56, P159, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;159::AID-JMV10&gt;3.0.CO;2-B
   Simoes M, 2012, BIOLOGICALS, V40, P399, DOI 10.1016/j.biologicals.2012.09.005
   Spoulou V, 2004, BONE MARROW TRANSPL, V33, P1187, DOI 10.1038/sj.bmt.1704476
NR 11
TC 2
Z9 2
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PY 2016
VL 12
IS 4
BP 937
EP 938
DI 10.1080/21645515.2015.1112475
PG 2
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA DN5RW
UT WOS:000377129200025
PM 26618995
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Ramos, JF
   Leal, FE
   Testagrossa, L
   Novis, YS
AF Avelino-Silva, Vivian Iida
   Ramos, Jessica Fernandes
   Leal, Fabio Eudes
   Testagrossa, Leonardo
   Novis, Yana Sarkis
TI Disseminated Fusarium infection in autologous stem cell transplant
   recipient
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Stem cell transplant; Autologous; Fusarium
ID HEMATOLOGICAL MALIGNANCIES; INVASIVE ASPERGILLOSIS; FILAMENTOUS FUNGI;
   SURVEILLANCE; EXPERIENCE; MANAGEMENT; LEUKEMIA; DISEASES
AB Disseminated infection by Fusarium is a rare, frequently lethal condition in severely immunocompromised patients, including bone marrow transplant recipients. However, autologous bone marrow transplant recipients are not expected to be at high risk to develop fusariosis. We report a rare case of lethal disseminated Fusarium infection in an autologous bone marrow transplant recipient during pre-engraftment phase. (C) 2014 Elsevier Editora Ltda.
C1 [Avelino-Silva, Vivian Iida; Ramos, Jessica Fernandes; Leal, Fabio Eudes] Univ Sao Paulo, Dept Infect & Parasit Dis, Sch Med, BR-05403000 Sao Paulo, SP, Brazil.
   [Avelino-Silva, Vivian Iida; Ramos, Jessica Fernandes; Leal, Fabio Eudes; Novis, Yana Sarkis] Hosp Sirio Libanes, Sao Paulo, SP, Brazil.
   [Leal, Fabio Eudes] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, BR-05403000 Sao Paulo, SP, Brazil.
   [Testagrossa, Leonardo] Fleury Med Diagnost, Sao Paulo, SP, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Fac Med, Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
EM viviansilva87@gmail.com
RI Avelino-Silva, Vivian I/L-2640-2013
OI Avelino-Silva, Vivian I/0000-0002-6660-3088
CR Auberger J, 2008, INT J HEMATOL, V88, P508, DOI 10.1007/s12185-008-0184-2
   Boutati EI, 1997, BLOOD, V90, P999, DOI 10.1182/blood.V90.3.999.999_999_1008
   Campo M, 2010, J INFECTION, V60, P331, DOI 10.1016/j.jinf.2010.01.010
   Candoni A, 2014, MYCOSES, V57, P342, DOI 10.1111/myc.12161
   Cherif H, 2013, SCAND J INFECT DIS, V45, P112, DOI 10.3109/00365548.2012.714906
   Debourgogne A, 2012, EUR J CLIN MICROBIOL, V31, P615, DOI 10.1007/s10096-011-1323-x
   Durand-Joly I, 2003, J CLIN MICROBIOL, V41, P4898, DOI 10.1128/JCM.41.10.4898-4900.2003
   Gil L, 2009, BONE MARROW TRANSPL, V43, P121, DOI 10.1038/bmt.2008.303
   Hao ZF, 2011, CHINESE MED J-PEKING, V124, P1970, DOI 10.3760/cma.j.issn.0366-6999.2011.13.009
   Lanini S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-317
   Mellouli F, 2010, BMC DERMATOL, V10, DOI 10.1186/1471-5945-10-10
   Muhammed M, 2013, MEDICINE, V92, P305, DOI 10.1097/MD.0000000000000008
   Nucci M, 2004, CLIN INFECT DIS, V38, P1237, DOI 10.1086/383319
   Nucci M, 2013, EMERG INFECT DIS, V19, P1567, DOI 10.3201/eid1910.120847
   ROBERTSON MJ, 1991, BONE MARROW TRANSPL, V8, P143
   Rubio PM, 2009, J PEDIAT HEMATOL ONC, V31, P642, DOI 10.1097/MPH.0b013e3181acd956
   Teixeira ABA, 2005, MYCOPATHOLOGIA, V160, P129, DOI 10.1007/s11046-005-0117-z
   Varon AG, 2014, J INFECTION, V68, P85, DOI 10.1016/j.jinf.2013.08.011
NR 18
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JAN-FEB
PY 2015
VL 19
IS 1
BP 90
EP 93
DI 10.1016/j.bjid.2014.08.009
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA CE9MS
UT WOS:000352168700016
PM 25307678
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Francelino, HS
   Kallas, EG
AF Avelino-Silva, Vivian Iida
   Francelino, Hilario Sousa
   Kallas, Esper Georges
TI YELLOW FEVER PREVENTION STRATEGIES AWARENESS AMONG HIV-INFECTED PATIENTS
   IN SAO PAULO, BRAZIL
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE HIV; AIDS; Yellow Fever; Vaccine; Questionnaire
ID RISK PERCEPTION; ATTITUDES; KNOWLEDGE; COMMUNICATION; TRAVELERS;
   DISEASES; AIRPORT
AB Introduction: Vaccination is the main preventive strategy against Yellow Fever (YF), which is a public health concern in Brazil. However, HIV-infected patients might have insufficient knowledge regarding YF, YF prevention, and vaccines in general. Methods: In this questionnaire-based study, data from 158 HIV-infected individuals were addressed in three distinct outpatient clinics in Sao Paulo. Information was collected on demographic and clinical characteristics, as well as patients' knowledge of vaccines, YF and YF preventive strategies. In addition, individual YF vaccine recommendations and vaccine status were investigated. Results: Although most participants adequately ascertain the vaccine as the main prevention strategy against YF, few participants were aware of the severity and lack of specific treatment for YF. Discrepancy in YF vaccine (patients who should have taken the vaccine, but did not) was observed in 18.8% of participants. Conclusion: YF is an important and preventable public health concern, and these results demonstrate that more information is necessary for the HIV-infected population.
C1 [Avelino-Silva, Vivian Iida; Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Francelino, Hilario Sousa; Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Discipline Clin Immunol & Allergy, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Avelino-Silva, Vivian I/L-2640-2013
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Kallas,
   Esper/0000-0003-2026-6925
FU CAPES (Ministerio da Educacao - Brazil)CAPES
FX The authors would like to thank Karina Takesaki Miyaji, Ana Marli
   Sartori and Marta Heloisa Lopes for reviewing the original survey and
   providing useful suggestions. The authors would also like to thank
   Tamara Newman Lobato Sousa, Jessica Fernandes Ramos and Fabiana Siroma
   for helping the application of the questionnaires. This study was
   supported by CAPES (Ministerio da Educacao - Brazil).
CR Brasil. Ministerio da Saude, 2008, SIT FEBR AM SILV BRA
   Brasil. Ministerio da Saude, 2009, EM SAUD PUBL IMP NAC
   Hamer DH, 2004, J TRAVEL MED, V11, P23, DOI 10.2310/7060.2004.13577
   Larson H, 2012, DRUG SAFETY, V35, P1053, DOI 10.2165/11635880-000000000-00000
   Lima JTF, 1985, CAD SAUDE PUBLICA, V1, P377
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Reyna VF, 2012, VACCINE, V30, P3790, DOI 10.1016/j.vaccine.2011.11.070
   Toovey S, 2004, J TRAVEL MED, V11, P16, DOI 10.2310/7060.2004.13587
   Van Herck K, 2004, J TRAVEL MED, V11, P3, DOI 10.2310/7060.2004.13609
NR 9
TC 2
Z9 2
U1 0
U2 7
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD SEP-OCT
PY 2014
VL 56
IS 5
BP 417
EP 420
DI 10.1590/S0036-46652014000500008
PG 4
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AS5TL
UT WOS:000344332300008
PM 25229222
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Song, ATW
   Avelino-Silva, VI
   Pecora, RAA
   Pugliese, V
   D'Albuquerque, LAC
   Abdala, E
AF Wan Song, Alice Tung
   Avelino-Silva, Vivian Iida
   Arruda Pecora, Rafael Antonio
   Pugliese, Vincenzo
   Carneiro D'Albuquerque, Luiz Augusto
   Abdala, Edson
TI Liver transplantation: Fifty years of experience
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Liver transplantation; History; Survival; Indications; Organ allocation
ID DUCT BILIARY RECONSTRUCTION; HEPATIC-ARTERY RECONSTRUCTION; WHOLE-ORGAN
   TRANSPLANTATION; VENO-VENOUS BYPASS; RIGHT LOBE GRAFT; DONOR LIVER;
   LIVING-DONOR; OPERATIONAL TOLERANCE; HEPATOCELLULAR-CARCINOMA;
   CALCINEURIN INHIBITORS
AB Since 1963, when the first human liver transplantation (LT) was performed by Thomas Starzl, the world has witnessed 50 years of development in surgical techniques, immunosuppression, organ allocation, donor selection, and the indications and contraindications for LT. This has led to the mainstream, wellestablished procedure that has saved innumerable lives worldwide. Today, there are hundreds of liver transplant centres in over 80 countries. This review aims to describe the main aspects of LT regarding the progressive changes that have occurred over the years. We herein review historical aspects since the first experimental studies and the first attempts at human transplantation. We also provide an overview of immunosuppressive agents and their potential side effects, the evolution of the indications and contraindications of LT, the evolution of survival according to different time periods, and the evolution of methods of organ allocation. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
C1 [Wan Song, Alice Tung; Arruda Pecora, Rafael Antonio; Pugliese, Vincenzo; Carneiro D'Albuquerque, Luiz Augusto; Abdala, Edson] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Liver & Digest Organ Transplantat Unit, BR-05403900 Sao Paulo, Brazil.
   [Wan Song, Alice Tung; Avelino-Silva, Vivian Iida] Univ Sao Paulo, Sch Med, Dept Infect Dis, BR-05403900 Sao Paulo, Brazil.
   [Wan Song, Alice Tung; Abdala, Edson] Univ Sao Paulo, Sch Med, Dept Infect Dis, Hepatitis Res Lab, BR-05403000 Sao Paulo, Brazil.
RP Song, ATW (corresponding author), Univ Sao Paulo, Sch Med, Dept Gastroenterol, Liver & Digest Organ Transplantat Unit, BR-05403900 Sao Paulo, Brazil.
EM alicetwsong@gmail.com
RI Abdala, Edson/H-5165-2012; D'ALBUQUERQUE, Luiz Carneiro
   Augusto/I-4011-2012; D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013;
   Song, Alice Tung Wan/F-2494-2014; Avelino-Silva, Vivian I/L-2640-2013
OI Abdala, Edson/0000-0003-0765-6654; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; Song, Alice Tung Wan/0000-0001-6992-9326;
   Avelino-Silva, Vivian I/0000-0002-6660-3088
FU PfizerPfizer
FX Edson Abdala has received fees as a travel grant and for serving as a
   speaker for MSD, as a travel grant from Pfizer, and for serving as a
   speaker for Novartis.
CR Abbasoglu O, 1997, TRANSPLANTATION, V63, P250, DOI 10.1097/00007890-199701270-00013
   Aberg F, 2011, SCAND J SURG, V100, P14, DOI 10.1177/145749691110000104
   Adam R, 2009, SEMIN LIVER DIS, V29, P3, DOI 10.1055/s-0029-1192052
   Adams D, 2011, AMYLOID, V18, P174, DOI 10.3109/13506129.2011.574354065
   Ahmed Aijaz, 2007, Clin Liver Dis, V11, P227, DOI 10.1016/j.cld.2007.04.008
   [Anonymous], 1984, JAMA, V252, P677
   Antonini TM, 2013, AM J TRANSPLANT, V13, P2734, DOI 10.1111/ajt.12378
   Aseni P, 2014, ANN SURG, V259, P157, DOI 10.1097/SLA.0b013e31827da6c9
   Barber K, 2007, GUT, V56, P279, DOI 10.1136/gut.2006.093195
   Barber K, 2011, TRANSPLANTATION, V92, P469, DOI 10.1097/TP.0b013e318225db4d
   Barbier L, 2013, J HEPATOL, V59, P1223, DOI 10.1016/j.jhep.2013.07.032
   Beckebaum S, 2013, LIVER INT, V33, P656, DOI 10.1111/liv.12133
   Benitez C, 2013, HEPATOLOGY, V58, P1824, DOI 10.1002/hep.26426
   BERNUAU J, 1986, HEPATOLOGY, V6, P648, DOI 10.1002/hep.1840060417
   BISMUTH H, 1984, SURGERY, V95, P367
   BISMUTH H, 1982, WORLD J SURG, V6, P3, DOI 10.1007/BF01656368
   BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005
   Bohne F, 2012, J CLIN INVEST, V122, P368, DOI 10.1172/JCI59411
   Brostoff JM, 2008, EUR J INTERN MED, V19, P374, DOI 10.1016/j.ejim.2007.10.013
   Busuttil RW, 2012, AM J TRANSPLANT, V12, P1385, DOI 10.1111/j.1600-6143.2012.04026.x
   CALNE RY, 1968, BMJ-BRIT MED J, V4, P535, DOI 10.1136/bmj.4.5630.535
   CALNE RY, 1979, LANCET, V2, P1033
   CALNE RY, 1978, LANCET, V1, P1183
   Cannon JA, 1956, TRANSPLAN B, V3, P7
   Chan SC, 2007, ANN SURG, V245, P110, DOI 10.1097/01.sla.0000225085.82193.08
   Chen CL, 2013, J HEPATO-BIL-PAN SCI, V20, P492, DOI 10.1007/s00534-013-0609-z
   Couinaud C, 1957, FOIE ETUDES ANATOMIQ
   Czaja AJ, 1999, LIVER TRANSPLANT SUR, V5, P460, DOI 10.1002/lt.500050512
   Dahm F, 2005, AM J TRANSPLANT, V5, P2605, DOI 10.1111/j.1600-6143.2005.01081.x
   DENMARK SW, 1983, SURG FORUM, V34, P380
   Devlin J, 1998, HEPATOLOGY, V27, P926, DOI 10.1002/hep.510270406
   Dienstag JL, 2012, NEW ENGL J MED, V367, P1483, DOI 10.1056/NEJMp1210159
   Doyle MBM, 2013, J AM COLL SURGEONS, V217, P102, DOI 10.1016/j.jamcollsurg.2013.03.003
   Dulundu E, 2004, TRANSPLANTATION, V78, P574, DOI 10.1097/01.TP.0000128912.09581.46
   EMOND JC, 1990, ANN SURG, V212, P14, DOI 10.1097/00000658-199007000-00003
   Fan ST, 2002, ANN SURG, V236, P676, DOI 10.1097/00000658-200211000-00019
   Feng S, 2012, JAMA-J AM MED ASSOC, V307, P283, DOI 10.1001/jama.2011.2014
   Ferraz-Neto Ben-Hur, 2007, Arq. Gastroenterol., V44, P187, DOI 10.1590/S0004-28032007000300001
   Francoz C, 2007, BEST PRACT RES CL GA, V21, P175, DOI 10.1016/j.bpg.2006.07.007
   Francoz C, 2011, LIVER TRANSPLANT, V17, P1137, DOI 10.1002/lt.22363
   Freeman RB, 2012, CURR OPIN ORGAN TRAN, V17, P211, DOI 10.1097/MOT.0b013e3283534dde
   de la Garza RG, 2013, LIVER TRANSPLANT, V19, P937, DOI 10.1002/lt.23686
   Garcia-Reyne A, 2013, TRANSPL INFECT DIS, V15, P405, DOI 10.1111/tid.12097
   Gokmen R, 2013, CURR OPIN ORGAN TRAN, V18, P416, DOI 10.1097/MOT.0b013e3283636fd5
   Gondolesi GE, 2004, TRANSPLANTATION, V77, P1842, DOI 10.1097/01.tp.0000123077.78702.0c
   GRIFFITH BP, 1985, SURG GYNECOL OBSTET, V160, P270
   Gurusamy KS, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008258.pub2
   HASHIKURA Y, 1994, LANCET, V343, P1233, DOI 10.1016/S0140-6736(94)92450-3
   Hwang S, 2006, LIVER TRANSPLANT, V12, P920, DOI 10.1002/lt.20734
   Icoz G, 2003, LIVER TRANSPLANT, V9, P575, DOI 10.1053/jlts.2003.50129
   Ikegami T, 2006, J HEPATO-BILIARY-PAN, V13, P105, DOI 10.1007/s00534-005-1015-y
   Ishiko T, 2002, ANN SURG, V236, P235, DOI 10.1097/00000658-200208000-00012
   Kanwal F, 2005, ALIMENT PHARM THER, V21, P169, DOI 10.1111/j.1365-2036.2005.02321.x
   Kasahara M, 2006, ANN SURG, V243, P559, DOI 10.1097/01.sla.0000206419.65678.2e
   Kasahara M, 2013, AM J TRANSPLANT, V13, P1830, DOI 10.1111/ajt.12276
   Kawachi S, 2002, SURGERY, V132, P48, DOI 10.1067/msy.2002.125314
   Kim SJ, 2011, CLIN TRANSPLANT, V25, P929, DOI 10.1111/j.1399-0012.2010.01385.x
   Kwon KH, 2003, YONSEI MED J, V44, P1069, DOI 10.3349/ymj.2003.44.6.1069
   Lee KW, 2004, LIVER TRANSPLANT, V10, P1158, DOI 10.1002/lt.20230
   Lee SG, 2001, TRANSPLANT P, V33, P3461, DOI 10.1016/S0041-1345(01)02491-5
   Lee WC, 2013, ANN SURG, V258, P306, DOI 10.1097/SLA.0b013e3182754b8e
   Levitsky J, 2013, HEPATOLOGY, V58, P1529, DOI 10.1002/hep.26576
   Levitsky J, 2011, LIVER TRANSPLANT, V17, P222, DOI 10.1002/lt.22265
   Li L, 2012, AM J TRANSPLANT, V12, P1218, DOI 10.1111/j.1600-6143.2011.03928.x
   Liu CL, 2004, TRANSPLANTATION, V77, P726, DOI 10.1097/01.TP.0000116604.89083.2F
   Lo CM, 1997, TRANSPLANTATION, V63, P1524, DOI 10.1097/00007890-199705270-00027
   Lucey MR, 2013, LIVER TRANSPLANT, V19, P3, DOI 10.1002/lt.23566
   Magder LS, 2012, TRANSPL INT, V25, P409, DOI 10.1111/j.1432-2277.2012.01431.x
   Martinez-Llordella M, 2007, AM J TRANSPLANT, V7, P309, DOI 10.1111/j.1600-6143.2006.01621.x
   Martinez-Llordella M, 2008, J CLIN INVEST, V118, P2845, DOI 10.1172/JCI35342
   Marubashi S, 2013, WORLD J SURG, V37, P2671, DOI 10.1007/s00268-013-2188-1
   Mazariegos GV, 1997, TRANSPLANTATION, V63, P243, DOI 10.1097/00007890-199701270-00012
   Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
   McCaughan GW, 2013, LIVER TRANSPLANT, V19, P933, DOI 10.1002/lt.23719
   McCormack L, 2010, HPB, V12, P456, DOI 10.1111/j.1477-2574.2010.00199.x
   Mehrabi A, 2008, LANGENBECK ARCH SURG, V393, P245, DOI 10.1007/s00423-007-0262-6
   Merion RM, 2011, TRANSPL INT, V24, P965, DOI 10.1111/j.1432-2277.2011.01274.x
   Millis JM, 2000, ANN SURG, V232, P104, DOI 10.1097/00000658-200007000-00015
   MOORE FD, 1960, ANN SURG, V152, P374, DOI 10.1097/00000658-196015230-00003
   MURRAY JE, 1976, ANN SURG, V184, P565, DOI 10.1097/00000658-197611000-00006
   Muzaale AD, 2012, GASTROENTEROLOGY, V142, P273, DOI 10.1053/j.gastro.2011.11.015
   *NIH CONS DEV C LI, 1984, HEPATOLOGY, V4, pS1
   OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4
   Park YS, 2011, RADIOLOGY, V260, P884, DOI 10.1148/radiol.11102257
   Parrilla P, 1999, TRANSPLANT P, V31, P2388, DOI 10.1016/S0041-1345(99)00394-2
   PICHLMAYR R, 1988, LANGENBECK ARCH CHIR, V373, P127, DOI 10.1007/BF01262776
   Prados E, 1998, TRANSPLANTATION, V66, P1645, DOI 10.1097/00007890-199812270-00013
   PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817
   RAIA S, 1989, LANCET, V2, P497
   Rodriguez-Peralvarez M, 2013, J HEPATOL, V59, P1193, DOI 10.1016/j.jhep.2013.07.012
   Saidi RF, 2012, ARCH IRAN MED, V15, P772, DOI 0121512/AIM.0011
   Samuel D, 2003, J HEPATOL, V39, P3, DOI 10.1016/S0168-8278(03)00213-7
   Sanchez-Fueyo A, 2011, GASTROENTEROLOGY, V140, P51, DOI 10.1053/j.gastro.2010.10.059
   Sass DA, 2011, GASTROENTEROL CLIN N, V40, P641, DOI 10.1016/j.gtc.2011.06.007
   Scatton O, 2001, ANN SURG, V233, P432, DOI 10.1097/00000658-200103000-00019
   Sebagh M, 2006, J HEPATOL, V44, P118, DOI 10.1016/j.jhep.2005.07.029
   Sempoux C, 1997, LIVER, V17, P311
   Serenari M, 2013, WORLD J GASTROENTERO, V19, P7922, DOI 10.3748/wjg.v19.i44.7922
   SHAW BW, 1984, ANN SURG, V200, P524, DOI 10.1097/00000658-198410000-00013
   SHAW BW, 1985, SURG GYNECOL OBSTET, V161, P66
   Sheiner PA, 1997, TRANSPLANTATION, V64, P1295, DOI 10.1097/00007890-199711150-00011
   Sotiropoulos GC, 2011, ANN SURG, V254, P694, DOI 10.1097/SLA.0b013e31823594ae
   STARZL TE, 1974, TRANSPLANT P, V6, P129
   STARZL TE, 1989, LANCET, V2, P1000
   STARZL TE, 1968, ANN SURG, V168, P392, DOI 10.1097/00000658-196809000-00009
   STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P659
   STARZL TE, 1960, SURG GYNECOL OBSTET, V111, P733
   Starzl TE, 2012, NAT MED, V18, P1489, DOI 10.1038/nm.2927
   STIEBER AC, 1995, HEPATO-GASTROENTEROL, V42, P403
   STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106
   Sugawara Y, 2011, SURGERY, V149, P841, DOI 10.1016/j.surg.2010.11.016
   Takatsuki M, 2001, TRANSPLANTATION, V72, P449, DOI 10.1097/00007890-200108150-00016
   TZAKIS A, 1989, ANN SURG, V210, P649, DOI 10.1097/00000658-198911000-00013
   Umeshita K, 2003, LANCET, V362, P687, DOI 10.1016/S0140-6736(03)14230-4
   Vagefi PA, 2011, ARCH SURG-CHICAGO, V146, P1052, DOI 10.1001/archsurg.2011.218
   Wei WI, 2004, ARCH SURG-CHICAGO, V139, P304, DOI 10.1001/archsurg.139.3.304
   Welch CS, 1955, TRANSPLAN B, V2, P54
   Yao FY, 2001, HEPATOLOGY, V33, P1394, DOI 10.1053/jhep.2001.24563
   Zarrinpar A, 2013, NAT REV GASTRO HEPAT, V10, P434, DOI 10.1038/nrgastro.2013.88
   Zhang S, 2011, TRANSPL P, V43, P3773, DOI 10.1016/j.transproceed.2011.08.100
NR 120
TC 35
Z9 37
U1 0
U2 13
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD MAY 14
PY 2014
VL 20
IS 18
BP 5363
EP 5374
DI 10.3748/wjg.v20.i18.5363
PG 12
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AH3TJ
UT WOS:000336048100020
PM 24833866
OA Green Published, Other Gold
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Miraglia, JL
   Gomes-Gouvea, MS
   Pinho, JRR
   Mendes-Correa, MC
AF Avelino-Silva, V. I.
   Miraglia, J. L.
   Gomes-Gouvea, M. S.
   Pinho, J. R. R.
   Mendes-Correa, M. C.
TI Absence of anti-hepatitis B virus (HBV) core in HIV/HBV coinfection with
   advanced immunosuppression
SO HIV MEDICINE
LA English
DT Letter
ID EPIDEMIOLOGY; HIV
C1 [Avelino-Silva, V. I.; Mendes-Correa, M. C.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, BR-05652901 Sao Paulo, Brazil.
   [Miraglia, J. L.] Univ Sao Paulo, Sch Med, Discipline Clin Immunol & Allergy, BR-05652901 Sao Paulo, Brazil.
   [Gomes-Gouvea, M. S.; Pinho, J. R. R.] Univ Sao Paulo, Inst Trop Med, Sch Med, Dept Gastroenterol, BR-05652901 Sao Paulo, Brazil.
   [Pinho, J. R. R.] Albert Einstein Jewish Hosp, Albert Einstein Diagnost Med, Sao Paulo, Brazil.
RP Pinho, JRR (corresponding author), Univ Sao Paulo, Inst Trop Med, Av Dr Eneas de Carvalho Aguiar 470, BR-05652901 Sao Paulo, Brazil.
EM jrrpinho@usp.br
RI Pinho, Joao R. R./G-2850-2012; Avelino-Silva, Vivian I/L-2640-2013;
   correa, maria cassia mendes/A-6779-2013
OI Pinho, Joao R. R./0000-0003-3999-0489; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; 
CR Mora MVA, 2010, J GEN VIROL, V91, P501, DOI 10.1099/vir.0.015958-0
   Sheng WH, 2007, CLIN INFECT DIS, V45, P1221, DOI 10.1086/522173
   Sitnik R, 2010, REV INST MED TROP SP, V52, P119, DOI 10.1590/S0036-46652010000300001
   Thio CL, 2003, SEMIN LIVER DIS, V23, P125
   Thng C, 2012, INT J STD AIDS, V23, P149, DOI 10.1258/ijsa.2011.011205
NR 5
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
EI 1468-1293
J9 HIV MED
JI HIV Med.
PD AUG
PY 2013
VL 14
IS 7
BP 453
EP 454
DI 10.1111/hiv.12040
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 279GU
UT WOS:000328949200009
PM 23815776
OA Bronze
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Leal, FE
   Sabino, EC
   Nishiya, AS
   Freire, MD
   Blumm, F
   Rocha, V
   Rodrigues, CA
   Novis, YS
   Kallas, EG
AF Avelino-Silva, V. I.
   Leal, F. E.
   Sabino, E. C.
   Nishiya, A. S.
   Freire, M. da Silva
   Blumm, F.
   Rocha, V.
   Rodrigues, C. A.
   Novis, Y. S.
   Kallas, E. G.
TI Yellow fever vaccine viremia following ablative BM suppression in AML
SO BONE MARROW TRANSPLANTATION
LA English
DT Letter
ID IMMUNE-RESPONSE; ADVERSE EVENTS; 17D; IMMUNIZATION; CHILDREN; PATIENT;
   BRAZIL; ASSAYS; VIRUS
C1 [Avelino-Silva, V. I.; Leal, F. E.; Sabino, E. C.; Kallas, E. G.] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Avelino-Silva, V. I.; Leal, F. E.; Blumm, F.; Rocha, V.; Rodrigues, C. A.; Novis, Y. S.; Kallas, E. G.] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Leal, F. E.; Kallas, E. G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Sabino, E. C.; Nishiya, A. S.] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Nishiya, A. S.] Univ Fed Sao Paulo, Infect Dis Div DIPA, Sao Paulo, Brazil.
   [Freire, M. da Silva] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Nishiya, Anna/Q-8156-2016; Sabino, Ester Cerdeira/F-7750-2010;
   Avelino-Silva, Vivian I/L-2640-2013; Rocha, Vanderson/AAO-1691-2020
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Kallas, Esper/0000-0003-2026-6925
CR Bae HG, 2008, J INFECT DIS, V197, P1577, DOI 10.1086/587844
   Centers for Disease Control and Prevention, 2010, MMWR-MORBID MORTAL W, V59, P32
   Chan RC, 2001, LANCET, V358, P121, DOI 10.1016/S0140-6736(01)05341-7
   Engel AR, 2006, VACCINE, V24, P2803, DOI 10.1016/j.vaccine.2006.01.009
   Galler R, 2001, VIROLOGY, V290, P309, DOI 10.1006/viro.2001.1168
   Gowda R, 2004, EUR J HAEMATOL, V72, P299, DOI 10.1111/j.1600-0609.2004.00218.x
   Kengsakul Kitisak, 2002, J Med Assoc Thai, V85, P131
   Lindsey NP, 2008, VACCINE, V26, P6077, DOI 10.1016/j.vaccine.2008.09.009
   Mantel N, 2008, J VIROL METHODS, V151, P40, DOI 10.1016/j.jviromet.2008.03.026
   Martin M, 2001, LANCET, V358, P98, DOI 10.1016/S0140-6736(01)05327-2
   Silva JRN, 2011, VACCINE, V29, P6327, DOI 10.1016/j.vaccine.2011.05.019
   National Institute for Biological Standards and Control, 2008, 1 INT REF PREP ANT F
   Niedrig M, 1999, TROP MED INT HEALTH, V4, P867, DOI 10.1046/j.1365-3156.1999.00496.x
   Pickering LK, 2009, CLIN INFECT DIS, V49, P817, DOI 10.1086/605430
   Pulendran B, 2008, J INFECT DIS, V198, P500, DOI 10.1086/590187
   Reinhardt B, 1998, J MED VIROL, V56, P159, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;159::AID-JMV10&gt;3.0.CO;2-B
   Thomas RE, 2012, AM J TROP MED HYG, V86, P359, DOI 10.4269/ajtmh.2012.11-0525
   Yax JA, 2009, J TRAVEL MED, V16, P365, DOI 10.1111/j.1708-8305.2009.00336.x
NR 18
TC 6
Z9 6
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD JUL
PY 2013
VL 48
IS 7
BP 1008
EP 1009
DI 10.1038/bmt.2012.277
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 176KF
UT WOS:000321302300026
PM 23334273
OA Bronze
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Gomes-Gouvea, MS
   Miraglia, JL
   Guastini, C
   Pinho, JR
   Mendes-Correa, MC
AF Avelino-Silva, Vivian I.
   Gomes-Gouvea, Michele S.
   Miraglia, Joao Luiz
   Guastini, Cristina
   Pinho, Joao R.
   Mendes-Correa, Maria Cassia
TI Absence of anti-HBc in HIV/HBV coinfected individuals with advanced
   immunosuppression
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Avelino-Silva, Vivian I.; Guastini, Cristina; Mendes-Correa, Maria Cassia] Univ Sao Paulo, Sch Med, Div Infect & Parasit Dis, Sao Paulo, Brazil.
   [Gomes-Gouvea, Michele S.; Pinho, Joao R.] Univ Sao Paulo, Sch Med, Inst Trop Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Pinho, Joao R.] Albert Eiinstein Jewish Hosp, Sao Paulo, Brazil.
   [Miraglia, Joao Luiz] Univ Sao Paulo, Sch Med, Discipline Clin Immunol & Allergy, Sao Paulo, Brazil.
RI Pinho, Joao R. R./G-2850-2012; Miraglia, Joao/H-5294-2013; correa, maria
   cassia mendes/A-6779-2013; Avelino-Silva, Vivian I/L-2640-2013
OI Pinho, Joao R. R./0000-0003-3999-0489; Avelino-Silva, Vivian
   I/0000-0002-6660-3088
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 500
BP 436A
EP 437A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955601499
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Novaes, CTG
AF Avelino-Silva, Vivian Iida
   Gallafrio Novaes, Christina Terra
TI Relapse of Intravenous Drug Use Triggered by Enfuvirtide, a Parenteral
   Antiretroviral Medication
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID HIV-INFECTED PATIENTS; FUSION INHIBITOR; PATIENT
AB Fuzeon (R) (enfuvirtide; Hoffmann-LaRoche, Nutley, NJ) is a parenteral medication prescribed to antiretroviral-experienced HIV patients. Clinicians are frequently concerned when prescribing enfuvirtide to former drug addicts because of the risk of triggering relapse, however, no previous report has described this adverse event. We describe two HIV-infected patients, previously abstinent from injection drug use, who experienced relapse or near-relapse situations after starting treatment with enfuvirtide. Along with the concerns related to adherence and to injection site reactions, clinicians who prescribe enfuvirtide should consider and discuss the risk of triggering relapse among former or recovering drug addicts.
C1 [Avelino-Silva, Vivian Iida; Gallafrio Novaes, Christina Terra] Univ Sao Paulo, Sch Med, Infect & Parasit Dis Dept, BR-05403000 Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Sch Med, Infect & Parasit Dis Dept, Av Dr Eneas de Carvalho Aguiar,470 Cerqueira Cesa, BR-05403000 Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Avelino-Silva, Vivian I/L-2640-2013; Ho, Yeh Li/A-7197-2013
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Ho, Yeh
   Li/0000-0001-8719-2508
CR Clotet B, 2004, AIDS, V18, P1137, DOI 10.1097/00002030-200405210-00007
   Cohen CJ, 2002, AIDS PATIENT CARE ST, V16, P327, DOI 10.1089/108729102320231162
   Connors GJ, 1996, ADDICTION, V91, pS5, DOI 10.1111/j.1360-0443.1996.tb02323.x
   Crombag HS, 2008, PHILOS T R SOC B, V363, P3233, DOI 10.1098/rstb.2008.0090
   Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026
   Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211
   Polk C, 2007, AIDS PATIENT CARE ST, V21, P75, DOI 10.1089/apc.2006.0091
   Rachlis Anita, 2006, Can J Infect Dis Med Microbiol, V17, P155
   Stewart J, 2008, PHILOS T R SOC B, V363, P3147, DOI 10.1098/rstb.2008.0084
NR 9
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD FEB
PY 2012
VL 26
IS 2
BP 71
EP 72
DI 10.1089/apc.2011.0343
PG 2
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 888KX
UT WOS:000300003500001
PM 22148866
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Leal, FE
   Coelho-Netto, C
   Cotti, GCD
   Souza, RAS
   Azambuja, RL
   Rocha, MD
   Kallas, EG
AF Avelino-Silva, Vivian Iida
   Leal, Fabio Eudes
   Coelho-Netto, Caio
   de Castro Cotti, Guilherme Cutait
   Souza, Ricardo A. S.
   Azambuja, Rodrigo Lautert
   Rocha, Manoel de Souza
   Kallas, Esper Georges
TI Sclerosing mesenteritis as an unusual cause of fever of unknown origin:
   a case report and review
SO CLINICS
LA English
DT Article
ID PANNICULITIS
C1 [Avelino-Silva, Vivian Iida; Leal, Fabio Eudes; Kallas, Esper Georges] Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian Iida; Leal, Fabio Eudes; Coelho-Netto, Caio; de Castro Cotti, Guilherme Cutait; Souza, Ricardo A. S.; Azambuja, Rodrigo Lautert; Rocha, Manoel de Souza; Kallas, Esper Georges] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Leal, Fabio Eudes; Kallas, Esper Georges] Univ Sao Paulo, Fac Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Rocha, Manoel de Souza] Univ Sao Paulo, Fac Med, Dept Radiol, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Rocha, Manoel S/C-6478-2013; Avelino-Silva, Vivian I/L-2640-2013
OI Rocha, Manoel S/0000-0002-4503-8374; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Kallas, Esper/0000-0003-2026-6925
CR Akram S, 2007, CLIN GASTROENTEROL H, V5, P589, DOI 10.1016/j.cgh.2007.02.032
   Arora Manish, 2008, Medscape J Med, V10, P30
   Bateman AC, 2009, HISTOPATHOLOGY, V55, P373, DOI 10.1111/j.1365-2559.2008.03217.x
   Chawla S, 2009, WORLD J GASTROENTERO, V15, P117, DOI 10.3748/wjg.15.117
   Cunha BA, 2007, INFECT DIS CLIN N AM, V21, P867, DOI 10.1016/j.idc.2007.09.002
   Ferrari TCA, 2008, CLINICS, V63, P843, DOI 10.1590/S1807-59322008000600023
   Garcia SR, 2007, AN MED INTERN, V24, P393
   Gu Guo-Li, 2008, Cases J, V1, P242, DOI 10.1186/1757-1626-1-242
   Hemaidan A, 1999, SOUTHERN MED J, V92, P513, DOI 10.1097/00007611-199905000-00013
   Issa I, 2009, WORLD J GASTROENTERO, V15, P3827, DOI 10.3748/wjg.15.3827
   Martinez Odriozola P, 2003, An Med Interna, V20, P254
   Mourad O, 2003, ARCH INTERN MED, V163, P545, DOI 10.1001/archinte.163.5.545
   Nobili C, 2009, GASTROENT RES PRACT, V2009, DOI 10.1155/2009/176793
   OTTO F, 1991, Z GASTROENTEROL, V29, P395
   Papadaki HA, 2000, DIGESTION, V61, P145, DOI 10.1159/000007748
   PETERSDORF R, 1961, MEDICINE, V40, P1, DOI 10.1097/00005792-196102000-00001
   SANS M, 1995, AM J GASTROENTEROL, V90, P1159
NR 17
TC 5
Z9 6
U1 0
U2 1
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2012
VL 67
IS 3
BP 293
EP 295
DI 10.6061/clinics/2012(03)16
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 919WN
UT WOS:000302362900016
PM 22473414
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Abdala, E
   de Azevedo, LSF
   Avelino-Silva, VI
   Costa, SF
   Caramori, ML
   Strabelli, TMV
   Pierrotti, LC
   da Silva, HHM
   Lopes, MH
   Varkulja, GF
   Santos, VA
   Shikanai-Yasuda, MA
AF Abdala, Edson
   Fonseca de Azevedo, Luis Sergio
   Avelino-Silva, Vivian Iida
   Costa, Silvia Figueiredo
   Caramori, Marlova Luzzi
   Varejao Strabelli, Tania Mara
   Pierrotti, Ligia Camera
   Marques da Silva, Heloisa Helena
   Lopes, Marta Heloisa
   Varkulja, Glaucia Fernanda
   Santos, Vera Aparecida
   Shikanai-Yasuda, Maria Aparecida
CA Comissao Infeccao Imunodeprimidos
   USP
TI Assessment of organ transplants from donors with markers of hepatitis B
SO CLINICS
LA English
DT Article
ID CORE ANTIBODY; POSITIVE DONORS; RECIPIENTS; INFECTION; KIDNEY; SAFE
C1 [Abdala, Edson] Univ Sao Paulo HCFMUSP, Fac Med, Hosp Clin, Liver Transplant Serv, Sao Paulo, Brazil.
   [Fonseca de Azevedo, Luis Sergio] Univ Sao Paulo HCFMUSP, Fac Med, Hosp Clin, Kidney Transplant Unit,Urol Div, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian Iida; Costa, Silvia Figueiredo; Lopes, Marta Heloisa; Shikanai-Yasuda, Maria Aparecida] Univ Sao Paulo FMUSP, Fac Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian Iida; Pierrotti, Ligia Camera] Univ Sao Paulo HCFMUSP, Fac Med, Hosp Clin, Clin Div Infect Dis,HCFMUSP, Sao Paulo, Brazil.
   [Caramori, Marlova Luzzi] Univ Sao Paulo INCOR HCFMUSP, Fac Med, Hosp Clin, Inst Coracao,Lung Transplant Unit, Sao Paulo, Brazil.
   [Varejao Strabelli, Tania Mara] Univ Sao Paulo INCOR HCFMUSP, Fac Med, Hosp Clin, Inst Coracao,Heart Transplant Area, Sao Paulo, Brazil.
   [Marques da Silva, Heloisa Helena] Univ Sao Paulo ICr HCFMUSP, Fac Med, Hosp Clin, Inst Crianca,HCFMUSP, Sao Paulo, Brazil.
   [Varkulja, Glaucia Fernanda] Univ Sao Paulo ICHC HCFMUSP, Fac Med, Hosp Clin, Infect Control Comm Inst Cent, Sao Paulo, Brazil.
   [Santos, Vera Aparecida] Univ Sao Paulo ICHC HCFMUSP, Fac Med, Hosp Clin, Div Cent Lab, Sao Paulo, Brazil.
RP Abdala, E (corresponding author), Univ Sao Paulo HCFMUSP, Fac Med, Hosp Clin, Liver Transplant Serv, Sao Paulo, Brazil.
EM shikanaiyasuda@gmail.com
RI Azevedo, Luiz/M-4147-2014; Yasuda, Maria Aparecida
   Shikanai/AAX-7693-2020; Rocha-Santos, Vinicius/O-9759-2018;
   ShikanaiYasuda, Maria A/A-9000-2013; Pierrotti, Ligia
   Camera/U-9225-2017; Abdala, Edson/H-5165-2012; Costa, Silvia
   F/K-4768-2012; Lopes, Marta H/J-3285-2012; Pierrotti, Ligia/C-5804-2015;
   Strabelli, Tania TMVS/B-1857-2015; Avelino-Silva, Vivian I/L-2640-2013
OI Yasuda, Maria Aparecida Shikanai/0000-0003-3864-041X; ShikanaiYasuda,
   Maria A/0000-0003-3864-041X; Pierrotti, Ligia
   Camera/0000-0002-0216-3028; Abdala, Edson/0000-0003-0765-6654; Costa,
   Silvia F/0000-0003-1087-752X; Strabelli, Tania TMVS/0000-0003-1955-1008;
   Avelino-Silva, Vivian I/0000-0002-6660-3088; Lopes, Marta
   Heloisa/0000-0001-5236-6248
FU Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao
   Paulo
FX We thank the Clinical Directors from Hospital das Clinicas da Faculdade
   de Medicina da Universidade de Sao Paulo (Prof. Jose Otavio Costa Auler
   Junior, Prof. Tarcisio Eloi Pessoa de Barros Filho and Prof. Eloisa
   Bonfa) for all their support.
CR Akalin E, 2005, CLIN TRANSPLANT, V19, P364, DOI 10.1111/j.1399-0012.2005.00350.x
   Avelino-Silva VI, 2010, CLIN TRANSPLANT, V24, P735, DOI 10.1111/j.1399-0012.2010.01254.x
   Barcena R, 2006, WORLD J GASTROENTERO, V12, P2070, DOI 10.3748/wjg.v12.i13.2070
   De Feo TM, 2006, TRANSPLANTATION, V81, P76, DOI 10.1097/01.tp.0000189930.89031.1b
   Fong TL, 2002, TRANSPLANTATION, V73, P85, DOI 10.1097/00007890-200201150-00016
   Gallegos-Orozco JF, 2007, J CLIN GASTROENTEROL, V41, P66, DOI 10.1097/01.mcg.0000225636.60404.bf
   GROSS PA, 1994, CLIN INFECT DIS, V18, P421, DOI 10.1093/clinids/18.3.421
   Hartwig MG, 2005, TRANSPLANTATION, V80, P320, DOI 10.1097/01.tp.0000165858.86067.a2
   Hui CK, 2005, AM J TRANSPLANT, V5, P1437, DOI 10.1111/j.1600-6143.2005.00887.x
   Idilman R, 2003, CLIN TRANSPLANT, V17, P438, DOI 10.1034/j.1399-0012.2003.00070.x
   Ko WJ, 2001, J HEART LUNG TRANSPL, V20, P865, DOI 10.1016/S1053-2498(01)00280-7
NR 11
TC 1
Z9 2
U1 0
U2 2
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2012
VL 67
IS 4
BP 399
EP 404
DI 10.6061/clinics/2012(04)15
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 931EV
UT WOS:000303199300015
PM 22522767
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Avelino-Silva, T
AF Avelino-Silva, Vivian Iida
   Avelino-Silva, Thiago
TI Evolution of a Jellyfish Sting
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Avelino-Silva, Vivian Iida; Avelino-Silva, Thiago] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Avelino-Silva, Thiago J/J-8794-2013; Avelino-Silva, Vivian I/L-2640-2013
OI Avelino-Silva, Thiago J/0000-0001-9347-0519; Avelino-Silva, Vivian
   I/0000-0002-6660-3088
NR 0
TC 4
Z9 6
U1 0
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUL 21
PY 2011
VL 365
IS 3
BP 251
EP 251
DI 10.1056/NEJMicm1009713
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 794QI
UT WOS:000292915500009
PM 21774713
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Ho, YL
   Avelino-Silva, TJ
   Santos, SD
AF Avelino-Silva, Vivian Iida
   Ho, Yeh-Li
   Avelino-Silva, Thiago Junqueira
   Santos, Sigrid De Sousa
TI Aging and HIV infection
SO AGEING RESEARCH REVIEWS
LA English
DT Review
DE Aging; Immunosenescence; HIV
ID ACTIVE ANTIRETROVIRAL THERAPY; T-CELL DEPLETION; IMMUNODEFICIENCY-VIRUS
   INFECTION; AGE-RELATED-CHANGES; PLASMA VIRAL LOAD; REPLICATIVE
   SENESCENCE; BONE-MARROW; IMMUNE ACTIVATION; TYPE-1 INFECTION; DENDRITIC
   CELLS
AB Introduction: Population aging has become a global phenomenon, and HIV infection among older individuals is also increasing. Because age can affect the progression of HIV infection, we aimed to evaluate the present knowledge on HIV infection in older patients.
   Methods: Literature review of the last 20 years.
   Results: Older HIV-infected patients have lower CD4(+) T cell counts, higher viral load and are more frequently symptomatic at diagnosis. The infection progresses more rapidly, with higher morbidity and lethality rates. However, older patients are more compliant to antiretroviral treatment; they experience a better virologic response, and treatment represents a positive clinical impact. Aging affects the complex interaction between HIV infection and the immune system. Both conditions contribute to the dysfunction of immune cells, including a decrease in the phagocytes' microbicidal capability, natural killer cells' cytolytic function, expression of toll-like receptors and production of interleukin-12. Chronic immune activation responsible for the depletion of CD4(+) and CD8(+) T cells in HIV infection appears to worsen with senescence. Older patients also exhibit a less robust humoral response, with the production of less avid and specific antibodies.
   Conclusion: Both HIV and aging contribute to immune dysfunction, morbidity and mortality. However, highly active antiretroviral therapy (HAART) is beneficial for older patients, and treatment of older patients should not be discouraged. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Avelino-Silva, Vivian Iida; Ho, Yeh-Li; Santos, Sigrid De Sousa] Univ Sao Paulo, Infect & Parasit Dis Div, Hosp Clin, Fac Med, BR-05403000 Sao Paulo, Brazil.
   [Avelino-Silva, Vivian Iida; Ho, Yeh-Li; Santos, Sigrid De Sousa] Univ Sao Paulo, Fac Med, Infect & Parasit Dis Dept, BR-05403000 Sao Paulo, Brazil.
   [Avelino-Silva, Thiago Junqueira] Univ Sao Paulo, Fac Med, Hosp Clin, Div Geriatr, BR-05403000 Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Rua Frei Caneca 557, BR-01307001 Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Avelino-Silva, Thiago J/J-8794-2013; Ho, Yeh Li/A-7197-2013; De Sousa
   dos Santos, Sigrid S/A-3180-2013; Avelino-Silva, Vivian I/L-2640-2013
OI Avelino-Silva, Thiago J/0000-0001-9347-0519; Ho, Yeh
   Li/0000-0001-8719-2508; De Sousa dos Santos, Sigrid
   S/0000-0003-0366-0250; Avelino-Silva, Vivian I/0000-0002-6660-3088
CR Adeyemi OM, 2003, CLIN INFECT DIS, V36, P1347, DOI 10.1086/374871
   Agrawal A, 2007, J IMMUNOL, V178, P6912, DOI 10.4049/jimmunol.178.11.6912
   Akbar AN, 2005, CURR OPIN IMMUNOL, V17, P480, DOI 10.1016/j.coi.2005.07.019
   Alexaki A, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000215
   Anderson RW, 1998, J ACQ IMMUN DEF SYND, V17, P245, DOI 10.1097/00042560-199803010-00010
   [Anonymous], 1999, MMWR Recomm Rep, V48, P1
   Aw D, 2007, IMMUNOLOGY, V120, P435, DOI 10.1111/j.1365-2567.2007.02555.x
   Babiker AG, 2001, J CLIN EPIDEMIOL, V54, pS16, DOI 10.1016/S0895-4356(01)00456-5
   Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181
   Ben-Yehuda A, 1998, MECH AGEING DEV, V103, P111, DOI 10.1016/S0047-6374(98)00004-9
   Beq S, 2004, EUR CYTOKINE NETW, V15, P279
   Bestilny LJ, 2000, AIDS, V14, P771, DOI 10.1097/00002030-200005050-00002
   Boyer O, 2004, BLOOD, V103, P3428, DOI 10.1182/blood-2003-07-2598
   *BRAS MIN SAUD DEP, 1980, CAS AIDS NOT BRAS DE
   Brenchley JM, 2008, MUCOSAL IMMUNOL, V1, P23, DOI 10.1038/mi.2007.1
   Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Bruunsgaard H, 2001, CURR OPIN HEMATOL, V8, P131, DOI 10.1097/00062752-200105000-00001
   Butcher SK, 2001, J LEUKOCYTE BIOL, V70, P881
   Butt AA, 2001, SOUTH MED J, V94, P397, DOI 10.1097/00007611-200194040-00008
   Cao W, 2009, AIDS RES HUM RETROV, V25, P183, DOI 10.1089/aid.2008.0140
   Cao W, 2009, JAIDS-J ACQ IMM DEF, V50, P137, DOI 10.1097/QAI.0b013e3181926c28
   Cardinali DP, 2008, NEUROIMMUNOMODULAT, V15, P272, DOI 10.1159/000156470
   CARRE N, 1994, AIDS, V8, P797, DOI 10.1097/00002030-199406000-00012
   Caruso Calogero, 2009, Immun Ageing, V6, P10, DOI 10.1186/1742-4933-6-10
   CARVALHO J, 1970, FECUNDIDADE MORTALID
   Casau NC, 2005, CLIN INFECT DIS, V41, P855, DOI 10.1086/432797
   Castle SC, 2000, CLIN INFECT DIS, V31, P578, DOI 10.1086/313947
   CASTRO MP, 2007, VIVER COM HIV AIDS P
   Chevalier M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-S3-P260
   Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0
   Coleman CM, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-51
   Compston JE, 2002, J ENDOCRINOL, V173, DOI 10.1677/joe.0.1730387
   Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204
   Cuellar ML, 2000, BEST PRACT RES CL RH, V14, P579, DOI 10.1053/berh.2000.0094
   Cuzin L, 2007, CLIN INFECT DIS, V45, P654, DOI 10.1086/520652
   Deeks Steven G, 2009, Top HIV Med, V17, P118
   Dejaco C, 2006, EXP GERONTOL, V41, P339, DOI 10.1016/j.exger.2006.01.008
   Della Bella S, 2007, CLIN IMMUNOL, V122, P220, DOI 10.1016/j.clim.2006.09.012
   Derhovanessian E, 2009, CURR OPIN IMMUNOL, V21, P440, DOI 10.1016/j.coi.2009.05.012
   Dlova NC, 2006, DERMATOL CLIN, V24, P439, DOI 10.1016/j.det.2006.06.002
   Doria-Rose NA, 2009, CURR OPIN HIV AIDS, V4, P426, DOI 10.1097/COH.0b013e32832d9fac
   Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374
   Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Dube MP, 2003, CLIN INFECT DIS, V37, P613, DOI 10.1086/378131
   Effros RB, 2000, VACCINE, V18, P1661, DOI 10.1016/S0264-410X(99)00503-4
   Effros RB, 2004, ANN NY ACAD SCI, V1019, P123, DOI 10.1196/annals.1297.022
   Effros RB, 1997, IMMUNOL TODAY, V18, P450, DOI 10.1016/S0167-5699(97)01079-7
   Effros RB, 1996, AIDS, V10, pF17, DOI 10.1097/00002030-199607000-00001
   Effros RB, 2008, CLIN INFECT DIS, V47, P542, DOI 10.1086/590150
   Ena J, 1998, J INFECTION, V37, P213, DOI 10.1016/S0163-4453(98)91828-X
   FAGIOLO U, 1993, EUR J IMMUNOL, V23, P2375, DOI 10.1002/eji.1830230950
   Fauci AS, 2005, NAT REV IMMUNOL, V5, P835, DOI 10.1038/nri1711
   FERRO S, 1992, J ACQ IMMUN DEF SYND, V5, P348
   Florence E, 2003, HIV Med, V4, P255, DOI 10.1046/j.1468-1293.2003.00156.x
   French RA, 2002, ENDOCRINOLOGY, V143, P690, DOI 10.1210/en.143.2.690
   Gavazzi G, 2002, LANCET INFECT DIS, V2, P659, DOI 10.1016/S1473-3099(02)00437-1
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Goetz MB, 2001, AIDS, V15, P1576, DOI 10.1097/00002030-200108170-00017
   Gomez CR, 2005, CURR OPIN IMMUNOL, V17, P457, DOI 10.1016/j.coi.2005.07.013
   Goodkin K, 2004, AIDS, V18, pS87, DOI 10.1097/00002030-200401001-00013
   Grabar S, 2004, AIDS, V18, P2029, DOI 10.1097/00002030-200410210-00007
   Grimes RM, 2002, CLIN INFECT DIS, V34, P1530, DOI 10.1086/340404
   Grossman Z, 2002, NAT MED, V8, P319, DOI 10.1038/nm0402-319
   Gruver AL, 2007, J PATHOL, V211, P144, DOI 10.1002/path.2104
   Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985
   Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625
   Hadrup SR, 2006, J IMMUNOL, V176, P2645, DOI 10.4049/jimmunol.176.4.2645
   HALLGREN HM, 1973, J IMMUNOL, V111, P1101
   Haynes L, 2005, CURR OPIN IMMUNOL, V17, P476, DOI 10.1016/j.coi.2005.07.003
   Haynes L, 2005, J EXP MED, V201, P845, DOI 10.1084/jem.20041933
   Haynes L, 2003, P NATL ACAD SCI USA, V100, P15053, DOI 10.1073/pnas.2433717100
   Haynes L, 2009, CURR OPIN IMMUNOL, V21, P414, DOI 10.1016/j.coi.2009.05.009
   Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724
   Hinkin CH, 2004, AIDS, V18, pS19, DOI 10.1097/00002030-200418001-00004
   Isgro A, 2005, AUTOIMMUN REV, V4, P486, DOI 10.1016/j.autrev.2005.04.014
   Kalayjian RC, 2005, J INFECT DIS, V192, P1577, DOI 10.1086/466527
   Kang IS, 2004, J IMMUNOL, V173, P673, DOI 10.4049/jimmunol.173.1.673
   Kapasi ZF, 2002, EUR J IMMUNOL, V32, P1567, DOI 10.1002/1521-4141(200206)32:6<1567::AID-IMMU1567>3.0.CO;2-P
   Kewenig S, 1999, GASTROENTEROLOGY, V116, P1115, DOI 10.1016/S0016-5085(99)70014-4
   Knobel H, 2001, AIDS, V15, P1591, DOI 10.1097/00002030-200108170-00025
   Kovaiou Rania D., 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000221
   Lamberts SWJ, 1997, SCIENCE, V278, P419, DOI 10.1126/science.278.5337.419
   Lange CG, 2003, AIDS, V17, P2015, DOI 10.1097/00002030-200309260-00002
   Larbi A, 2006, CELL SIGNAL, V18, P1017, DOI 10.1016/j.cellsig.2005.08.016
   Lederman MM, 2000, AIDS, V14, P2635, DOI 10.1097/00002030-200012010-00002
   Leng QB, 2001, J ACQ IMMUN DEF SYND, V27, P389, DOI 10.1097/00126334-200108010-00010
   Licastro Federico, 2005, Immun Ageing, V2, P8
   Linsk N L, 2000, AIDS Read, V10, P430
   Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
   Maloy KJ, 2003, J EXP MED, V197, P111, DOI 10.1084/jem.20021345
   Mandl JN, 2008, NAT MED, V14, P1077, DOI 10.1038/nm.1871
   Manfredi R, 2000, AIDS, V14, P1475, DOI 10.1097/00002030-200007070-00034
   Manfredi R, 2003, JAIDS-J ACQ IMM DEF, V33, P112, DOI 10.1097/00126334-200305010-00016
   MANTEGANI P, 2009, IMMUNOLOGY
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   Meier A, 2009, NAT MED, V15, P955, DOI 10.1038/nm.2004
   Miller RA, 1997, IMMUNOL REV, V160, P79, DOI 10.1111/j.1600-065X.1997.tb01029.x
   Moanna Abeer, 2005, Curr HIV/AIDS Rep, V2, P16, DOI 10.1007/s11904-996-0004-3
   Moir S, 2009, NAT REV IMMUNOL, V9, P235, DOI 10.1038/nri2524
   MUSHER DM, 1986, J INFECT DIS, V154, P245, DOI 10.1093/infdis/154.2.245
   Myers Jeffrey D, 2009, JAAPA, V22, P20
   Napolitano LA, 2002, AIDS, V16, P1103, DOI 10.1097/00002030-200205240-00003
   Nasi M, 2006, AGING CELL, V5, P167, DOI 10.1111/j.1474-9726.2006.00204.x
   Nel AE, 2002, J ALLERGY CLIN IMMUN, V109, P901, DOI 10.1067/mai.2002.124965
   Nogueras M, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-159
   Noursadeghi M, 2006, LANCET INFECT DIS, V6, P794, DOI 10.1016/S1473-3099(06)70656-9
   OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105
   OPERSKALSKI EA, 1995, J INFECT DIS, V172, P648, DOI 10.1093/infdis/172.3.648
   Orenstein JM, 2001, IMMUNOBIOLOGY, V204, P598, DOI 10.1078/0171-2985-00098
   Panda A, 2009, TRENDS IMMUNOL, V30, P325, DOI 10.1016/j.it.2009.05.004
   Paredes R, 2000, ARCH INTERN MED, V160, P1123, DOI 10.1001/archinte.160.8.1123
   Pawelec G, 1999, MECH AGEING DEV, V108, P1
   Pawelec G, 2004, TRENDS IMMUNOL, V25, P406, DOI 10.1016/j.it.2004.05.006
   Pawelec G, 2009, REV MED VIROL, V19, P47, DOI 10.1002/rmv.598
   Perez JL, 2003, CLIN INFECT DIS, V36, P212, DOI 10.1086/345669
   PHILLIPS AN, 1991, J ACQ IMMUN DEF SYND, V4, P970
   Piazza P, 2002, CLIN LAB MED, V22, P773, DOI 10.1016/S0272-2712(02)00006-9
   Plackett TP, 2004, J LEUKOCYTE BIOL, V76, P291, DOI 10.1189/jlb.1103592
   Plunkett FJ, 2007, J IMMUNOL, V178, P7710, DOI 10.4049/jimmunol.178.12.7710
   Prasad AS, 2009, CURR OPIN CLIN NUTR, V12, P646, DOI 10.1097/MCO.0b013e3283312956
   Renshaw M, 2002, J IMMUNOL, V169, P4697, DOI 10.4049/jimmunol.169.9.4697
   Rouse BT, 2007, EXPERT OPIN BIOL TH, V7, P1301, DOI 10.1517/14712598.7.9.1301
   Roussanov BV, 2000, AIDS, V14, P2715, DOI 10.1097/00002030-200012010-00011
   Saha K, 2001, J ACQ IMMUN DEF SYND, V26, P199, DOI 10.1097/00126334-200103010-00001
   Sanders GD, 2008, ANN INTERN MED, V148, P889, DOI 10.7326/0003-4819-148-12-200806170-00002
   Saurwein-Teissl M, 2002, J IMMUNOL, V168, P5893, DOI 10.4049/jimmunol.168.11.5893
   Shah SS, 2002, CLIN INFECT DIS, V35, P1238, DOI 10.1086/343048
   SIMMONDS P, 1991, LANCET, V338, P1159, DOI 10.1016/0140-6736(91)92029-2
   Skiest DJ, 1996, AM J MED, V101, P605, DOI 10.1016/S0002-9343(96)00329-4
   Soriano V, 1998, J INFECTION, V36, P307, DOI 10.1016/S0163-4453(98)94351-1
   St Groth B. F. de, 2008, AIDS, V22, P671, DOI 10.1097/QAD.0b013e3282f466da
   STALL R, 1994, ARCH INTERN MED, V154, P57, DOI 10.1001/archinte.154.1.57
   Steinmann G G, 1986, Curr Top Pathol, V75, P43
   Stuart JC, 2002, AIDS, V16, P2263, DOI 10.1097/00002030-200211220-00005
   Sugimoto K, 2003, HEPATOLOGY, V38, P1437, DOI 10.1016/j.hep.2003.09.026
   Szabo P, 1998, J IMMUNOL, V161, P2248
   Teixeira L, 2001, AIDS, V15, P1749, DOI 10.1097/00002030-200109280-00002
   Torre D, 2002, CLIN DIAGN LAB IMMUN, V9, P983, DOI 10.1128/CDLI.9.5.983-986.2002
   Tripathi A K, 2005, J Assoc Physicians India, V53, P705
   Tsuboi I, 2004, EXP BIOL MED, V229, P494
   Tumbarello M, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-46
   Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427
   Viard JP, 2001, J INFECT DIS, V183, P1290, DOI 10.1086/319678
   Vrisekoop Nienke, 2009, Journal of Biology (London), V8, P91, DOI 10.1186/jbiol198
   WANG CQ, 1995, AGING-CLIN EXP RES, V7, P379, DOI 10.1007/BF03324349
   Webster RG, 2000, VACCINE, V18, P1686, DOI 10.1016/S0264-410X(99)00507-1
   Weinberg A, 2008, CLIN VACCINE IMMUNOL, V15, P1398, DOI 10.1128/CVI.00479-07
   Weinberger B, 2008, CLIN INFECT DIS, V46, P1078, DOI 10.1086/529197
   Weksler ME, 2000, J CLIN IMMUNOL, V20, P240, DOI 10.1023/A:1006659401385
   Wellons MF, 2002, J AM GERIATR SOC, V50, P603, DOI 10.1046/j.1532-5415.2002.50152.x
   Wikby A, 1998, MECH AGEING DEV, V102, P187, DOI 10.1016/S0047-6374(97)00151-6
   WIKBY A, 1994, EXP GERONTOL, V29, P531, DOI 10.1016/0531-5565(94)90036-1
   World Health Organisation, 2010, DEF OLD ELD PERS
   Wu DY, 2001, J NUTR, V131, p382S
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
   Yamashita TE, 2001, AIDS, V15, P735, DOI 10.1097/00002030-200104130-00009
NR 158
TC 16
Z9 18
U1 2
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568-1637
EI 1872-9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD JAN
PY 2011
VL 10
IS 1
SI SI
BP 163
EP 172
DI 10.1016/j.arr.2010.10.004
PG 10
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA 717SY
UT WOS:000287068900017
PM 20974294
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   Avelino-Silva, TJ
   Miraglia, JL
   Miyaji, KT
   Jacob, W
   Lopes, MH
AF Avelino-Silva, Vivian Iida
   Avelino-Silva, Thiago Junqueira
   Miraglia, Joao Luiz
   Miyaji, Karina Takesaki
   Jacob-Filho, Wilson
   Lopes, Marta Heloisa
TI Campaign, counseling and compliance with influenza vaccine among older
   persons
SO CLINICS
LA English
DT Article
DE Influenza immunization; Campaign; Medical recommendation; Adherence;
   Geriatric
ID IMPACT; HOSPITALIZATION; POPULATION; PREVALENCE; MORTALITY; RATES
AB OBJECTIVES: Population aging raises concerns regarding the increases in the rates of morbidity and mortality that result from influenza and its complications. Although vaccination is the most important tool for preventing influenza, vaccination program among high-risk groups has not reached its predetermined aims in several settings. This study aimed to evaluate the impacts of clinical and demographic factors on vaccine compliance among the elderly in a setting that includes a well-established annual national influenza vaccination campaign.
   METHODS: This cross-sectional study included 134 elderly patients who were regularly followed in an academic medical institution and who were evaluated for their influenza vaccination uptake within the last five years; in addition, the demographic and clinical characteristics and the reasons for compliance or noncompliance with the vaccination program were investigated.
   RESULTS: In total, 67.1% of the participants received the seasonal influenza vaccine in 2009. Within this vaccination-compliant group, the most common reason for vaccine uptake was the annual nationwide campaign (52.2%; 95% CI: 41.4-62.9%); compared to the noncompliant group, a higher percentage of compliant patients had been advised by their physician to take the vaccine (58.9% vs. 34.1%; p<0.01).
   CONCLUSION: The education of patients and health care professionals along with the implementation of immunization campaigns should be evaluated and considered by health authorities as essential for increasing the success rate of influenza vaccination compliance among the elderly.
C1 [Avelino-Silva, Vivian Iida; Miyaji, Karina Takesaki; Lopes, Marta Heloisa] Univ Sao Paulo, Fac Med, Infect & Parasit Dis Dept, Sao Paulo, Brazil.
   [Avelino-Silva, Thiago Junqueira; Jacob-Filho, Wilson] Univ Sao Paulo, Fac Med, Div Geriatr, Hosp Clin, Sao Paulo, Brazil.
   [Miraglia, Joao Luiz] Butantan Fdn, Clin Trials Unit, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Fac Med, Infect & Parasit Dis Dept, Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Avelino-Silva, Vivian I/L-2640-2013; Avelino-Silva, Thiago
   J/J-8794-2013; Miyaji, Karina T/B-1319-2016; Lopes, Marta H/J-3285-2012;
   Miraglia, Joao/H-5294-2013
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Avelino-Silva, Thiago
   J/0000-0001-9347-0519; Miyaji, Karina T/0000-0003-2653-3975; Miraglia,
   Joao Luiz/0000-0002-4788-6254; Lopes, Marta Heloisa/0000-0001-5236-6248
CR *BRAS MIN SAUD, 2007, CAMP NAC VAC ID INF
   Burns VE, 2005, VACCINE, V23, P3604, DOI 10.1016/j.vaccine.2004.12.031
   Daufenbach LZ, 2009, EPIDEMIOL SERV SAUDE, V18, P29
   de Lataillade C, 2009, J PUBLIC HEALTH POL, V30, P83, DOI 10.1057/jphp.2008.40
   Dip RM, 2010, CAD SAUDE PUBLICA, V26, P1035, DOI 10.1590/S0102-311X2010000500025
   Francisco PMSB, 2005, REV SAUDE PUBL, V39, P75, DOI 10.1590/s0034-89102005000100010
   Gravenstein S, 2002, CLIN INFECT DIS, V35, P729, DOI 10.1086/341246
   Kroneman MW, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-113
   Landi F, 2005, VACCINE, V23, P3896, DOI 10.1016/j.vaccine.2005.03.008
   Lau JTF, 2006, VACCINE, V24, P5526, DOI 10.1016/j.vaccine.2006.04.014
   de Andres A, 2007, EUR J PUBLIC HEALTH, V17, P272, DOI 10.1093/eurpub/ckl242
   Lu PJ, 2005, ARCH INTERN MED, V165, P1849, DOI 10.1001/archinte.165.16.1849
   Mangtani P, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-249
   MERECKIENE J, 2010, EUROSURVEILLANCE, V4, P44
   Moura M, 2004, B EPIDEMIOLOGICO PAU, V1, P8
   Nichol KL, 2005, DRUG AGING, V22, P495, DOI 10.2165/00002512-200522060-00004
   Nichol KL, 2006, CLEV CLIN J MED, V73, P1009, DOI 10.3949/ccjm.73.11.1009
   O'Malley AS, 2006, AM J PREV MED, V31, P150, DOI 10.1016/j.amepre.2006.03.021
   Partridge J, 2010, VACCINE, V28, P4709, DOI 10.1016/j.vaccine.2010.04.083
   Patel MS, 2006, PREV MED, V42, P240, DOI 10.1016/j.ypmed.2005.12.004
   Pawelec G, 1999, MECH AGEING DEV, V108, P1
   Takahashi H, 2001, JPN J INFECT DIS, V54, P184
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   van Essen GA, 2003, VACCINE, V21, P1780, DOI 10.1016/S0264-410X(03)00072-0
   WHO/NMH/NPH, 2002, ACT AG POL FRAM, P59
   2005, WEEKLY EPIDEMIO 0819
NR 27
TC 10
Z9 12
U1 0
U2 5
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2011
VL 66
IS 12
BP 2031
EP 2035
DI 10.1590/S1807-59322011001200006
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 865SU
UT WOS:000298331400006
PM 22189726
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Avelino-Silva, VI
   D'Albuquerque, LAC
   Bonazzi, PR
   Song, ATW
   Miraglia, JL
   Neves, AD
   Abdala, E
AF Avelino-Silva, Vivian Iida
   Carneiro D'Albuquerque, Luiz Augusto
   Bonazzi, Patricia Rodrigues
   Song, Alice Tung Wan
   Miraglia, Joao Luiz
   Neves, Alan de Brito
   Abdala, Edson
TI Liver transplant from Anti-HBc-positive, HBsAg-negative donor into
   HBsAg-negative recipient: is it safe? A systematic review of the
   literature
SO CLINICAL TRANSPLANTATION
LA English
DT Review
DE expanded donor pool; hepatitis B virus; liver transplant; prophylaxis;
   serology
ID HEPATITIS-B-VIRUS; EXTENDED CRITERIA DONOR; CORE-ANTIBODY;
   SURFACE-ANTIGEN; ACTIVE IMMUNIZATION; LAMIVUDINE THERAPY;
   PEDIATRIC-PATIENTS; INFECTION; PREVENTION; ALLOGRAFTS
AB Introduction:
   After liver transplant (LT) from Anti-HBc+/HBsAg- donors into HBsAg- recipients, transmission of hepatitis B virus (HBV) may occur (de novo HBV infection). This study analyzes the incidence of de novo HBV infection in HBsAg- recipients of Anti-HBc+/HBsAg- LT with respect to: (i) the recipients' HBV serology and (ii) the type of preventive therapy adopted.
   Methods:
   A systematic review of the literature using the electronic database Medline.
   Results:
   Five hundred and fifty-two LT in 36 articles were selected. Lamivudine, Hepatitis B immune globulin (HBIG), revaccination, and combined therapies were employed in multiple strategies as preventive interventions. Naive recipients had a high risk of de novo HBV infection, with smaller incidences when HBIG and lamivudine were used, either alone or in association. Vaccinated recipients or those with isolated hepatitis B core antibodies (Anti-HBc) and previous HBV infection had lower risks of viral transmission, additionally reduced by any prophylaxis adoption.
   Discussion:
   LT from Anti-HBc+/HBsAg- donors into HBsAg- recipients is apparently safe, as long as the recipient is vaccinated or presents an isolated Anti-HBc or previous HBV infection and some prophylaxis is employed. Currently lamivudine seems the best alternative; other nucleoside analogs and revaccination strategies should be considered in future studies. Follow-up and preventive therapies should be maintained for five yr or preferably throughout the recipients' life span.
C1 [Miraglia, Joao Luiz] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Carneiro D'Albuquerque, Luiz Augusto; Bonazzi, Patricia Rodrigues; Abdala, Edson] Univ Sao Paulo, Sch Med, Liver Transplantat Serv, Dept Gastroenterol, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian Iida; Bonazzi, Patricia Rodrigues; Song, Alice Tung Wan; Neves, Alan de Brito; Abdala, Edson] Univ Sao Paulo, Sch Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian Iida; Song, Alice Tung Wan] Univ Sao Paulo, Sch Med, Clin Hosp, Div Infect & Parasit Dis, Sao Paulo, Brazil.
RP Avelino-Silva, VI (corresponding author), Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM viviansilva87@gmail.com
RI Song, Alice Tung Wan/F-2494-2014; Avelino-Silva, Vivian I/L-2640-2013;
   Abdala, Edson/H-5165-2012; Miraglia, Joao/H-5294-2013; D'ALBUQUERQUE,
   Luiz Carneiro Augusto/I-4011-2012; D'Albuquerque, Luiz Augusto
   Carneiro/A-8812-2013
OI Song, Alice Tung Wan/0000-0001-6992-9326; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Abdala, Edson/0000-0003-0765-6654; D'Albuquerque,
   Luiz Augusto Carneiro/0000-0001-7607-7168; Miraglia, Joao
   Luiz/0000-0002-4788-6254
CR Bacchella T, 2008, SAO PAULO MED J, V126, P161, DOI 10.1590/S1516-31802008000300005
   Barcena R, 2006, WORLD J GASTROENTERO, V12, P2070, DOI 10.3748/wjg.v12.i13.2070
   Castells L, 2002, LIVER TRANSPLANT, V8, P892, DOI 10.1053/jlts.2002.35555
   Chang SH, 2003, HEPATOLOGY, V37, P1329, DOI 10.1053/jhep.2003.50227
   Chen YS, 2002, CLIN TRANSPLANT, V16, P405, DOI 10.1034/j.1399-0012.2002.01133.x
   Cholongitas E, 2010, J HEPATOL, V52, P272, DOI 10.1016/j.jhep.2009.11.009
   De Feo TM, 2005, TRANSPL P, V37, P1238, DOI 10.1016/j.transproceed.2004.12.041
   Dickson RC, 1997, GASTROENTEROLOGY, V113, P1668, DOI 10.1053/gast.1997.v113.pm9352871
   Dodson SF, 1997, TRANSPLANTATION, V64, P1582, DOI 10.1097/00007890-199712150-00013
   Dodson SF, 1999, TRANSPLANTATION, V68, P1058, DOI 10.1097/00007890-199910150-00028
   Donataccio D, 2006, TRANSPL INT, V19, P38, DOI 10.1111/j.1432-2277.2005.00225.x
   Douglas D D, 1997, Liver Transpl Surg, V3, P105, DOI 10.1002/lt.500030202
   Dumortier J, 2002, J HEPATOL, V37, P876, DOI 10.1016/S0168-8278(02)00320-3
   Fabrega E, 2003, LIVER TRANSPLANT, V9, P916, DOI 10.1053/jlts.2003.50190
   Holt D, 2002, ARCH SURG-CHICAGO, V137, P572, DOI 10.1001/archsurg.137.5.572
   Jankowska I, 2007, TRANSPL P, V39, P1511, DOI 10.1016/j.transproceed.2006.11.013
   Kobak AC, 2007, TRANSPL P, V39, P1488, DOI 10.1016/j.transproceed.2006.11.015
   Kwon Choon Hyuck, 2006, Korean J Hepatol, V12, P191
   Lee KW, 2004, TRANSPL P, V36, P2311, DOI 10.1016/j.transproceed.2004.08.139
   Lin CC, 2007, AM J TRANSPLANT, V7, P195, DOI 10.1111/j.1600-6143.2006.01618.x
   Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190
   LOPEZNAVIDAD A, 2003, S, V17, P308
   Loss GE, 2003, LIVER TRANSPLANT, V9, P1258, DOI 10.1016/j.lts.2003.09.010
   LOWELL JA, 1995, LANCET, V345, P1084, DOI 10.1016/S0140-6736(95)90819-6
   Manzarbeitia C, 2002, LIVER TRANSPLANT, V8, P556, DOI 10.1053/jlts.2002.33451
   Marugan RB, 2002, AM J GASTROENTEROL, V97, P2398, DOI 10.1111/j.1572-0241.2002.05994.x
   Mittler J, 2008, TRANSPLANTATION, V86, P895, DOI 10.1097/TP.0b013e318186ad7a
   Moraleda G, 2006, AM J TRANSPLANT, V6, P438, DOI 10.1111/j.1600-6143.2005.01189.x
   Mullhaupt B, 2008, J HEPATOL, V48, pS58, DOI 10.1016/j.jhep.2008.01.013
   Nery JR, 2003, TRANSPLANTATION, V75, P1179, DOI 10.1097/01.TP.0000065283.98275.FE
   Park JB, 2008, TRANSPL INT, V21, P346, DOI 10.1111/j.1432-2277.2007.00618.x
   Perrillo R, 2009, LIVER TRANSPLANT, V15, P223, DOI 10.1002/lt.21675
   Prakoso E, 2006, CLIN TRANSPLANT, V20, P369, DOI 10.1111/j.1399-0012.2006.00495.x
   Prieto M, 2001, LIVER TRANSPLANT, V7, P51, DOI 10.1053/jlts.2001.20786
   Rodriguez-Luna Hector, 2003, Clin Liver Dis, V7, P573, DOI 10.1016/S1089-3261(03)00056-4
   RODRIGUEZLUNA H, 2003, CLIN LIVER DIS, V7, pR6
   Rokuhara A, 2000, J MED VIROL, V62, P471, DOI 10.1002/1096-9071(200012)62:4&lt;471::AID-JMV12&gt;3.0.CO;2-X
   ROQUEAFONSO AM, 2002, ANTIBODIES, V50, P95
   Su WJ, 2009, J PEDIATR GASTR NUTR, V48, P203, DOI 10.1097/MPG.0b013e3181819ad4
   Suehiro T, 2005, LIVER INT, V25, P1169, DOI 10.1111/j.1478-3231.2005.01165.x
   Sugauchi F, 2002, INTERVIROLOGY, V45, P6, DOI 10.1159/000050081
   Uemoto S, 1998, TRANSPLANTATION, V65, P494, DOI 10.1097/00007890-199802270-00007
   Wright TL, 2006, AM J GASTROENTEROL, V101, pS1, DOI 10.1111/j.1572-0241.2006.00469.x
   Yataco ML, 2009, CLIN TRANSPLANT, V23, P282, DOI 10.1111/j.1399-0012.2008.00929.x
   Yen RD, 2006, AM J TRANSPLANT, V6, P1077, DOI 10.1111/j.1600-6143.2006.01313.x
   Yoshida EM, 2000, LIVER, V20, P411, DOI 10.1034/j.1600-0676.2000.020005411.x
   Yu AS, 2001, LIVER TRANSPLANT, V7, P513, DOI 10.1053/jlts.2001.23911
NR 47
TC 30
Z9 31
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
EI 1399-0012
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD NOV-DEC
PY 2010
VL 24
IS 6
BP 735
EP 746
DI 10.1111/j.1399-0012.2010.01254.x
PG 12
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 688YZ
UT WOS:000284894800011
PM 20438579
DA 2020-12-01
ER

EF